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Abstract 
Tinea versicolor (TV) and skin dermatophytes (SD) infections are 
common diseases widely spread in tropical areas and among poor 
populations. There are some chemical drugs used in the treatment of TV 
and S.D infections. These drugs have side effects; especially oral drugs 
which have toxic effects on liver and kidneys. Some are very expensive and 
recurrence rate of the disease is high. 
The aim of this study was to prepare a new, non expensive, effective 
and safe pharmaceutical formulation for treatment of TV and SD infections 
using a naturally available volcanic stone extract. 
This volcanic stone is native to Yemen where it is used traditionally 
for treatment of TV and SD infections by soaking in water and wiping the 
affected areas of the skin. 
In this study chemical analysis was done for the stone which 
identified its constituents and the amount of each constituent. 
In vitro microbiological studies were done to know the effect of the 
stone extracts on cultures of different fungi and bacteria. Comparative 
studies were carried out to investigate the microbiological activity of the 
stone extracts with other drugs used for treatment of fungi infections. The 
results achieved showed high microbiological activity of stone extracts 
against TV and other dermatophytes infections. 
The stone extract was then formulated in a suitable pharmaceutical 
formulation (aqueous cream) and the physical and chemical properties of 
this formulation were determined. The stability of the finished formulation 
was carried out. 
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Pharmacological studies of the stone extract were done for the 
smooth muscle receptors in the small intestine and aortic muscle from the 
rabbit and on the receptors of the skeletal muscle from the frog, and also on 
the receptors of the uterus muscle from the rat. The results of these studies 
showed that there are no pharmacological effects on these receptors. 
Toxicological studies of the stone extract (100 mg/kg) were tried on 
twelve rats; six were used as control and the others six as test. The drug 
was given to the test group for twenty one days (sub chronic study) in high 
doses (100 mg/kg) and after that blood was taken from both groups. Blood 
was analyzed for all parameters and different enzymes and the results were 
compared with the control groups. The results showed that there were no 
significant difference between the two groups this indicate that the drug is 
free of toxic effects. 
The five important organs of the control rat (liver, Kidney, heart, 
small intestine and spleen) were taken. Specimens were prepared for 
histopathological studies. The results confirmed that there is no damage or 
effect on these organs. 
 Clinical trials using the pharmaceutical formulation were carried out 
in Sudan after the approval of the study by the Ethics Committee of the 
Research Administration, Federal Ministry of Health, Sudan. Clinical 
comparative studies were done on one hundred volunteers; fifty were 
treated with clotrimazole cream and the other fifty with the new cream 
formulation. The results were analyzed and statistically compared using 
SPSS. This showed that the new cream formulation was effective for the 
treatment of TV and other S.D infections with no recurrences. 
v  
 ﻣﺴــﺘﺨـﻠـﺺ
  
إن ﻣﺮض اﻟﺒﻬﻖ واﻟﻔﻄﺮﻳﺎت اﻟﺠﻠﺪﻳﺔ ﻣﻦ أآﺜﺮ اﻷﻣﺮاض اﻟﺸﺎﺋﻌﺔ واﻟﻤﻨﺘﺸﺮة ﺧﺼﻮﺻﺎ ﻓﻲ 
  .اﻟﻤﻨﺎﻃﻖ اﻟﺴﺎﺧﻨﺔ وﺑﻴﻦ اﻟﻄﺒﻘﺎت اﻟﻔﻘﻴﺮة
 هﻨﺎك ﻋﺪة أدوﻳﺔ آﻴﻤﻴﺎﺋﻴﺔ ﺗﺴﺘﺨﺪم ﻟﻌﻼج اﻟﺒﻬﻖ واﻟﻔﻄﺮﻳﺎت اﻟﺠﻠﺪﻳﺔ وﻟﻜﻦ ﺁﺛﺎرهﺎ اﻟﺠﺎﻧﺒﻴﺔ
 اﻟﺴﺎم ﻋﻠﻰ اﻟﻜﺒﺪ واﻟﻜﻠﻰ وآﺬﻟﻚ أﺳﻌﺎرهﺎ  ﺧﺼﻮﺻًﺎ اﻷدوﻳﺔ اﻟﺘﻲ ﺗﻌﻄﻰ ﻋﻦ ﻃﺮﻳﻖ اﻟﻔﻢ ﻟﺘﺄﺛﻴﺮهﺎآﺜﻴﺮة
وآﺬﻟﻚ اﻷدوﻳﺔ اﻟﻤﻮﺿﻌﻴﺔ ﻣﺜﻞ اﻟﺸﺎﻣﺒﻮهﺎت ، اﻟﻤﺮﺗﻔﻌﺔ ﺧﺼﻮﺻًﺎ أن اﻟﻤﺮض ﻳﺼﺐ اﻟﻄﺒﻘﺎت اﻟﻔﻘﻴﺮة
  . ﻣﻌﺮوﻓﺔواﻟﻜﺮﻳﻤﺎت أﺳﻌﺎرهﺎ اﻟﻤﺮﺗﻔﻌﺔ وﺁﺛﺎرهﺎ اﻟﺠﺎﻧﺒﻴﺔ ﻋﻠﻰ اﻟﺠﻠﺪ
وﺁﻣﻦ ﻟﻠﺒﻬﻖ واﻟﻔﻄﺮﻳﺎت اﻷﺧﺮى ﻓﻌﺎل  ﻟﺬﻟﻚ آﺎن اﻟﻬﺪف ﻣﻦ هﺬﻩ اﻟﺪراﺳﺔ هﻮ إﻳﺠﺎد ﻋﻼج
  .ورﺧﻴﺺ
 ﺑﻮاﺳﻄﺔ اﻟﻤﺎء وﺗﺴﺘﺨﺪم ﺷﻌﺒﻴًﺎ ﻟﻌﻼج ﻣﻮادهﺎ ﻓﻲ اﻟﻴﻤﻦ هﻨﺎك أﺣﺠﺎر ﺑﺮآﺎﻧﻴﺔ ﻳﺘﻢ اﺳﺘﺨﻼص
  .ﻣﺮض اﻟﺒﻬﻖ واﻟﻔﻄﺮﻳﺎت اﻟﺠﻠﺪﻳﺔ
ﺗﻢ ﻋﻤﻞ اﻟﺪراﺳﺔ اﻟﻜﻴﻤﻴﺎﺋﻴﺔ ﻟﻬﺬﻩ اﻷﺣﺠﺎر وﺗﻢ اﻟﺘﻌﺮف ﻋﻠﻰ ﻣﻜﻮﻧﺎﺗﻬﺎ وﻧﺴﺐ هﺬﻩ اﻟﻤﻜﻮﻧﺎت 
  ﻓﻲ اﻷﺣﺠﺎر 
ﻴﺮ اﻟﻌﻼج ﻋﻠﻰ اﻟﻔﻄﺮﻳﺎت اﻟﻤﺨﺘﻠﻔﺔ وآﺬﻟﻚ ﻋﻠﻰ ﺗﻢ ﻋﻤﻞ اﻟﺪراﺳﺔ اﻟﻤﻴﻜﺮوﺑﻴﻮﻟﻮﺟﻴﺔ ﻟﻤﻌﺮﻓﺔ ﺗﺄﺛ
 .اﻟﺒﻜﺘﻴﺮﻳﺎ اﻟﻤﺰرﻋﺔ ﻓﻲ أﻃﺒﺎق ﺗﺰرﻳﻊ وﻣﻘﺎرﻧﺘﻪ ﻣﻊ أدوﻳﺔ أﺧﺮى وﻗﺪ أﻋﻄﻰ ﻧﺘﺎﺋﺞ ﺟﻴﺪة ﺟﺪًا
وﻋﻤﻞ ( آﺮﻳﻢ)ﺗﻢ اﺳﺘﺨﻼص هﺬﻩ اﻟﻤﻜﻮﻧﺎت وﺗﺤﻀﻴﺮﻩ ﻋﻠﻰ ﺷﻜﻞ ﺻﻴﺪﻻﻧﻲ ﻣﻨﺎﺳﺐ 
  .اﻟﺪراﺳﺎت اﻟﻤﻨﺎﺳﺒﺔ ﻟﻪ وآﺬﻟﻚ دراﺳﺔ اﻟﺜﺒﺎﺗﻴﺔ ﻟﻬﺬا اﻟﻤﺴﺘﺤﻀﺮ
ﺪراﺳﺔ اﻟﻔﺎرﻣﺎآﻮﻟﻮﺟﻴﺔ ﻟﻠﻌﻼج ﻋﻠﻰ اﻟﻤﺴﺘﻘﺒﻼت اﻟﻤﺨﺘﻠﻔﺔ ﻓﻲ ﻋﻀﻼت اﻟﺠﺴﻢ ﻟﻜﻞ ﺗﻢ ﻋﻤﻞ اﻟ
ﻣﻦ اﻟﻌﻀﻼت اﻟﻤﻠﺴﺎء وﻋﻀﻠﺔ اﻷورﻃﻲ ﻓﻲ اﻷراﻧﺐ وﻋﻀﻼت اﻟﺮﺣﻢ ﻓﻲ اﻟﻔﺌﺮان وﻋﻀﻼت 
اﻟﻬﻴﻜﻠﻴﺔ ﻓﻲ اﻟﻀﻔﺎدع ووﺟﺪ ﻣﻦ ﺧﻼل هﺬﻩ اﻟﺪراﺳﺔ أﻧﻪ ﻻﻳﻮﺟﺪ أي ﺁﺛﺎر ﻓﺎرﻣﺎآﻮﻟﻮﺟﻴﺔ ﻋﻠﻰ 
  .ﺔ ﻟﻠﺠﺴﻢاﻟﻤﺴﺘﻘﺒﻼت ﻓﻲ اﻟﻌﻀﻼت اﻟﻤﺨﺘﻠﻔ
ﺗﻢ ﻋﻤﻞ دراﺳﺔ اﻟﺴﻤﻴﺔ ﻟﻠﻌﻼج ﻋﻠﻰ ﻓﺌﺮان ﺣﻴﺚ ﺗﻢ ﺗﻘﺴﻴﻢ اﻟﻔﺌﺮان ﻟﻤﺠﻤﻮﻋﺘﻴﻦ ﻣﺠﻤﻮﻋﺔ 
أﻋﻄﻴﺖ اﻟﻌﻼج ﺑﺠﺮﻋﺎت ﻗﺎﺗﻠﺔ ﻟﻤﺪة واﺣﺪ وﻋﺸﺮﻳﻦ ﻳﻮم واﻟﻤﺠﻤﻮﻋﺔ اﻷﺧﺮى ﻟﻠﻤﻘﺎرﻧﺔ وﺑﻌﺪ ذﻟﻚ ﺗﻢ 
ﻞ وﺗﻢ ﻋﻤﻞ اﻟﺘﺤﻠﻴ.أﺧﺬ ﻋﻴﻨﺎت دم ﻣﻦ آﻞ اﻟﻔﺌﺮان وﺗﻢ ﻋﻤﻞ ﺗﺤﻠﻴﻞ ﻟﻜﻞ ﻣﻜﻮﻧﺎت اﻟﺪم وآﺬﻟﻚ اﻷﻧﺰﻳﻤﺎت
iv  
ﺗﻮﺟﺪ أي اﺧﺘﻼﻓﺎت إﺣﺼﺎﺋﻴﺔ ﻓﻲ اﻹﺣﺼﺎﺋﻲ ﻟﻠﻨﺘﺎﺋﺞ ﻣﻘﺎرﻧﺔ ﻣﻊ اﻟﻤﺠﻤﻮﻋﺔ اﻷﺧﺮى ووﺟﺪ أﻧﻪ ﻻ
  .اﻟﻨﺘﺎﺋﺞ
اﻷﻣﻌﺎء اﻟﺪﻗﻴﻘﺔ ، اﻟﻄﺤﺎل، اﻟﻜﻠﻲ، اﻟﻜﺒﺪ) وأﺧﺬ اﻷﻋﻀﺎء  اﻟﺘﻲ أﺧﺬت اﻟﻌﻼجآﺬﻟﻚ ﺗﻢ ذﺑﺢ اﻟﻔﺌﺮان
ﺮ ﻟﻠﻌﻼج ﻋﻠﻰ  وﺗﻢ ﻋﻤﻞ دراﺳﺔ اﻷﻧﺴﺠﺔ ﻟﻬﺬﻩ اﻷﻋﻀﺎء ووﺟﺪ أﻧﻪ ﻻﻳﻮﺟﺪ أي ﺗﺄﺛﻴ ﻟﻜﻞ ﻓﺄر(واﻟﻘﻠﺐ
  .هﺬﻩ اﻷﻋﻀﺎء
اﻻﺗﺤﺎدﻳﺔ ﺑﺠﻤﻬﻮرﻳﺔ اﻟﺴﻮدان  أﺧﻴﺮًا وﺑﻌﺪ ﻣﻮاﻓﻘﺔ ﻟﺠﻨﺔ أﺧﻼﻗﻴﺎت اﻟﺒﺤﻮث ﻓﻲ وزارة اﻟﺼﺤﺔ
ﻋﻠﻰ إﺟﺮاء اﻟﺪراﺳﺔ اﻹآﻠﻴﻨﻴﻜﻴﺔ ﻋﻠﻰ ﻣﻄﻮﻋﻴﻦ ﺗﻢ ﻋﻤﻞ دراﺳﺔ ﻣﻘﺎرﻧﺔ إآﻠﻴﻨﻴﻜﻴﺔ ﻟﻠﻌﻼج ﻣﻊ 
ﻗﺴﻢ - اﻟﺴﻮداﻧﻲاﻟﻜﻠﻮﺗﺮاﻳﻤﺎزول آﺮﻳﻢ ﻋﻠﻰ ﻣﺎﺋﺔ ﻣﺘﻄﻮع ﻟﻤﺪة ﺛﻼﺛﺔ أﺷﻬﺮ ﻓﻲ اﻟﻤﻌﻤﻞ اﻟﻘﻮﻣﻲ
اﻟﻔﻄﺮﻳﺎت اﻟﺠﻠﺪﻳﺔ ﺑﺎﻟﺘﻌﺎون ﻣﻊ ﻣﺴﺘﺸﻔﻰ اﻟﺨﺮﻃﻮم اﻟﺘﻌﻠﻴﻤﻲ ﻟﻸﻣﺮاض اﻟﺠﻠﺪﻳﺔ واﻟﺘﻨﺎﺳﻠﻴﺔ وﻗﺪ أﻋﻄﻰ 
  ﻧﺘﺎﺋﺞ ﺟﻴﺪة 
  .ﻻ ﻳﻮﺟﺪ أي إﻋﺎدةﺛﺒﺖ اﻧﻪ  ﻣﺘﺎﺑﻌﺔ إﻋﺎدة اﻟﻤﺮض ﻓﻲ ﺑﻌﺾ اﻟﻤﻄﻮﻋﻴﻦ ﺧﻼل ﺳﻨﺔ وﺖآﻤﺎ ﺗﻤ
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1. INTRODUCTION AND LITERATURE REVIEW 
 Mycology is the study of fungi. There are more than 50000 species 
of fungi but most are beneficial to humankind. They reside in nature and 
are essential in breaking down and recycling organic matter. Some fungi 
enhance quality of life by contribution to the production of food and 
spirits.  
 Other fungi have served medicine by providing useful bioactive 
secondary metabolites such as antibiotics e.g. penicillin and 
immunosusuppressive drugs e.g. (cyclosporine). Only a few hundred 
species of fungi have been implicated in human disease, and 90% of 
human infection by fungi can be attributed to a few dozen species. 
 Fungal infections are called mycoses. Most pathogenic fungi are 
exogenous, their natural habitats being water, soil and organic debris. The 
mycoses with the highest incidence-candidiasis and dermatophytosis-are 
caused by fungi that are part of the normal microbial flora or highly 
adapted to survival on the human host. 
 Mycoses may be classified as superficial, cutaneous, subcutaneous, 
systemic and opportunistic (Table 1.1, Brooks, et al 2004). 
1.1 General properties and classification of fungi 
 Fungi grow in two basic forms, as yeasts and molds. Growth in the 
mold form occurs by production of multicultural filamentous colonies. 
These colonies consist of branching cylindrical tubules called hyphae, 
varying in diameter from 2 µm to 10 µm.  
The mass of intertwined hyphae that accumulate during active 
growth is a mycelium. Some hyphae are divided into cells by cross-walls 
or septa, typically forming at regular intervals during hyphal growth. One 
class of medically important molds, the zygomycetes, produces hyphae 
that are rarely septated. 
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Table 1.1 Classification of mycosis according to the causative fungi and 
major mycosis. 
Type of mycosis Causative fugal agents Mycosis 
Superficial 
Malassezia species 
Hortaea werneckii 
Trichosporon species 
Piedraia hortae 
Pityriasis versicolor 
Tinea nigra 
White piedra 
Black piedra 
Cutaneous 
Microsporum species, trichophyton 
species and epidermophyton floccosum 
Candida albicans and other candida 
species 
Dermatophytosis 
 
Candidiasis of skin, 
mucosa or nails 
Subcutaneous 
Sporothrix schenckii 
Phialophora verrucosa, Fonsecaea 
Pedrosoi and others 
Pseudallescheria boydii, Madurella 
mycetomatis and others 
Exophiala, bipolaris, exserohilum and 
others 
Sporotrichosis 
 
Chromoblastomycosis 
Mycetoma 
 
Phaeohyphomycosis 
 
Endemic(primary, 
systemic) 
Caccidioides immitis, Cposadasii 
Histoplasma capsulatum 
Blastomyces dermatitidis 
Paracoccidioides 
Coccidioidomycosis 
Histoplasmosis 
Blastomycosis 
paracoccidioidomycosis
Opportunistic 
Candida albicans and other candida 
species 
Cryptococcus neoformans 
Aspergillus fumigatus and other 
aspergillus species. 
Species of rhizopus, absidia, mucor and 
other zygomycetes 
Penicillum marneffei 
Systemic candidiasis 
 
Cryptococcosis 
Aspergillosis 
 
Mucormycosis(zygomy
cosis) 
penicilliosis 
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Hyphae that penetrate the supporting medium and absorb nutrients 
are the vegetative or substrate hyphea. 
 Yeasts are single cells, usually spherical to ellipsoid in shape. Most 
yeasts reproduce by budding. All fungi have an essential rigid cell wall 
that determines their shape. Cell walls are composed largely of 
carbohydrate layers, glycoprotein and lipids. Some yeasts and molds have 
melanized cell walls, imparting a brown or black pigment, such fungi are 
dematiaceous. In addition to their vegetative growth as yeasts or molds, 
fungi can produce spores to enhance their survival. Spores that can be 
readily dispersed are more resistant to adverse condition and can 
germinate when conditions for growth are favorable. The medical fungi 
produce two major types of asexual spores, i.e. conidia and in the 
zygomycetes, sporangiospores. 
1.1.1 Classification 
The classification of fungi is based in the mechanism and spores that 
result from sexual reproduction as follow 
• Zygomycetes 
Sexual reproduction results on a zygospore; asexual reproduction 
occurs via sporangia. e.g. Rhizopus, absidia, mucor, pilobolus. 
• Ascomycetes 
Sexual reproduction involves a sac or ascus in which karyogamy 
and meiosis occur producing ascospores. Asexual reproduction is 
via conidia. e.g. Ajellomyces (blastomyces, histoplasma), 
arethroderma (Microsporum, trichophyto) and yeast genera such 
as saccharomycesb. 
• Basidiomycetes 
Sexual reproduction results in four progny basidiospores 
supported by a club-shaped basidium. e.g. Mushrooms, 
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Filobasidiella neoformans (anamorph, Cryptococcus 
neoformans). 
• Deuteromycetes 
This is an artificial grouping of the imperfect fungi for which a 
teleomorph or sexual reproduction has not been discovered. The 
anamorphic state is characterized by asexual conidia. e.g. 
Coccidioides immitis, Paracoccidioides brasiliensis, Candida 
albicans. 
1.1.2 Growth and isolation of fungi 
 Most fungi occur in nature and grow readily on simple sources of 
nitrogen and carbohydrate. Traditionally, Sabouraud's agar, which 
contains glucose and modified peptone pH 7.0, has been used because it 
does not readily support the growth of bacteria. The morphologic 
characteristics of fungi used for identification have been described from 
growth on sabouraud's agar. However, other media, such as inhibitory 
mold agar have facilitated the recovery of fungi from clinical specimens. 
 To culture medical fungi from nonsterile specimens, antibacterial 
antibiotics e.g. (gentamicin, chloramphenicol) and cycloheximide are 
added to the media to inhibit bacteria and saprophytic molds. 
1.2 Superficial mycosis 
1.2.1 Malassezia species  
1.2.1.1 Definition and taxonomy  
Taxonomic classification 
Kingdom: Fungi 
Phylum: Basidiomycota 
Class: Hymenomycetes 
Order: Tremellales 
Family: Filobasidiaceae 
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Genus: Malassezia 
 Malassezia yeasts are part of normal microflora, the genus 
Malassezia is now thought to be composed of several different species 
include M. dermatis, M. furfur, M. globosa, M. obtuse, M. pachydermatis, 
M. restricta, M. slooffiae, and M. sympodialis (Ogunbiyi, 2005 and 
Oswald et al. 2006). 
 However, Morishita, et al. (2006), Rademaker et al. (2005), 
Crespo-Erchiga, et al. (2006) and Carvalho et al. (2006), mentioned that 
eleven species were recognized from genus Malassezia these include in 
addition to the above, M. japonica, M. yamatoenis and M. nana.  
 The Malassezia genus comprises yeasts with natural habitat of the 
skin of warm-blooded animals. They are universally present as 
commensals among the normal skin microbiota, but they can also be 
agents of disease notably in the dermatological condition, pityriasis 
versicolor (Hort, et al. 2006).  
 It is a chronic, superficial fungal disease of the skin characterized 
by well-demarcated white, pink, fawn or brownish lesion, coalescing, and 
covered with thin furfuraceous scales, (Ellis, 2005). In recent years they 
have also been recognized as opportunistic pathogens causing invasive 
infections.  
Comprehensive review of the disease caused by Malassezia 
especially Malassezia furfur as the causative agent of pityriasis versicolor 
was published by Marcon and Powell in 1992, covering the many aspects 
of the biology of these organisms, as well as their role as pathogens. 
Malassezia spp. has an affinity for lipids as substrates and the term 
'lipophilic yeasts' is frequently used to identify the genus. Most of the 
species, in fact, show an absolute requirement for lipids and they are 
seldom isolated in the laboratory unless specific nutrients are provided in 
the medium selected  
 6
Morphologically they are characterized by the way in which they 
form blastoconidia or buds, this being enteroblastic and phialidic. 
The genus Malassezia has been placed among the Basidiomycota 
in the family Cryptococcaceae. Although no teleomorph has been 
described for any of malassezia spp., their affinities have been indicated 
by the possession of characteristics that are found in other 
basidiomycetous yeasts. 
 M. yeasts are part of normal microflora, under certain conditions 
they cause superficial skin infection. Eleven species have been identified 
within this genus which is associated with several common 
dermatological dis-orders such as PV, Seborrhoeic dermatitis, atopic 
dermatitis and folliculitis (Crespo-Erchiga, et al, 2006 and Ashbee, et al. 
2002). 
1.2.1.2 History 
 The yeasts now identified as Malassezia spp. were first recognized 
in 1846 when Eichstedt realized the fungal nature of the disease, 
pityriasis versicolor. He reported the presence of yeasts and filaments 
which he had observed in skin from patients with that infection. In 
subsequent years, the yeasts alone were observed by many authors in 
samples of healthy skin and also in conditions such as psoriasis, 
seborrhoeic dermatitis and pityriasis capitis (dandruff); they were placed 
in the genus Pityrosporum.  
 The history of the nomenclature used for the Malassezia is 
complex. A detailed review of the history of the two genera, Malassezia 
and pityrosporum has been given by Slooff (1970). 
Malassezia is now recognized as synonymous with the genus 
pityrosporum, but both names are to be found in the literature. From 
Slooff's review, it is clear that, in the early studies, a distinction was made 
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between the agent of pityriasis versicolor, named M. furfur by Baillon in 
1889, and those yeasts that inhibit either normal skin or the scales from 
conditions such as seborrhoeic dermatitis or dandruff. The latter were 
assigned by Sabouraud in 1904 to the genus Pityrosporum as P.  
malassezii but the species was later described as P. ovale by Castellani 
and Chalmers in 1913, acknowledging an earlier name, Saccharomyces 
ovalis. 
 Two paths can therefore be traced in successive studies of these 
yeasts, one following the attempts to culture the agent of pityriasis 
versicolor and the other investigating the isolation and the biology of 
those organisms so frequently seen in material from the scalp. The 
similarity between the two genera has been recognized. Sabouraud (1904) 
acknowledged the similarity in his choice of the specific epithet for his 
species P. malassezii and later, Acton and Panja (1927) even chose to 
keep the yeasts in a single genus by creating a second Malassezia species, 
M. ovalis for the scalp organism. 
 A second pityrosporum species, P. pachydermatis, was described 
after the isolation of yeast with a similar morphology to that of P. ovale, 
from the skin of a captured Indian rhinoceros (Rhinoceros unicornis) 
(Weidman 1925). In 1951 Gordon described a third species, P. 
orbiculare.  
Although this was associated with healthy skin, he also identified 
his yeast with the organism M.furfur. The agent pityriasis versicolor 
which is recognized in vivo in infected scales. 
The need to assign all of these yeasts to a single genus has long 
been recognized by taxonomists. The genus Malassezia created by 
Baillon predates Sabouraud's Pityrosporum, so it has precedence and is 
recognized as the correct name in the taxonomic publication. The species 
mentioned above were all accommodated in the genus Malassezia by 
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Yarrow and Ahearn in 1984. The lipid dependent organisms although 
showing diversity in their morphology, were all placed in the original M. 
furfur as a single taxon. The species included the type culture of P. ovale 
(CBS 1878) as well as the new type of M. furfur (CBS7019). At the same 
time P. pachydermatis was recognized as M. pachydermatis although the 
species had been assigned to Malassezia in 1935. Later Simmons and 
Gueho (1990) described an additional lipid-dependent species, M. 
sypodialis in 1996, four further species M. globosa, M. slooffiae, M. 
restricta and M. obtuse were added to the genus and all seven were 
distinguished by their morphology, physiology and also by molecular 
features (Gueho, et al. 1996). 
1.2.1.3 Characteristics of Malassezia spp. 
The morphology of Malassezia 
1.2.1.3.1 Morphology in vivo  
 As the yeasts of the Malassezia spp. are members of the normal 
skin microbiota, particularly in areas rich in sebaceous glands they are 
readily observed by microscopic examination of material for these sites. 
The conventional method of treating skin scales in 20-30% 
potassium hydroxide (KOH) for mycological investigation is satisfactory 
for their observation in vivo, but their appearance is greatly enhanced if 
ink (Parker Permanent Blue/Black Quink) is incorporated with the 
potassium hydroxide in equal proportion. M spp. takes up the stain 
immediately so the organisms appear blue against a clear background. 
Also KOH mount for superficial infections using cellophane tape for 
detected fungal elements (Thirumurthy, 2002). 
 The cellular morphology shown by the organisms in skin 
specimens is sufficiently characteristic for them to be immediately 
identified as Malassezia spp. The main feature of the cell is the 
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appearance given by their method of cell division, i.e. monopolar budding 
and the resulting formation of the scar or collaret at the base of the bud. 
There is however considerable variation in the cell shape and spherical, 
ovoid or elongated cells can be observed in pathological material. Several 
forms may colonize a single site, or groups of yeasts may be observed 
showing a unique morphology (Figure 1.1). (Guillt, et al 1996). 
 
Figure 1.1 Culture of M. furfur on Dixon's agar 
 
The appearance of the organism in scales from pityriasis versicolor 
lesions is the characteristic feature which, in fact, gives the laboratory 
diagnosis of this disease. The spherical yeasts, 2-8µm in diameter are 
arranged in clusters and they are always associated with hyphae which 
consist of elements 10-25µm wide. They are aligned end to end or 
separated; so that they form septate, angular filaments of varying lengths. 
This is the classic form of the organism as seen in cases of 
pityriasis versicolor in temperate countries.  
In tropical countries the appearance of the organism in the skin 
may reveal yeasts, which are ovoid or cylindrical in shape together with 
filaments. 
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1.2.1.3.2 Morphology in vitro 
 The descriptions given here for the colonial and microscopic 
morphology of the cultures of Malassezia spp. are based on cultures 
grown on a medium modified from the Dixon formula described by 
(Kindo, et al. 2004). The medium consisted of 3.6% malt extract, 0.6% 
mycological peptone 2% desiccated ox bile, 1% tween 40, 0.2%  
glycerol, 0.2% oleic acid and 1.2% agar. The medium was always used 
within one week of preparation and incubation was at 32˚C. After at least 
2 short-term transfers to ensure actively growing organisms, the growth 
was assessed after incubation for 10 days. The species were recognized in 
comparison with isolates previously confirmed according to the 
molecular studies of Gueho, et al. (1996).  
 The colonies of Malassezia spp. have a characteristic brittle texture 
which is particularly pronounced in some species. Colonies on Sabouraud 
dextrose agar overlaid with olive oil and incubated at 30° C are cream to 
yellowish, and typically smooth to slightly wrinkled (Figure 1.1) 
(Kurtzman, and Fell, 2000). 
When a potion of a colony is removed with an incubation loop or 
needle, it is difficult to prepare an even suspension on a glass slide or on 
the surface of an agar medium, because the cells stick together forming 
small clumps. 
Malassezia furfur forms thick, convex or umbonate colonies. The 
surface is usually smooth but rough variants occur. The texture is soft and 
the cells are easier to emulsify than those of other Malassezia spp. the 
color of the colonies is cream.  
 The cellular morphology is variable with elongated, spherical or 
oval yeasts but most isolates show elongated cells reaching 6.0 µm in 
length. 
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Malassezia sympodialis (Simmons and Gueho 1990) forms flat or 
slightly convex colonies, cream to buff in color with smooth shiny 
surface. The yeasts are small 2.5-5 µm in length, ovoid in shape. 
Malassezia pachydermatis: (Weidman, 1925) forms thick, pale-
colored, convex colonies with a smooth surface, similar to M. furfur. As 
this species is not lipid dependent, the cells are small 2.5-4 µm in length. 
Malassezia globosa: (Gueho, et al. 1996) is a species that 
corresponds morphologically to P. orbiculare, as described by Gordon 
(1951a). It produces slow-growing, rough colonies with a deeply folded 
surface, cream to buff in color and a texture that is very brittle and 
particularly difficult to emulsify. The cells are spherical, reaching 6-8 µm 
in diameter. 
Malassezia slooffiae: (Gueho, et al. 1996) is less frequently 
isolated from humans but appears to be associated particularly with the 
skin of pigs. It has colonies with a finely folded surface, cream to buff in 
color and brittle texture. The cells are small and cylindrical, 1.5-3.5 µm in 
long. 
There are also two other species; M. restricta and M. obtusa which 
are identified by (Gueho, et al 1996). 
1.2.1.4 Growth requirements 
 With the exception of M. pachydermatis, Malassezia spp. has an 
absolute requirement for lipids which can be supplied by the inclusion of 
medium or long chain fatty acids in the culture medium  
Natural products have been used as supplements and the most 
frequent has been olive oil, or its principal ingredient oleic acid, usually 
as an overlay on a solid medium. More satisfactory for the recognition 
and enumeration of colonies is a medium where the lipid is incorporated 
as an emulsion, such as the modified Dixon agar. Enhanced recovery of 
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Malassezia spp. on primary cultures of skin samples or skin surface 
washings was reported by Leeming and Notman (1987) when comparing 
their formula with other published media. However, differences between 
species in colonial morphology are more pronounced on the modified 
Dixon agar which has been used for the culture illustrated. The lipids 
incorporated in these various media include oleic acid, olive oil, glycerol 
monostearate, tweens and lipids present in bile salts and cows' milk. The 
use of tweens as a sole lipid source.  
This indicates the existence of variation among isolates of 
Malassezia spp. in their requirements for specific lipids, and points to a 
factor in their physiological properties which aids in the differentiation of 
individual species.  
Three species of Pityrosporum (Malassezia) that were recognized 
at the time and subsequent studies have explored the requirement for 
lipids as supplied by the incorporation of tween 20, 40, 60 and 80 in the 
medium to confirm the differentiation shown by other criteria (Gueho, et 
al. 1996). 
Other growth factors found that, although isolates of the 
Pityrosporum (Malassezia) were stimulated by the presence of glucose 
and of asparagines in the medium, they were not essential for the 
recovery of the yeasts. 
Malassezia pachydermatis is stimulated by the inclusion of lipids 
in the culture medium but it is not an absolute requirement for the growth 
of this species. Routine laboratory media may therefore be used for the 
isolation and maintenance of M. pachydermatis. However, isolates have 
been reported where growth was poor or absent when transfers were 
made from primary cultures or from cultures prepared on a lipid-
containing medium onto a lipid-free substrate (Bond and Anthony, 1995).  
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To obtain the correct identification, it is important to investigate 
any apparent lipid-dependent cultures from animal sources by repeated 
attempts to subculture without lipids and by careful study of the micro 
morphology of the yeasts. 
 Although most Malassezia spp. are able to grow at 37˚ C, this 
temperature is not recommended because there are some isolates that will 
be inhibited. The optimum temperature for growth of most of the species 
is between 32˚ C and 35˚ C, and all the isolates described here have been 
cultured and maintained at 32˚C for good growth (Kindo, et al. 2004). 
It is essential to use a freshly prepared medium and a humid 
atmosphere. If Petri dishes are used and depending on the conditions in 
the incubator, they may need to be in side the container or bag to retain 
sufficient moisture. Growth will also occur under microaerophilic 
conditions. 
1.2.1.5 The ecology of Malassezia spp. 
 The natural habitat for Malassezia spp. is the skin of worm blood 
animals. Although most studies on these organisms have been concerned 
with the yeast biota of human skin, the genus has been frequently 
reported from animal sources and a wide variety of hosts is now 
recognized (Guillot, 1994).  
In human host, the distribution of these lipophilic yeasts has been 
shown to reflect the density of sebaceous glands so that the highest 
numbers are found on the scalp, face and central areas of the chest upper 
arms and back (Ellis, 2005).  
They can often be seen in large numbers of patches in skin, 
particularly colonized hair follicles, but they can also be scattered among 
the coenocytes or in groups associated with lipid droplets in the skin 
scales (Figure 1.2, Bolognia, et al. 2003). 
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Figure 1.2 Shape, color and the place of spread of MF on the skin  
 
 The estimation of numbers of organisms has been achieved by 
several methods such as the direct microscopy of tape stripping from the 
skin, culture of serial dilutions from scrub washings and the estimation of 
colony-forming units from a contact plate where the agar surface is 
pressed against the area of skin to be sampled. 
 A correlation between the prevalence of Malassezia spp. and age of 
the subject has been observed with a low recovery in infants and an 
increase occurring at puberty. The estimates of the prevalence given in 
these publications showed an increase up to age 12 years and 15 years. 
which is related to the age when the activity of the sebaceous glands 
increases, so giving a higher concentration of skin lipids. 
Surveys on the presence of these yeasts on the skin of young babies 
in hospital environment have shown an increase in the prevalence of M. 
furfur with figures reaching 84% in neonatal special care units (Bell, 
1988). However, a report from Thailand on the recovery of M. furfur 
from 47% of babies, even in a group of healthy neonates, indicates that 
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climatic or genetic influences may also be relevant in the colonization of 
neonatal skin (Imwidthaya and Thianprasit, et al. 1988).  
The presence of yeasts of Malassezia spp. on the skin in these 
situations would provide the source of infection for catheter-associated 
systemic infections which have been reported in neonatal units.  
Epidemiological studies to trace the transfer of organisms in 
outbreaks of breaks of bloodstream infections are now becoming 
possible, with the development of molecular techniques to distinguish 
different strains (Welbel et al. 1994). However, an external source of 
infection must always be indicated when M. pachydermatis is involved, 
because this species is not normally encountered on human skin.  
1.2.1.6 Pathophysiology  
 Malassezia furfur is a lipophilic, saprophytic, budding, unipolar, 
dimorphic, gram-positive, double-walled, oval- to round yeast. M furfur 
is part of the normal skin flora. It is suggested that the similar yeasts P. 
orbiculare and P. ovale are actually identical and that they are 
morphologic variants of M. furfur. 
 Malassezia yeasts are classified as superficial mycoses that by 
definition do not invade past the cornified epithelium. In pityrosporum 
folliculitis (PF), however, the organism is present in the ostium and 
central and deep segments of the hair follicle. 
Malassezia yeasts require free fatty acids for survival. Usually, 
they are found in the stratum corneum and in pillar folliculi in areas with 
increased sebaceous gland activity such as the chest and back.  
1.2.1.6.1 Frequency of spread 
i. United States  
 Tinea versicolor occurs more frequently in areas with higher 
temperatures and higher relative humidity. The national prevalence of this 
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condition is 2-8% of the population. Malassezia organisms can be found 
on the skin in 75-98% of the healthy people. These organisms are part of 
the normal skin florae of many individuals who do not have signs or 
symptoms of folliculitis or other disease. Colonization by M furfur begins 
soon after birth, and the peak presence of the yeasts occurs in late 
adolescence and early adult life, coinciding with increasing activity of 
sebaceous glands and concentration of lipids in the skin (Oswald, et al. 
2006). 
ii. International 
 Tinea versicolor occurs worldwide, with prevalence reported to be 
as high as 50% in the humid, hot environment of Western Samoa and as 
low as 1.1% in the colder temperatures of Sweden. (Oswald, et al. 2006). 
 pityrosporum ovale is present on 90-100% of the surface of healthy 
skin; higher numbers of the yeast are present on the chest and back. 
Certain climates influence the percentage of people with P. ovale and the 
number of people with pityrosporum folliculitis (PF). People living in 
warm and humid climates have a higher incidence of PF. One clinic in the 
Philippines documented that 16% of all patient visits were a result of PF 
(Jacinto-Jamora, et al, 1991). 
iii. Sudan and Yemen 
Tinea versicolor commonly spread in Sudan and Yemen because 
all factors which cause this disease are found in these countries. There are 
no national statistical records for this disease in these countries. There are 
some statistics from some hospitals such as the information center at the 
Skin and Sexually transmitted diseases, Khartoum Teaching Hospital.  
The records show the patients who visited the out-patient clinics 
(Emergency room) during 2007 classified according to the type of disease 
(table 1.2).  
 
 17
Table 1.2 Number of patients visited the out-patient clinics of Skin 
and Sexually Transmitted Diseases, Khartoum Teaching Hospital during 
2007. 
 
Type of disease Number of patients 
during 2007 
Number of patients 
per day 
Tinea versicolor 2673 9 
All others tinea 6621 22 
Fungal infection 1115 4 
 
From the information in the table 1.2 above, nine patients with TV 
visit only one out-patient clinic per day. 
In Yemen no statistical records for such patients were available. 
1.2.1.6.2 Morbidity/ Mortality  
Tinea versicolor is a benign skin disease that causes scaly macules or 
papules on the skin. As the name implies (versi means several), the 
condition can lead to discoloration of the skin, with colors ranging from 
white to red to brown. The condition is not considered to be contagious 
because the causative fungal pathogen is a normal inhabitant of the skin.  
The skin of an individual who is affected may be either 
hypopigmented or hyperpigmented. In the case of hypopigmentation, 
tyrosinase inhibitors (resulting from the inhibitory action of tyrosinase of 
dicarboxylic acids formed through the oxidation of some unsaturated 
fatty acids of skin surface lipids) competitively inhibit a necessary 
enzyme of melanocyte pigment formation. In hyperpigmented macules in 
tinea versicolor, the organism induces an enlargement of melanosomes 
made by melanocytes at the basal layer of the epidermis (Burkhart, 2006).  
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1.2.1.6.3 Race 
 Although the alteration in skin pigmentation is more apparent in 
darker-skinned individuals, the incidence of Tinea versicolor appears to 
be the same in all races (Burkhart, 2006).  
1.2.1.6.4 Sex 
 Reports vary from a male-to-female ratio of 1:1 to a predominance 
of one or the other sex. In the literature, the consensus is that the female-
to male ratio is 1.5:1 (Burkhart, 2006). 
1.2.1.6.5 Age 
 The disease is recognized as one that affects youths and young and 
middle-aged adults; PF is most common in those aged 13-45 years 
(Archer-Dubon, et al., 1999).  
 In the United States, the disease is most common in person age 15-
24 years, when the sebaceous glands are more active. 
Jena, et al., (2005) studied pityriasis versicolor (PV) in pediatric age 
group and concluded that PV is not an uncommon disease among 
children in the tropics. There is a sudden resurgence of cases in the hot 
monsoons and even infants are not spared. 
1.2 1.7 Skin diseases caused by Malassezia species 
 The skin as an outer cover of the body is prone to several types of 
disease. These are caused by different types of microorganisms. Skin 
infections could be bacterial e.g. impetigo, cellulites and acne; fungal e.g. 
pityriasis versicolor, candidiasis; viral e.g. herpes zoster and herpes 
simplex; parasitic e.g. scabies, pediculosis and leishmaniasis. The skin is 
also susceptible to many inflammatory conditions such as eczema and 
dermatitis. In addition to these disease, there are conditions that are 
related to pigmentation (Hyperpigmentation e.g. chloasma or 
hypopigmentation e.g. vitiligo). 
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Pityriasis versicolor is a chronic mild superficial infection of the 
stratum corneum the common spread mainly in the tropical area. 
1.2.1.7.1 Pityriasis versicolor 
 Synonyms: Tinea alba, Tinea versicolor, tinea flava, achromia 
parasitica and dermatomycosis furfuracea. 
Pityriasis versicolor is a common skin complaint in which flaky 
discolored patches appear mainly on the chest and back. The term 
"pityriasis” is used to describe skin conditions in which the scale appears 
similar to bran. The multiple colors arising in the disorder give rise to the 
second part of the name “versicolor” (Oakley, 2005). 
Pityriasis versicolor is a superficial fungal infection of the skin, 
appearing most commonly on the upper trunk, back, neck and upper 
aspect of the arms. 
The oval lesions caused by Malassezia yeast vary in color and can 
be hypopigmented (white) or hyperpigmented (black, brown, tan or pink) 
(Berman, 2006). There is a postulation that this disease occurs when 
Malassezia yeast that normally colonize the skin change from the round 
yeast form to a pathological mycelial form, which them invades the 
stratum corneum of the skin (Gupta, et al. 2004). 
It’s a chronic mild superficial infection of the stratum corneum 
caused by M. globosa, M. restricta and other member of the M. furfur 
complex. (Brooks, et al 2004, and Oakley, 2005). 
However, Crespo-Erchiga, et al. 2000; Aspiroz, et al., 2002; 
Gaitanis, et al. 2006; Rincon, et al. 2005; Morishita, et al. 2006; Prohic, 
2007 and Tajima, et al. 2008), conclude that M. globosa is the causative 
agent of PV.  
Most references, Ellis, (2005) and Pillinger, (2005) described 
Malassezia furfur as the causative agent of PV.  
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Kalinowska-Pujdak, et al., (2006) re that in pityriasis versicolor, M. 
globosa was the dominant species found in 62% of cases. In addition M. 
furfur was found in 60% of dandruff cases. 
PV is defined as a hypopigmented or depigmented variant of 
pityriasis versicolor characterized by maculous, partly pityriasiform, 
scaly depigmented lesions (Thomas, et al. 2005). 
 This superficial fungal infection has a world-wide distribution. The 
usual clinical feature is a macular rash of the upper trunk and shoulders 
with profuse fine scaling which usually fluoresces a golden color under 
the illumination of a Woods lamp (Ultraviolet light of 365 nm wave 
length). It is a chronic condition which is generally asymptomatic, 
although there are some reports of histological and immunological 
changes in the host (Marcon and Powell, 1992).  
The lesions may appear darker than the surrounding skin or as red 
patches but often, particularly if the patients are suntanned; the presenting 
feature is of depigmented area where the superficial infected scales have 
been shed.  
Aste et al. (2002) described PV as irregular, slightly scaly patches, 
varying in color red / light brown to white. The disease is caused by the 
invasion of the outer layers of the stratum corneum by Malassezia furfur 
after its conversion from the commensal to the parasitic filamentous 
form. The laboratory diagnosis is confirmed by the observation on 
microscopy of skin of the characteristic morphology of both filaments 
and yeasts of M. furfur which is usually abundant in the scales. 
 Pityriasis versicolor is a common skin disorder and generally 
appears in the late teens (adolescents) with a peak in the 20s, and is only 
rarely found in the aged. There is some variation found in the distribution 
of the lesions on the body according to the age and to the geographical 
location of the subject. The condition is uncommon in young children 
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but, when it does occur, the face is frequently involved, although this site 
is generally spared in adult patients at least in temperate zones (Terragni 
et al. 1991, Boralevi, et al., 2006). Facial lesions have been reported in 
tropical countries as also has the involvement of the lower abdomen and 
limbs (Bélec, et al., 1991). 
The appearance of oval yeasts associated with filaments is found 
more frequently in the tropics; it is also seen in sites such as the limbs, 
abdomen and the face. In contrast, patients in temperate climates 
generally show the classic form of the pathogen with spherical yeasts and 
the usual body distribution with lesions over the upper trunk. Invasion of 
the cornified skin and the host responses are both minimal. Discrete, 
serpentine, hipper or hypopigmented maculae occur on the skin, usually 
on the chest, upper back, arms or abdomen (Figure 1.2, Brooks, et al 
2004, Freedberq, et al. 2003). 
 
Malassezia folliculitis Pityriasis versicolor Seborrhoeic dermatitis 
 
Fig.1.3 Pathogenicity of infections with Malassezia spp. 
The conditions that influence the change from commensal to 
pathogen in the yeast are not fully understood, but the disease is certainly 
more prevalent in tropical climates and predisposing factors of the host 
have been shown to include increased temperature and humidity. The 
condition is also associated with transplant recipients, the administration 
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of systemic corticosteroids, malnutrition and possibly with pregnancy and 
the use of oral contraceptives.  
There does not appear to be any greater prevalence of pityriasis 
versicolor among subjects with HIV infection. Although humoral 
antibody responses to Malassezia spp. have been reported, there is no 
apparent increased reaction among patients with pityriasis versicolor.  
Various studies have also been undertaken on cell-mediated 
immunity, but they have given conflicting results (Ingham and 
Cunningham, 1993). The production of azelaic acid, a metabolite which 
can affect pigment formation in the skin, from cultural preparations of M. 
furfur has indicated a possible mechanism for the depigmentation seen in 
some patients. 
Mellen, et al. (2004) determine the frequency of visits for pityriasis 
versicolor and assess how it is being treated from the years 1990-1999. 
The result of this study reported 2.9 million visits per year in which PV 
was listed as diagnosis; this corresponds to a visit rate of 110 visits per 
100000 persons per year. 
1.2.1.7.2 Other superficial Diseases  
 Malassezia spp. yeasts have been implicated in other skin diseases 
such as seborrhoeic dermatitis (an inflammatory condition of the areas 
rich in sebaceous glands), folliculitis, dandruff, atopic dermatitis of the 
head and neck area, and seborrhea blepharitis (Barbanoj, et al. 2005, 
Tajima, 2005, Boralevi, 2006 and Pierard, et al. 2006). 
1.2.1.7.3 Seborrheic Dermatitis  
 Seborrheic dermatitis is a disease that causes flaking of the skin. It 
usually affects the scalp. In adolescents and adults, it is commonly called 
"dandruff." In babies, it is known as "cradle cap." Seborrheic dermatitis 
can also affect the skin on other parts of the body, such as the face and 
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chest, and the creases of the arms, legs and groin. Seborrheic dermatitis 
usually causes the skin to look a little greasy and scaly or flaky. 
 Seborrheic dermatitis most often occurs in babies younger than 3 
months of age and in adults from 30 to 60 years of age. In adults, it's 
more common in men than in women. The exact cause isn't known. The 
cause may be different in infants and adults. Seborrheic dermatitis may be 
related to hormones, because the disorder often appears in infancy and 
disappears before puberty, the cause might be the fungus, Malassezia. 
This organism is normally present on the skin in small numbers, but 
sometimes its numbers increase, resulting in skin problems. Seborrheic 
dermatitis has also been linked to neurologic disorders such as 
Parkinson's disease and epilepsy. The reason for this relationship isn't 
known. 
The results of the study of Nakabayashi (2000) on identification of 
malassezia species isolated from patients with seborrheic dermatitis 
showed the presence of Malassezia furfur. 
The treatment of Seborrheic dermatitis depends on its location on 
the body. Treatment also depends on the person's age.  
1.2.1.7.4 Seborrheic dermatitis of the scalp (dandruff) in adults and 
adolescents  
 Dandruff is usually treated with a shampoo that contains salicylic 
acid (some brand names: X-Seb®, Scalpicin®), the prescription medicine 
selenium sulfide (brand names: Selsun Blue®, Exsel®) or zinc pyrithione 
(some brand names: DHS Zinc®, Head & Shoulders®). These shampoos 
can be used 2 times a week. Shampoos with coal tar (some brand names: 
DHS Tar®, Neutrogena T/Gel®, Polytar®) may be used 3 times a week. If 
the dandruff starts, treat by using one of these shampoos daily until the 
dandruff is controlled, and then used 2 or 3 times a week.  
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Steroid lotion once or twice daily, was a prescribed medicine in 
addition to the shampoo for skin creases in adolescents and adults.  
1.2.1.7.5 Seborrheic dermatitis of the scalp (cradle cap) in babies  
 Seborrheic dermatitis of the scalp in babies is treated with products 
that are not as strong as those used in adults. Start with a mild, 
nonmedicated baby shampoo. Brushing the baby's scalp with a soft brush, 
like a toothbrush, can help loosen scales or flakes. Massage or brush the 
baby's scalp gently since a break in the skin makes it vulnerable to 
infection. If a nonmedicated shampoo doesn't work, it is advised to talk to 
a doctor about switching to a shampoo that contains tar or prescription 
shampoo that contains 2% ketoconazole (Nizoral®). Gentle steroid lotions 
or creams are used to treat Seborrheic dermatitis in the skin creases of 
babies (Rebert, et al., 2007). 
1.2.1.8 Systemic infections 
 Malassezia spp. has been identified as agents of opportunistic 
systemic infections. The successful isolation of M. furfur from deep sites 
using lipid containing media has followed the recognition of the 
characteristic yeasts in tissues or in deposits from body fluids. Most cases 
of systemic infection have been in neonates and associated with the 
administration of lipid emulsions through an indwelling central venous 
catheter. There is a wide spectrum in the severity of symptoms in these 
cases and the role of Malassezia spp. is not easy to assess because the 
patients often have serious complications as the result of their permaturity 
or their underlying disease. Clusters of blood stream infections have been 
reported in special care neonatal units involving both M. furfur and M. 
pachydermatis (Macron and Powell, 1992, Welbel et al. 1994, and Chang 
et al. 1995). 
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1.2.1.9 Identification of isolates 
 There are no diagnostic values for investigations of the skin 
diseases because these organisms could be isolated from most, if not all, 
individuals as part of the normal microbiota. For this reason, cultures of 
Malassezia spp. are rarely prepared to confirm the diagnosis of the 
superficial infections. Cultural isolates will nevertheless be of value to the 
laboratory if susceptibility studies with antifungal preparations are 
requested. 
 In systemic infections, however, the recognition and recovery of 
the yeasts are essential to achieve the correct diagnosis. The presence of 
these yeasts should be suspected particularly where patients are receiving 
lipid through a central venous catheter (Nelson et al. 1995). 
The initial identification of Malassezia spp. isolates relies largely 
on the observation of the morphology of the yeasts that is so typical of the 
genus.  
As a result of their exacting nutritional requirements, they are 
usually only encountered when they have been specifically cultured, and 
confirmation of the genus can readily be performed by microscopy. In 
further identification the naming of individual species requires 
recognition of the particular characteristics described elsewhere in this 
chapter concerning the colony form and shape of the yeast cell, and this 
would only be confidently achieved after gaining some familiarity with 
the Malassezia genus. 
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1.2.1.9.1 Laboratory diagnosis  
i. Clinical material: skin scraping from patients with superficial 
lesions, blood and indwelling catheter tips from patients with 
suspected fungaemia. 
ii. Direct microscopy: skin scrapings taken from patients with PV 
stain rapidly when mounted in 10% KOH, glycerol and Parker ink 
solution and show characteristic clusters of thick walled round, 
budding yeast-like cells and short angularhypha forms up to 8µm 
in diameter. These microscopic features are diagnostic for M. 
furfur and culture preparations are usually not necessary. 
iii. Culture: is only necessary in cases of suspected fungaemia. M. 
furfur is lipophilic yeast, therefore, in vitro growth must be 
stimulated by natural oils or other fatty substances. The most 
common method used is to overlay Subouraud's dextrose agar 
containing cycloheximide (actidione) with olive oil. 
iv. Serology: there are no commercially available serological 
procedures for diagnosis of Malassezia infections. 
v. Identification: microscopic evidence of inipolar, broad base 
budding yeast cells and special lipid requirements for growth in 
culture are usually diagnostic (Ellis, 2005).  
1.2.1.9.2 Molecular studies 
 A number of molecular methods have been applied to the 
Malassezia genus. Hort, et al. (2006) used molecular techniques to 
differentiate ten species of Malassezia spp. The status of species was 
confirmed in 1990 by Simmons and Guého by estimation of the 
percentage G + C content of DNA and by the resuscitation of DNA 
between different isolates and recently karyotyping, using pulse field 
electrophoresis.  
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Tajima, et al., (2005) used molecular analysis of Malassezia spp. 
isolated from three cases of Akatsuki diseaseth analyzed using PCR based 
non culture method. Sequencing of the large subunit of rRNA (Guillot 
and Guého, 1995), have added more information on the taxonomy of the 
genus so that species suspected by morphological and immunological 
studies have been confirmed and also use of RAPD-PCR for analyses 
Malassezia spp. from the disease (Guého, et al. 1996 and Rinaldo, et al. 
2006). 
Strain typing is feasible using the comparison of the restriction 
fragment length polymorphisms revealed after treatment of extracted 
DNA and this has been applied in situations where clusters of blood 
stream infections with M. pachydermatis have occurred (Chang et al., 
1995). In addition, the application of molecular probes and the use of 
polymerase chain reaction methods to discriminate strains even further 
are now possible (Gaitanis, et al. 2006).  
Morishita, (2006) used molecular analysis for Malassezia 
microflora from patients with PV and Seborrhoeic dermatitis. 
1.2.1.9.3 Clinical appearance 
 Most individuals with Tinea versicolor complain of cosmetically 
disturbing, abnormal pigmentation. The involved skin regions are usually 
the trunk, the back, the abdomen, and the proximal extremities. The face, 
the scalp, and the genitalia are less commonly involved. The color of each 
lesion varies from almost white to reddish brown or fawn colored. A fine, 
dust like scale covers the lesions. Patients often complain that the 
involved skin lesions fail to tan in the summer. Occasionally, a patient 
also complains of mild pruritus. 
 
 
 28
1.2.1.9.4 Physical forms 
Tinea versicolor can present in 3 forms: 
Form1: 
 The most common appearance of the disease is as numerous, well- 
marginated, finely scaly, oval-to- round macules scattered over the trunk 
and or the chest, with occasional extension to the lower part of the 
abdomen, the neck, and the proximal extremities. 
The macules tend to coalesce, forming irregularly shaped patches 
of pigmentary alteration. As the name versicolor implies, the disease 
characteristically reveals a variance in skin hue. The involved areas can 
be either darker or lighter than the surrounding skin.  
The condition is more noticeable during the summer months when 
the discrepancy in color from the normal skin becomes more apparent. 
Light scraping of the involved skin with a scalpel blade 
characteristically yields a copious amount of keratin. 
Form2: 
 An inverse form of Tinea versicolor also exists in which the 
condition has an entirely different distribution, affecting the flexural 
regions, the face, or isolated areas of the extremities. This form of Tinea 
versicolor is more often seen in immunocompromised hosts. This form of 
the disease can be confused with candidiasis, seborrheic dermatitis, 
psoriasis, erythrasma, and dermatophyte infections. 
Form3: 
 The third form of M furfur infections of the skin involves the hair 
follicle. This condition is typically localized to the back, the chest, and 
the extremities. 
This form can be clinically difficult to differentiate from bacterial 
folliculitis. The presentation of Pityrosporum folliculitis is a 
perifollicular, erythematous papule or pustule. 
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Predisposing factors include diabetes, high humidity, steroid or antibiotic 
therapy, and immunosuppressant therapy. Additionally several reports 
reveal that M furfur also plays a role in seborrheic dermatitis. 
1.2.1.10 Causes 
Most cases of tinea versicolor are in healthy individuals with no 
immunologic deficiencies. Several factors predispose some people to 
develop this condition. These factors include: 
• Humidity 
• Sweating 
• Oily skin  
• High temperature (Aljaber, 2005 and Rademaker, 2005). 
• Cushing disease. 
• Malnutrition. 
The reason why this organism causes Tinea versicolor infection in 
some individuals while remains as normal flora in others is not entirely 
known. Several factors, such as the organism's nutritional requirements 
and the host's immune response to the organism, are significant. 
Faergemant, 2000, Ogunbiyi, 2005 and Ashbee, et al. 2002, 
mentioned some factors such as extensive work, which change the 
organism from it's commensally to its pathogenic state, genetic factor, 
hyper-hidrosis, depressed immunity, occlusion of the skin, malnutrition, 
hereditary factors and abuse of corticosteroids. 
Psychiatric patients are more suspected with skin disorders 
specially PV (Kuruvila, et al., 2004). 
The organism is lipophilic, and lipids are essential for its growth in 
vitro and in vivo. Furthermore, the mycelial stage can be induced in vitro 
by the addition of cholesterol and cholesterol esters to the appropriate 
medium. Because the organism more rapidly colonizes humans during 
 30
puberty when skin lipids are increased more than that of adolescent levels 
and tinea versicolor is manifested in sebum-rich areas (e.g. chest, back), 
individual variations in skin surface lipids are hypothesized to play a 
major role in disease pathogenesis . However, patients with tinea 
versicolor and control subjects do not demonstrate any quantitative or 
qualitative differences in skin surface lipids. Skin surface lipids are 
significant for the normal presence of M furfur on human skin, but they 
probably play little role in the pathogenesis of Tinea versicolor. 
Another significant causative factor is the patient's immune system. 
Although sensitization against M furfur antigens is routinely present in 
the general population (as proven by lymphocyte transformation studies), 
lymphocyte function on stimulation with the organism has been shown to 
be impaired in patients who are affected (Oswald, et al., 2006). 
1.2.1.11 Treatment of Pityriasis versicolor  
To control the disease, predisposing factors like increased 
sweating, sharing towels and clothes, malnutrition and synthetic clothing 
must be avoided (Rao, et al. 2002). Pityriasis can be treated by 
antimycotics, followed by ultraviolet therapy (Thoma, et al. 2005, and 
Darsow, et al. 2005). Pityriasis versicolor can also be treatment with 
propylene glycol, sodium thiosulphate solution, terbinafine gel, ciclopirox 
cream or solution and Zinc pyrithione shampoo. (Faergemann, 2000, 
Oakley 2005 and Ellis 2005). 
Azoles treatment 
There are different types of azoles antifungal drugs (imidazole, 
fluconazole, itraconazole, clotrimazole, miconazole, econazole and 
Ketoconazole in various formulations). They are used systemically or 
topically for the treatment of PV.  
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Ketoconazole is used to treat systemic and superficial mycoses by 
inhibiting sterol synthesis in fungi (Chou and Lin, 2000). 
Itraconazole is a broad spectrum triazole antifungal agent which 
have favorable pharmacodynamic and pharmacokinetic profiles and is 
available is both oral and i.v. formulations which have a wide range of 
treating superficial fungal infections including difficult to treat 
dermatophytoses and onychomycoses (Pierard, et al. 2000).  
The efficacy of Itraconazole in the prophylactic treatment of PV 
was studied by Jan Faergemann et al. (2002). They concluded that 
prophylactic itraconazole treatment is efficacious for PV after six months, 
as is itraconazole treatment of PV.  
Rukayadi, and Hawang, (2007) reported that Xanthorrhizol which 
is isolated from Curcuma xanthorrhiza inhibited growth of M. furfur and 
M. pachydermatis and is a useful alternative for treating Malassezia-
associated diseases. Terbinafine and benzyl peroxide can also be used 
(Vermeer, et al. 1997). 
Butenafine  
Is a synthetic benzylaine antifungal that is used as fungicidal 
against PV (Gupta, 2002). 
Oral or topical treatments with Azoles (ketoconazole, imidazole, 
fluconazole, itraconazole, clotrimazole   ect.) are expensive and have a 
risk of kidney and liver toxicity (Usatine, 2000). 
Selenium Sulfide 
Selenium sulfide is an anti-infective agent used as a shampoo to 
relieve itching and flaking of the scalp. In people prone to dandruff, an 
uninflamed form of seborrhoeic dermatitis, the fungus Malassezia can 
cause irritation, itching and increased shedding of dead skin cells in area 
of skin scalp. Selenium sulfide treats the excess shedding and irritation by 
eliminating excess scalp fungus and controlling the rate of shedding of 
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dead skin cells. In addition to controlling the symptoms of dandruff, it is 
also used to treat PV (a fugal infection of the skin) and Tinea capitis, (a 
fungal infection of the scalp). 
Selenium sulfide is prepared as 1% lotion and 2.5% of shampoo 
(Selsun®, Exsel®). It must be used by prescription and not used frequently 
because it is very toxic. It also has other side effects such as oiliness or 
dryness of hair or scalp, increase in normal hair loss and hair 
discoloration (Ngan, et al., 2005). 
PV can be treated topically by selenium sulfide shampoo but 
recurrence following treatment with these agents is likely and rapid 
(Savin, 1996).  
Sulfur 
Sulfur has antifungal, antibacterial and keratolytic activity. In the 
past, it was widely used in dermatological disorders such as acne 
vulgaris, rosacea, seborrheic dermatitis, dandruff, pityriasis versicolor, 
scabies and warts. Adverse events associated with topically applied sulfur 
are rare and mainly involve mild application site reactions (Gupta, and 
Nicol, 2004). 
Recurrences and side effects for the drugs are used for treatment of 
Pityriasis versicolor occur commonly as described by Ogunbiyi, and 
George (2005). It is characterized by fine scaly macular eruption and has 
chronic relapsing nature and it is due to infection with Malassezia 
whether treated topically or systemically, high relapse may occur so 
prophylactic treatment is advocated in preventing relapses. 
Malassezia furfur the main causative agent of pityriasis versicolor 
being a part of the normal flora on the human skin, is impossible to 
eradicate (Bandyopaphyay 2007 and Oakley 2005). 
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Traditional products 
Stone from the volcanic diggings crushed and dissolved in water 
are used traditionally, over the years, in Yemen for the treatment of PV 
with no observed recurrence of the infection. Those stones are the focus 
of the present study. 
1.3 Cutaneous Mycosis 
1.3.1 Dermatophytes 
Dermatophytes are fungi that require keratin for growth. These 
fungi can cause superficial and cutaneous infections of the skin, hair, and 
nails.  
Dermatophytes are spread by direct contact from other people 
(anthropophilic organisms), animals (zoophilic organisms), and soil 
(geophilic organisms), as well as indirectly from fomites.  
Dermatophyte infections can be readily diagnosed based on the 
history, physical examination, and wet smears treated with potassium 
hydroxide (KOH). Diagnosis occasionally requires Wood's lamp 
examination and fungal culture or histologic examination (Barry, 2003) 
Dermatophytes obtain nutrients from keratinized material from the 
hair, skin and nail. Dermatophytes usually do not invade living tissue of 
the host, but colonize the outer layer of the skin. Clinical condition 
known as ring worm or tinea occurs due to host reaction to the invading 
agent. 
Abanmi et al. (2008) investigated the characteristics of superficial 
fungal infections in the Riyad region of Saudi Arabia and concluded that 
the prevalence of superficial fungal infections (SFIs) were twofold 
greater in females than males. Children were most commonly affected by 
Tinea capitis, whereas adults generally suffered from Tinea pedis. The 
frequency of onychomycosis was nearly three times higher in adults. This 
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study clearly shows that SFIs are of concern in both genders and in all 
age groups. 
1.3.1.2 Genera of dematophytes 
There are three genera belonging to Dermatophytes 
• Microsporum 
Fungi in this genus invade hair and skin but not nail. They 
produces numerous macroconidia and microconidia is also present  
• Trichophyton 
The fungi here invade hair, skin and nail. They produce 
numerous microconidia and macroconidia is rare. 
• Epidermophyton 
Fungi invade nail and skin but not hair. They produce 
numerous macroconidia but microconidia are absent.  
1.3.1.3 Mycology of dermatophyte infections 
Mycology is the study of fungi. Dermatophyte fungi are the 
ringworm fungi (Tinea). They depend on their host, which may be an 
animal ("zoophilic") or a human ("anthropophilic") and need to spread 
from one host to another to survive. Dermatophytes may also prefer to 
live in the soil ("geophilic").  
Anthropophilic dermatophytes are so well adapted to living on 
human skin that they provoke minimal inflammatory reaction. Zoophilic 
or geophilic dermatophytes will often provoke a more vigorous 
inflammatory reaction when they attempt to invade human skin.  
There are three genera of dermatophytes, recognised by the nature of their 
macroconidae (asexual spores):  
Trichophyton ("T")  
Microsporum ("M")  
Epidermophyton ("E")  
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There are about 40 species. Their spores can live for more than a 
year in human skin scales in the environment.  
Anthropophilic organisms include  
Trichophyton rubrum (Worldwide and most common in New Zealand)  
Trichophyton interdigitale  
Trichophyton tonsurans (Worldwide and very common in the USA)  
Microsporum audouinii (Eastern Europe and rare in North America) 
Trichophyton violaceum (North Africa, East Africa, and Middle East) 
Microsporum. ferrugineum (Africa, India, China and Japan) 
Trichophyton schoenleinii (Europe, Asia and Africa) 
Trichophyton megninii (Spain, Portugal and Sardinia) 
Trichophyton soudanense (Africa) 
Trichophyton yaoundei  
Zoophilic organisms include  
Microsporum canis (originating from cats and dogs)  
Trichophyton equinum (originating from horses)  
Trichophyton erinacei (originating from hedgehogs and other animals)  
Trichophyton verrucosum (originating from cattle)  
Microsporum nanum (originating from pigs)  
Microsporum distortum (a variant of M canis).  
Geophilic organisms include:  
Microsporum gypseum  
Microsporum fulvum  
1.3.1.4 Diagnosis 
The presence of a dermatophyte infection is confirmed by 
microscopy and culture of skin scrapings. 
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1.3.1.5 Cutaneous Infections 
These fungi are not really parasitic in the sense of attacking living 
tissue. They attack the dead cells of the epidermis, and cause a kind of 
dermatitis. The irritation caused by the fungus stimulates the skin cells to 
divide more rapidly. This means that more flakes of skin containing 
infective mycelium will be shed.  
Some fungi can grow on your skin, causing several different 
conditions including jock itch, athlete's foot and ringworm. These fungi 
are known as dermatophytes. 
Twenty of the dermatophytes grow only on people, causing 
diseases called ‘Tineas'. These occur on various parts of the body. They 
may affect the scalp ‘Tinea capitis' (ringworm of the scalp), the groin 
‘Tinea cruris' (jock itch) and the feet ‘Tinea pedis' (athlete's foot).  
‘Tinea capitis' is often caused by Microsporum audouinii or 
Trichophyton tonsurans. 
Ringworm of the scalp is recognized as round, spreading patches of 
irritation and baldness. 
‘Tinea cruris' ‘Crotch Rot' and ‘tinea pedis' athlete's foot is 
caused by Epidermophyton floccosum produces short-lived infections 
and relies on shed skin for quick spread to other hosts.  
Usually these fungi are contracted in change rooms from small 
pieces of shed skin, but spores can survive in carpets and upholstery for 
up to 2 years.  
Microsporum canis has its reservoir in the cat. It can cause 
ringworm of the scalp or body. It can be transmitted to dogs or people but 
will die out after one or two person to person transfers. 
Trichophyton rubrum causes chronic infections of the foot and 
toenails and can produce infective material for several years (Zuber, and 
Baddam, 2001).  
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Trichophyton verrucosum is one of the more common chronic 
zoophilic dermatophytes. Its presentation is diverse, including aggressive 
inflammatory skin lesions, and it can be accompanied by constitutional 
symptoms, such as fever and lymphadenopathy (Silver, et al. 2008). 
1.3.1.6 Identification of Common Dermatophytes. 
Microscopic morphology of the micro and macroconidia is the 
most reliable identification character, but it needs a good slide 
preparation and stimulation of sporulation in some strains. Culture 
characteristics such as surface texture, topography and pigmentation are 
variable and are therefore the least reliable criteria for identification. 
Clinical information such as the site, appearance of the lesion, geographic 
location, travel history, animal contacts and race is also important, 
especially in identifying rare non-sporulation species like M. audouini, T. 
concentricum and T. schoenleinii etc. Note: mating experiments are not 
practical for the clinical mycology laboratory. 
Three genera are recognized: 
Epidermophyton: Smooth thin-walled Macroconidia only present, no 
microconidia, colonies  have a green-brown to khaki color. 
Microsporum: Macroconidia with rough walls present, microconidia may 
also be present. 
Trichophyton: Microconidia present, smooth-walled macroconidia may 
or may not be present. 
1.3.1.7 Treatment 
Topical treatments for athlete's foot and ringworm are Tolnaftate 
(Tinactine®) Clotrimazole (Canesten®), haloprogin, miconazole nitrate, 
Ketoconazole, topical and systemic, and fluconazole.  
More persistent cases can be treated by oral doses of Griseofulvin, 
an antifungal antibiotic derived from Penicillium griseofulvum. 
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Gupta, et al. (2004) and Harrell, et al. (2000) used a new orally 
active fungicidal agent, terbinafine (SF 86–327, Lamisil®) in the 
treatment of patients with dermatophyte onychomycosis. 
Sulphite transporters could be a new target for antifungal drugs in 
dermatology, since proteolytic digestion of hard keratin would not be 
possible without prior reduction of disulphide bridges (Lechenne, et al. 
2007). 
1.4 The skin 
1.4.1 The structure of the skin 
 The structure of the skin is highly complex. The skin consists of 
three main parts, the epidermis (outer layer), underneath this layer, the 
dermis and subcutaneous tissue is located below the dermis and serves to 
attach the skin to the underlying structures (Figure 1.4).(from skin care 
analysis health care 2007). The thickness of the skin and of the individual 
layers varies in different parts of the body. 
• The epidermis  
 Morphologically distinct layers of the epidermis represent stages in 
the process of differentiation which the keratinocytes (about 90% of the 
epidermal cells) undergo during their migration from the basal layer, 
where they originate, to the skin surface. In healthy skin the total turnover 
time of keratinocytes from the basal layer to shedding averages four 
weeks. 
Dead keratinocytes (corneocytes) build up the horny layer; the 
stratum corneum. On most body areas the stratum corneum contains 10-
15 layers of horny cells, which vary between 0.5 and 1.5µm in thickness 
and between 30 and 50 µm in lateral diameter. Corneocytes are 
embedded in a matrix of intercellular lipids. This two-component system 
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is referred to by Elias 1983 as the bricks (cells) and Mortar (intercellular 
lipids) model. 
The epidermis layer divided into two layer Horny layer and Cellular 
layer. 
• The dermis  
 The region contains dense, irregular connective tissues and various 
types of cells, including fibroblast, histocytes (phagocytes), mast cells, 
hair follicles, sweat glands, superficial sebaceous glands and various 
amount of muscle are also found in this layer. The dermis is also the site 
of many of the key phases of the inflammation process. In numerous skin 
diseases it is the major barrier to the diffusion of most topically applied 
drugs. 
• The subcutaneous tissue 
 The subcutaneous fat (subcutis, hypoderm), which contain blood 
and lymphatic vessels and nerves. It provides a mechanical cushion and a 
thermal barrier; it synthesizes and stores readily available high energy 
chemicals (Aulton and Michael, 2003). 
1.4.2 The function of the skin 
 The skin is the largest organ of the body and performs a great 
number of functions. It acts as a barrier to physical, chemical, 
microbiological, heat, radiation, mechanical shock and electrical stimuli. 
It prevents the loss of vital body components and bars the entry of 
noxious substances from the environment into the body.  
The skin mediates sensation (pressure, heat, pain…etc.) and 
regulates body temperature. It also has a capability for synthesis and 
metabolism. In addition, the skin is very flexible and self-repairing. 
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Figure 1.4 Structure of the skin. 
 
1.4.2.1 Pharmacokinetic aspects 
 A detailed knowledge of the structure of the skin, and the 
numerous studies of the release and absorption of active ingredients with 
the aim of establishing generally valid criteria and the steady 
improvement in analytical methods now make it possible to formulate a 
dermatologic preparation fulfilling rational criteria in regard to 
pharmacokinetics. 
1.4.2.2 Drug administration and absorption  
 The absorption of drugs through the skin is expected to be a difficult 
matter since, as previously being mentioned, the function of the skin is to act 
as a barrier between the outside environment and the tissues under the skin. 
Yet drugs are absorbed, sometimes quite efficiently from the skin. 
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 The transepidermal route through the mostly lipoidal, intercellular 
stratum corneum seems to be especially important for most drugs. The 
transfolicular route (via hair follicles), may also be important for some 
drugs. There is little reason to believe that the transeccrine route (via 
eccrine gland) is of importance where passive diffusion is involved but 
there is some indication that the eccrine sweat glands are involved in the 
iontophoretic delivery of drugs. 
Iontophoresis induces a bulk flow of water through the eccrine 
glands and other openings in the skin which sweeps even non-electrolyte 
drugs across these pores (Flynn, 1990). 
Since the fractional cross-sectional area of the skin appendages 
(hair follicles and eccrine glands) is very small (0.1% of the skin area), 
this route is assumed not to contribute very much to the absorption 
process of most drugs. 
While some polar drugs may penetrate the stratum corneum 
transcellulary, most drugs are thought to follow mainly the very tortuous 
intercellular route. The drug permeability of the stratum corneum is much 
lower than that of the epithelial barriers of the human body. 
Factors that may influence the penetration and absorption of active 
substances through the skin are summarized in table 1.3. 
Table 1.3: Factors that may influence the skin penetration and absorption 
of active substances. 
Biological factors Physicochemical factors 
Age 
Skin condition 
 
Regional skin site 
Skin metabolism 
Circadian rhythms 
Species differences 
Degree of skin hydration 
Distribution coefficient of active  
substance between base and skin 
Molecular weight of active substance 
Base-skin interaction 
Base-active substance interaction 
Penetration enhancers 
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1.4.2.3 Distribution  
 Drugs can bind to proteins in the stratum corneum and dermis, or 
to fat in the subcutaneous layer. 
1.4.2.4 Metabolism  
 A review by Tauber et al. (1990) evaluated drug metabolism in the 
skin. Biotransformation processes take place mainly in the living skin 
cells. These processes include oxidation, reduction, hydrolysis and 
conjugation reactions. Dermal first pass effect may very much impede the 
(trans) dermal delivery of drugs.  
Binding to proteins and fats in the skin and skin first pass effect are 
the major drawbacks for administration of drugs to the skin. 
1.4.2.5 Excretion  
 The excretion of drugs into the sweat is a well established fact. 
Iodine, bromine, benzoic acid, lead, arsenic, mercury, iron, alcohol and 
antipyrine are some of the compounds that are excreted in the sweat. 
1.5 Semisolid dosage forms 
 Ointments, creams and gels are semisolid dosage forms intended 
for topical application. They may be applied to the skin, placed on the 
surface of the eye, or used nasally, vaginally, or rectally. Most these 
preparations are used for the effects of the therapeutic agents they 
contain. The unmedicated ones are used for their physical effects as 
protectants or lubricants. 
Topical preparations are used for both local and systemic effects. 
Systemic drug absorption should always be considered when using 
topical products if the patient is pregnant or nursing, because drugs can 
enter the fatal blood supply and breast milk and be transferred to the fetus 
or nursing infant.  
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Topical applications can be designed for either local effects or 
systemic absorption.  
The following distinction is an important one with regard to 
dermatologic applications. A topical dermatological product is designed 
to deliver drug into the skin in treating dermal disorders with the skin as 
the target organ. A transdermal product is designed to deliver drugs 
through the skin (percutaneous absorption) to the general circulation for 
systemic effects, with the skin not being the target organ. (Shah, et al. 
1992 and Allen et al. 2005). 
1.5.1 Ideal properties of semisolid dosage form  
i. PHYSICAL PROPERTIES  
a)  Smooth texture  
b)  Elegant in appearance  
c)  Non dehydrating  
d)  Non gritty  
e)  Non greasy and non staining  
f)  Non hygroscopic  
ii. PHYSIOLOGICAL PROPERTIES 
a)  Non irritating  
b)  Do not alter membrane / skin functioning  
c)  Miscible with skin secretion  
d)  Have low sensitization index  
iii. APPLICATION PROPERTIES 
a)  Easily applicable with efficient drug release.  
b)  High aqueous washability (Jani, 2003). 
1.5.2 Inactive ingredients used in semisolids dosage forms 
Antimicrobial Preservatives: Some base, although, resist microbial attack 
but because of their high water content, it requires an antimicrobial 
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preservative. Commonly used preservatives include Methyl-hydroxyl 
benzoate, Propyl-hydroxybenzoate, Chlorocresol, Benzoic acid, Phenyl 
mercuric nitrate, Benzalkonium chloride, Chlorhexidine acetate, Benzyl 
alcohol and Mercurial.  
Antioxidants: Example of commonly used antioxidants includes 
Butylated hydroxy anisole, Butylated hydroxy toluene.  
Chelating Agents: Example of commonly used chelating agents include 
Citric acid, Maleic acid  
Humectants: Example of commonly used humectants includes Poly 
Ethylene Glycol, Glycerol, Propylene glycol, and Sorbitol.  
Fragrances: Examples of widely use fragrances are Lavender oil, Rose 
oil, Lemon oil, Almond oil  
1.5.3 Ointments  
 Ointments are semisolid preparations intended for external 
application to the skin or mucous membranes. Ointments are used 
topically for several purposes, e.g. protectants, antiseptics, emollients, 
lubricants, antipruritics, keratolytics, and astringents. The vehicle or base 
of an ointment is of prime importance if the finished product is expected 
to function as any one of the above categories.  
In the case of a protective ointment, it serves to protect the skin 
against moisture, air, sun rays and other external factors. It is necessary 
that the ointment neither penetrates the human skin barriers nor facilitates 
the absorption of substances through this barrier.  
An antiseptic ointment is used to destroy or inhibit the growth of 
bacteria. Frequently bacterial infections are deeply seated; a base which 
has the capacity to either penetrate or dissolve and release the medication 
effectively is therefore desired. 
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Ointments used for their emollient effect should be easy to apply, 
be non-greasy and effectively penetrate the skin. 
1.5.3.1 Ointment bases 
There are five classes or types of ointment bases which are 
differentiated on the basis of their physical composition (Reilly, 2006). 
These are 
1. Oleaginous bases. 
 White wax                5%  
 White petrolatum        95%  
2. Absorption bases. 
 Cholesterol               3%  
 Stearyl alcohol          3%  
 White wax                8%  
 White petrolatum       86%  
3. Water in oil emulsion bases. 
 White wax                  12%  
 Cetyl esters wax          12.5%  
 Mineral oil                   56%  
 Sodium borate            0.5% 
 Water                        19% 
4. Oil in water emulsion bases. 
 Sodium lauryl sulfate        1% 
 Propylene glycol             12% 
 Stearyl alcohol                25% 
 White petrolatum            25% 
 Water                              37% 
5. Water soluble or water miscible bases 
 Polyethylene glycol 400         60% 
 Polyethylene glycol 3350        40% 
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1.5.3.2 Properties of ointment bases 
 Each ointment base type has different physical characteristics and 
therapeutic uses based upon the nature of its components. Table 1.4 
summarizes the composition, properties, and common uses of each of the 
five types of ointment bases. 
1.5.3.3 Selection of the appropriate base 
Selection of the base to use in the formulation of an ointment depends 
on careful assessment of a number of factors, including the following: 
• Desired release rate of the drug substance from the ointment base  
• Desirability of topical or percutaneous drug absorption 
• Desirability of occlusion of moisture from the skin 
• Stability of the drug in the ointment base 
• Effect if any of the drug on the consistency or other features of the 
ointment base 
• Desire for a base that is easily removed by washing  with water 
• Characteristics of the surface to which it is applied 
For example, an ointment is generally applied to dry, scaly skin; a cream 
is applied to weeping or oozing surface, and lotion is applied to the 
intertriginous areas or where friction may occur, as between the thighs or 
under the armpit. The base that provides the best combination of the most 
desired attributes should be selected. 
1.5.3.4 Preparation of ointments 
Ointments are prepared by two general methods, (a) Incorporation (b) 
Fusion, depending on the nature of the ingredients. 
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1.5.3.4.1 Incorporation 
The components are mixed until a uniform preparation is attained. 
On a small scale, as in extemporaneous compounding, the pharmacist 
may mix the components using a mortar and pestle or a spatula may be 
used to rub the ingredients together on an ointment slab (Allen, 2005). 
1.5.3.4.2 Incorporation of solids  
When preparing an ointment by spatulation the pharmacist works 
the ointment with a stainless steel spatula having a long broad blade and 
periodically removes the accumulation of ointment on the large spatula 
with a smaller one. If the component of an ointment reacts with metal, 
hard rubber spatulas may be used.  
The ointment is prepared by thoroughly rubbing and working the 
components together on the hard surface until the product is smooth and 
uniform. The ointment base is placed on one side of the working surface 
and the powdered components, previously reduced to fine powdered and 
thoroughly blended in a mortar, on the other side.  
A small portion of the powder is mixed with a portion of the base 
until uniform. Geometric dilution is continued until all portions of the 
powder and base are combined and thoroughly and uniformly blended.  
It often is desirable to reduce the particle size of a powder or 
crystalline material before incorporation into the ointment base so that the 
final product will not be gritty this may be done by levigating, or mixing 
the solid material in a vehicle in which it is insoluble to make a smooth 
dispersion. 
1.5.3.4.3 Incorporation of liquids  
Liquid substances or solutions of drugs, as described above, are 
added to an ointment only after due consideration of an ointment base's 
capacity to accept the volume required. For example, as noted previously, 
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only very small amount of an aqueous solution may be incorporated into 
an oleaginous ointment, where as hydrophilic ointment bases readily 
accept aqueous solution.  
When it is necessary to add an aqueous preparation to a 
hydrophobic base, the solution first may be incorporated into a minimum 
amount of a hydrophilic base and then that mixture added to the 
hydrophobic base. However, all bases even if hydrophilic have their 
limits to retain liquids, beyond which they become too soft or semi liquid. 
1.5.3.4.4 Fusion 
By the fusion methods, all or some of components of an ointment 
are combined by being melted together and cooled with constant stirring 
until congealed. 
Components not melted are added to the congealing mixture as it is 
being cooled and stirred. Naturally, heat labile substances and any 
volatile components are added last, when the temperature of the mixture 
is low enough not to cause decomposition or volatilization of the 
components. 
Substances may be added to the congealing mixture as solutions or 
as insoluble powders levigated with portion of base. 
On small scale, fusion may be conducted in a porcelain dish or 
glass beaker. On a large scale, it is carried out in large steam-jacketed 
kettles. Once congealed, the ointment may be passed through an ointment 
mill or rubbed with a spatula or in mortar to ensure a uniform texture. 
Medicated ointments and ointment bases which do not lend 
themselves well to mixture by incorporation, are prepared by fusion. 
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1.5.3.5 Compendia requirements for ointments 
Ointments and other semisolid dosage forms must meet standard 
tests for microbial content, minimum fill, packaging, storage and labeling 
(United States Pharmacopeia (USP, 2003). 
1.5.3.5.1 Microbial content 
With the exception of ophthalmic preparations, topical applications 
are not required to be sterile. They must, however, meet acceptable 
standards for microbial preservatives. Preparations that contain water 
tend to support microbial growth to a greater extent than water-free 
preparations. Among the antimicrobial preservatives used to inhibit 
microbial growth in topical preparations are methylparaben, 
propylparaben, phenols, benzoic acid, sorbic acid, and quaternary 
ammonium salts. 
Microbial limits are stated for certain articles in the USP. For 
example, Betamethazone Valerate ointment, USP, must meet the 
requirements of the tests for absence of Staphylococcus aureus and 
Pseudomonas aeruginosa. These particular microbes have special 
importance in dermatologic preparation because of their capacity to infect 
the skin which for patients being treated for a skin condition, is already 
compromised. 
In the USP chapter titled "Microbiological attributes of nonsterile 
pharmaceutical products" emphasis is placed on strict adherence to 
environmental control and application of good manufacturing practices to 
minimized pharmaceutical products (United States Pharmacopeia, 2003).  
This involves the testing of raw materials used of acceptable water, 
in-process controls and final product testing. 
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1.5.3.5.2 Minimum fill 
The USP's minimum fill test is determination of the net weight or 
volume of the contents of filled containers to ensure proper contents 
compared with the labeled amount. 
1.5.3.5.3 Packaging, storage, and labeling 
Ointments and other semisolid preparations are packaged either in 
large-mouth ointment jars or in metal or plastic tubes. Semisolid 
preparations must be stored in well-closed containers to protect against 
contamination and in a cool place to protect against product separation in 
heat. When required, light-sensitive preparations are packaged in opaque 
or light-resistant containers. 
In addition to the usual labeling requirements for pharmaceutical 
products, the USP directs that the labeling for certain ointments and 
creams include the type of base used. 
Storage of semisolids should be at temperatures not exceeding 
25°C unless otherwise authorized. They should not be allowed to freeze 
and must be stored in a well-closed container or, if the preparation 
contains water or other volatile ingredients, store in an air-tight container. 
The containers are preferably collapsible metal tubes from which the 
preparation may be readily extruded. If the preparation is sterile, store in 
a sterile, airtight, tamper-proof container. Definition and storage/test 
conditions for four climatic zones are shown in table 1.5. 
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Table 1.5 Definition and storage/test conditions for four climatic zones. 
Climatic zones  Definition  Storage/test 
conditions  
Example  
I  Temp. climate  21°C + 2°C and 
45% RH* + 5% 
RH  
Northern Europe, 
Canada  
II  Mediterranean & 
subtropical climate 
25°C + 2 °C and 
60% RH + 5% RH 
Southern Europe, 
Japan, US  
III  Hot dry climate  30°C + 2°C and 
35% RH + 5% RH 
Egypt, Sudan  
IV  Hot, humid climate 30°C + 2°C and 
75% RH + 5% RH 
Central Africa, 
South Pacific  
*RH = Relative Humidity  
1.5.3.5.4 Additional Standards 
In addition to the USP requirements, manufactures often examine 
semisolid preparations for viscosity and for in vitro drug release to ensure 
within-lot and lot-to-lot uniformity in vitro drug release tests include 
diffusion cell studies to determine the drug's release profile from the 
semisolid product. 
1.5.4 Creams 
Definition: Creams are homogeneous, semi-solid preparations consisting 
of opaque emulsion systems. Their consistency and rheological properties 
depend on the type of emulsion, either water-in-oil (W/O) or oil-in-water 
(O/W) and on the nature of the solids in the internal phase. Creams are 
intended for application to the skin or certain mucous membranes for 
protective, therapeutic, or prophylactic purposes, especially where an 
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occlusive effect is not necessary. The term "cream" is most frequently 
used to describe soft, cosmetically acceptable types of preparations. 
Generally, O/W creams are prepared at an elevated temperature 
and then cooled down to room temperature in order for the internal phase 
to solidify (Swarbrick, et al. 1996). 
The semi-solid form of a W/O cream is attributable to the character 
of the external phase. 
Hydrophobic creams (W/O) 
Hydrophobic creams are usually anhydrous and absorb only small 
amounts of water. They contain w/o emulsifying agents such as wool fat, 
sorbitan esters, and monoglycerides. 
Hydrophilic creams (O/W) 
Hydrophilic creams contain bases that are miscible with water. They 
also contain O/W emulsifying agents such as sodium or triethanolamine 
soaps, sulfated fatty alcohols, and polysorbates combined, if necessary, 
with w/o emulsifying agents. These creams are essentially miscible with 
skin secretions. 
O/W creams are elegant drug delivery system, pleasing in both 
appearance and feel post application. O/W creams are non greasy and are 
rinsable, they are good for most topical purpose and are considered 
particularly suited for application to oozing wounds. 
According to the type of emulsion, these bases are classified as 
either W/O or O/W. All W/O emulsions are not water-washable as the oil 
is in the external phase and O/W emulsions are used in dermatological 
preparations and cosmetic creams. Some of the popular creams include 
cold creams, vanishing creams. Skin creams, emollient creams, 
foundation creams, hand creams etc. Fundamentally creams can be 
divided into cold and vanishing types.  
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Types of creams depending on formulation are as follow  
1) Sterol Creams: They are water in oil emulsions where emulgent is 
wool fat or wool alcohol. Classical example is lanolin.  
2) Soap Creams: Triethanolamine Creams are neutral soaps, produces 
o/w emulsion with oleic acid and triethanolamine (good emulgents for 
liquid paraffin). 
3) Anionic Emulsifying Wax Creams: These emulsifiers produce oil in 
water type.  
4) Cationic Emulsifying Wax Creams: These emulsifiers produce water 
in oil type.  
5) Creams Emulsified with Non-ionic Surfactants: Cream bases 
prepared with self emulsifying monostearin, a sorbitan ester, a macrogol 
ester, a non emulsifying wax containing a macrogol ether etc.  
6) Divalent Creams: Classical example is Lime creams which is of water 
in oil type. Emulgent in these is Oleic acid and Calcium hydroxide.  
7) Vanishing Creams: They are oil in water type creams which when 
rubbed onto the skin and disappear with little or no trace of their former 
presence (Chater, 2001).  
Novel Advances in Creams Dosage Forms  
a) Creams containing microspheres   
Albumin microsphere containing vitamin A can be administered by 
using creams topically. 222 ± 25 µm size of microsphere of vitamin A 
were produced by emulsion method. The in vitro and in vivo drug release 
of a microencapsulated and nonmicroencapsulated vitamin A cream was 
studied. The in vivo study in six volunteers revealed that these 
microspheres were able to remain on the skin for a long period of time, 
and as a consequence they were able to prolong the release of vitamin A 
(Gohel et al. 1992). 
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b) Lamellar faced creams  
They are liquid paraffin in water emulsion prepared from 
cetrimide/fatty alcohol like mixed emulsifiers and ternary system formed 
by dispersing the mixed emulsifier in require quantity of water. The 
cationic emulsifying wax showed phenomenal swelling in water and this 
swelling was due to electrostatic repulsion whish can be suppressed by 
addition of salt and can be reduced by changing surfactant counter ion 
(Gohel et al. 2000)  
c) Cream containing lipid Nanoparticles  
Occlusion of cream is important criteria since it increases the 
penetration of topical drugs. This can be achieved by using oils and fats 
like liquid and semisolid paraffin in large quantities. However, such 
formulations have the limitations of poor cosmetic properties since they 
have greasy feel and glossy appearance.  
The development of a water-in-oil cream containing small particles 
of solid paraffin was studied. A high degree of occlusivity was obtained 
with smooth, flexible films prepared by drying aqueous dispersions of 
solid paraffin particles with a mean size of 200 nm (nanoparticle 
dispersion). However, this nanodispersion revealed a rough texture when 
applied. The development of a water-in-oil cream wherein the aqueous 
phase was divided into small droplets solved this problem. Nanoparticles 
were incorporated in the aqueous phase. Hence, the oil phase in which the 
water droplets were dispersed served as a lubricant for nanoparticles, 
thereby preventing a rough feel during application.  
Mineral oils are added to petrolatum to lower its fusion point, 
however by doing so problem of phase separation on storage is seen. This 
separation can be prevented by the addition of small quantities of natural 
waxes like ozokerite, ceresine or microcrystalline wax (Gohel et al. 2000)  
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1.5.5 Gels 
 Gels are semisolid systems consisting of dispersions of small or 
large molecules in an aqueous liquid vehicle rendered jellylike by the 
addition of a gelling agent. Among the gelling agents used are synthetic 
macromolecules, such as carbomer934; cellulose derivatives, such as 
carboxymethylcellulose or hydroxypropyl methylcellulose; and natural 
gums, such as tragacanth. Carbomers are high-molecular-weight water-
soluble polymers of acrylic acid cross-linked with allyl ethers of sucrose 
and/or pentaerythritol. Their viscosity depends on their polymeric 
composition. 
 Single-phase gels are gels in which the macromolecules are 
uniformly distributed throughout a liquid with no apparent boundaries 
between the dispersed macromolecules and the liquid. A gel mass 
consisting of floccules of small distinct particles is termed a two-phase 
system, often referred to as magma. Milk of magnesia or (magnesia 
magma), which consists of a gelatinous precipitate of magnesium 
hydroxide, is such a system. Gels may thicken on standing, forming a 
thixotrope, and must be shaken before use to liquefy the gel and enable 
pouring. 
 In addition to the gelling agent and water, gels may be formulated 
to contain a drug substance, solvents, such as alcohol and/or propylene 
glycol; antimicrobial preservatives, such as methylparaben and 
propylparaben or chlorhexidine gluconate; and stabilizers, such edentate 
disodium. Medicated gels prepared for administration by various routes, 
including the skin, the eye, the nose, the vagina, and the rectum. 
1.5.6 Transdermal preparations 
Recent years have seen an increase in the number of topical 
ointments, creams, and gels designed to deliver a drug systemically. This 
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is often accomplished by addition of penetration enhancers to the topical 
vehicle. Penetration enhancers include dimethyl sulfoxide (DMSO), 
ethanol, propylene glycol, glycerin, polyethylene glycol, urea, dimethyl 
acetamide, sodium lauryl sulfate, the poloxamers, spans, tweens, lecithin, 
terpenes, and many others. 
A trandermal preparation commonly compounded is pluronic 
lecithin organogel (PLO gel). It consists of a pluronic (Poloxamer) F127 
gel (usually 20% or 30% concentration) mixed at a ratio of approximately 
1:5 with a mixture of equal parts of isopropyl palmitate and lecinthin.  
This gel vehicle aids in rapid penetration of many active drugs 
through the skin. 
1.5.7 Miscellaneous semisolid preparations 
1.5.7.1 Pastes  
Are semisolid preparations intended for application to the skin. 
They generally contain a larger proportion of solid material (such as 
25%) than ointments and therefore are stiffer. 
Pastes can be prepared in the same manner as ointments by direct 
mixing or the use of heat to soften the base prior to incorporating the 
solids. Which have been comminuted and sieved. However, when a 
levigating agent is to be used to render the powdered component smooth, 
a portion of the base is often used rather than a liquid, which would 
soften the paste. 
Because of the stiffness of the pastes, they remain in place after 
application and are effectively employed to absorb serous secretions. 
Because of their stiffness and impenetrability, pastes are not suited for 
application to hairy parts of the body. 
Among the few pastes in use today in zinc oxide paste which is 
prepared by mixing 25% each of zing oxide and starch with white 
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petrolatum. The product is very firm and is better able to protect the skin 
and absorb secretions than is zinc oxide ointment. 
1.5.7.2 Plasters  
 Are solid or semisolid adhesive masses spread on a backing of 
paper, fabric, moleskin, or plastic. The adhesive material is a rubber base 
or a synthetic resin. Plasters are applied to the skin to provide prolonged 
contact at the site. Unmedicated plasters provide protection or mechanical 
support at the site of application. Adhesive tape used to be official under 
the title adhesive plaster the use of this material being well known. 
Medicated plasters provide effects at the site of application. They 
may be cut to size to conform to the surface to be covered. Among the 
few plasters in use today is salicylic acid plaster used on the toes for the 
removal of corns. The horny layers of skin are removed by the keratolytic 
action of salicylic acid. The concentration of salicylic acid used in 
commercial corn plasters ranges from 10 to 40 %. 
1.5.7.3 Glycerogelatins  
 Are plastic masses containing gelatin (15%), glycerin (40%), water 
(35%), and an added medicinal substance (10%), such as zinc oxide.  
They are prepared by first softening the gelatin in water for about 
10 minutes, heating on a steam bath until the gelatin is dissolved, adding 
the medicinal substance mixed with the glycerin, and allowing the 
mixture to cool with stirring until congealed. 
Glycerogelatins are applied to the skin for the long term. They are 
melted before application, cooled to slightly above body temperature, and 
applied to the affected area with a fine brush. Following application, the 
glycerogelatin hardens, is usually covered with a bandage, and is allowed 
to remain in place for weeks. The most recent official glycerogelatin was 
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zinc gelatin, used in the treatment of varicose ulcers. It was also known as 
zinc gelatin boot because of its ability to form a pressure bandage. 
1.5.8 Packaging semisolid preparations 
Topical dermatological products are packaged in either jars or 
tubes, whereas ophthalmic, nasal, vaginal, and rectal semisolid products 
are almost always package in tubes. 
So-called ointment jars are made of clear or opaque glass or plastic. 
Some are colored green, amber, or blue. Opaque jars, used for light-
sensitive products, are porcelain white, dark green, or amber. 
Commercially available empty ointment jars vary in size from about 0.5 
ounce to 1 pound. 
In commercial manufacture and packaging of topical products, the 
jars and tubes are first tested for compatibility and stability for the 
intended product. This includes stability testing of filled containers at 
room temperatures (e.g. 20oc) as well as under accelerated stability 
testing conditions (e.g. 40 and 50oC). 
Tubes used to package topical pharmaceutical products are gaining 
in popularity. They are light in weight, relatively inexpensive, convenient 
for use, and compatible with most formulative components, and they 
provide greater protection against external contamination and 
environmental conditions than jars. 
Ointment tubes are made of aluminum or plastic. When the 
ointment is to be used for ophthalmic, rectal, vaginal, aural, or nasal 
application, they are packaged with special applicator tips. Tubes 
aluminum generally is coated with an epoxy resin, vinyl, or lacquer to 
eliminate any interactions between the contents and the tube. Plastic tubes 
are made of high- or low-density polyethylene (HDPE or LDPE) or a 
blend of each, polypropylene (PP), polyethylene terephthalate (PET), and 
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various plastic, foil, and / or paper laminates, sometimes 10 layers thick 
(Forcinio. 1998). 
1.5.9 Filling ointment jars and tubes 
 Ointment jars are filled on a small scale in the pharmacy by 
carefully transferring the weighed amount of ointment into the jar with a 
spatula. The ointment is packed on the bottom and along the sides of the 
jar, avoiding entrapment of air. The size should allow the ointment to 
reach near the top of the jar but not so high as to touch the lid when 
closed. 
Tubes are filled from the open back end of the tube, opposite from 
the cap end. Ointments prepared by fusion may be poured while still soft 
but viscous directly into the tubes with caution to prevent stratification of 
the components. On small scale, as in the extemporaneous filling of an 
ointment in the pharmacy the tube may be filled manually or with a 
small-scale filling machine. 
Industrial, automatic filling, closing, crimping and labeling 
machines are used for large scale tube packaging of semisolid 
pharmaceuticals (Allen, et al. 2005). 
1.10 Tinea versicolor and Skin dermatophytes in Sudan and Yemen 
As has been previously discussed, TV and SD are worldwide 
diseases. They are found in Sudan and Yemen because of the suitability 
of the climatic conditions (temperature and high humidity) and life style 
of the population such as soldiers. PV changes the pigmentation of the 
skin (hypopigmention or hyperpigmentation) in men or women and 
spread in all part of body especially the Neck, arms, chest, back and 
rarely face. This causes a lot of worry especially among females. The 
problems of this disease is that most drugs which are used for treatment 
are expensive, have side effects (kidney and liver) and high recurrences. 
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Volcanic stone traditionally used in Yemen for treatment of this 
disease, by extracting with water and topically rubbing the affected areas, 
are very effective and shows no recurrence. 
Formulation of naturally occurring products as suitable dosage 
forms is known since ages ago (Khilline, Senna, Digitalis….ect). 
Nowadays it became more attention-grabbing since natural resources are 
generally safe and free of side effects.  
In the present study an attempt was made to formulate a volcanic 
stone into a suitable semisolid dosage form for the treatment of PV and 
other skin dermatophytes. 
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2. AIMS AND OBJECTIVES  
Pityriasis versicolor and skin disease (Tinea spp.) are very common 
and spread widely in the tropical area and between the poor populations. 
 These diseases have high recurrences for most of drugs. The drugs 
which are used to treat the disease are also expensive and have side 
effects. Therefore, the aim of this study was to formulate a new drug 
which is safe, effective and with no recurrences. 
2.1 Aims  
Formulation of a new drug for treatment of pityriasis 
versicolor.and skin dermatophytes infections. 
2.2 Objectives 
• Chemical analysis for stone extract to identify its constituents. 
• Microbiology studies in vitro. 
• Pharmacological studies for stone extract. 
• Toxicological studies for stone extract 
• Pharmaceutical formulation of the stone extract in a suitable 
semisolid dosage form. 
• Clinical trial of stone formulation on volunteers with PV and skin 
dermatophytes and comparison with other used drugs. 
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3. EXPREMENTAL 
3.1 CHEMICAL ANALYSIS 
3.1.1 Materials 
3.1.1.1 Chemicals 
The chemicals which are used for the chemical analysis study are 
shown in table 3.1.1. 
Table 3.1.1 Chemicals used for chemical analysis study 
NO Chemicals Company Country 
1 Alizarin red monohydrate Falcon U.K 
2 Ammonium carbonate Merck U.K 
3 Ammonium chloride BDH U.K 
4 Ammonium hepta molybdate Merck U.K 
5 Ammonium hydroxide Scharlau Spain 
6 Ammonium oxalate Scharlau Spain 
7 Ammonium thiocyanate Scharlau Spain 
8 Barium chloride Falcon U.K 
9 Boric acid Falcon U.K 
10 Bromine water Scharlau Spain 
11 Calcium carbonate Falcon U.K 
12 Cesium chloride Falcon U.K 
13 Copper sulphate Merck U.K 
14 Diphenylamine Merck U.K 
15 EDTA Scharlau Spain 
16 Ethanol Scharlau Spain 
17 Ferrous ammonium sulfate BDH U.K 
18 Hydrochloric acid Biomark India 
19 Hydrofluoric acid BDH U.K 
 64
20 Hydroxyl ammonium chloride  Biomark India 
21 Hydroxymethyl amino methane  BDH U.K 
22 Lanthanum chloride Falcon U.K 
23 Methyl red indicator BDH U.K 
24 Nitric acid Biomark India 
25 N-Octyl Alcohol Falcon U.K 
26 Orthophosphoric acid Merck U.K 
27 Perchloric acid BDH U.K 
28 Potassium bromide BDH U.K 
29 Potassium dichromate Falcon U.K 
30 Potassium ferricynide  BDH U.K 
31 Potassium Iodide BDH U.K 
32 Potassium permmanganate Falcon U.K 
33 Potassium Sulphate Scharlau Spain 
34 Reduced Iron Falcon U.K 
35 Silver nitrate BDH U.K 
36 Sodium acetate BDH U.K 
37 Sodium hydroxide  Scharlau Spain 
38 sodium meta disulphite Falcon U.K 
39 sodium sulphite Falcon U.K 
40 Sulfuric acid Scharlau Spain 
41 Tartaric acid BDH U.K 
42 Thioglycolic acid solution  Falcon U.K 
 
3.1.12 Instruments 
The instruments used for the chemical analysis experiments are 
summarized in table 3.1.2. 
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Table 3.1.2 Instrument used for chemical analysis study 
NO Instrument company Country
1 Atomic Absorption 
spectrophotometer 
Perkin-Elmer 
No.2380 
USA 
2 Automatic titrator connected to a 
pH-meter
Sartorius Germany
3 Block digester. Sartorius Germany
4 Crushing machine KHP Humboldt 
wedges AG. 
Germany
5 Distillation unit. Sartorius Germany
6 Fourier Transform Infrared 
spectrophotometer (FTIR-8900) 
Shemadzue Japan 
7 Laboratory glasse ware (flasks, 
beakers, test tubes   ect) 
Local market Sudan 
8 Milling machine Siebtechnik Germany
9 pH meter Sartorius Germany
10 Sensitive balance Sartorius Germany
11 Ultra Violet spectrophotometer 
(UV-160 IPC) 
Shemadzue Japan 
 
3.1 2 Methods 
3.1.2.1 Specifications of the volcanic stones 
Physicochemical properties of the stone were determined. The 
color of the outer layer and inner layer of the stone was established. 
pH meter was used to determined the pH of the stone extract by 
dissolving a 1gm of sample in 100ml of distilled water then its pH was 
measured.  
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Solubility: The solubility of the stone in different solvents was 
studied. The stone was found to be soluble in water, alcohols and mixture 
of both.  
3.1.2.2 Crushing and milling the stone 
The process of crushing and milling the stone was done before 
analysis by using crushing and milling machines. First the stone was 
crushed to small particles. Then particle size was reduced further by a 
milling machine to produce appropriate powder (Figure 4.1.). 
3.1.2.3 Elemental analysis 
Elemental analysis was done at the Ministry of Science and 
Technology (The National Center for Research-Environment and Natural 
Resources Research Institute) for the determination of the Carbon and 
Nitrogen atoms to know if the stone contain organic or inorganic 
compounds (Page et al., 1982). 
3.1.2.3.1 Identification of organic carbon 
Reagents 
A- Potassium dichromate solution (K2Cr2O7): 
Potassium dichromate solution was dried for 2 hour in an oven at 
105˚C and cooled in a desiccator (silica gel). 49.04 gm was 
weighed in a 500 ml beaker and dissolved in deionized (DI) water 
and to a 1liter volumetric flask was transferred and brought to 
volume. 
B- Concentrated Sulfuric Acid (H2SO4). 
C- Concentrated Orthophosphoric acid (H3PO4). 
D- 0.5M Ferrous Ammonium Sulfate (FAS) [(NH4)2SO4.FeSO4.6H2O] 
196 gm of FAS was weighed, transferred to a 500 ml beaker and 
dissolved in deionized water. Five ml of conc. H2SO4 were added. 
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The mixture was then transferred to a volumetric flask and diluted 
with deionized water to 1 liter 
E- 1gm of Diphenylamine indicator was dissolved in 100ml of conc. 
H2SO4. 
 
Method 
One gm of the stone sample was weighed into 500 ml beaker and 
10 ml of potassium dichromate solution (reagent A) was added then 20 
ml of conc. H2SO4 was added using a dispenser. The beaker was swirled 
to mix the suspension. It was allowed to stand for 30 min then 200 ml of 
deionized water was added and 10 ml of H3PO4 acid (reagent C) using a 
dispenser. The mixture was allowed to cool. 
10-15 drops diphenylamine indicator solution (reagent E) was added and 
a Teflon coated magnetic stirring bar was added and the beaker was 
placed on magnetic stirrer then titrated with ferrous ammonium sulfate 
solution (reagent D) until the color changes from violet-blue to green. 
Two blanks were prepared containing all reagents but no sample of stone 
and treated in exactly the same way as the sample suspension. 
Calculations 
(blank) ml
10M =  
Where: 
M = molarity of ferrous ammonium sulfate (FAS) solution (approx 0.5M) 
ml (blank) = FAS solution required to titrate 10 ml of potassium 
dichromate solution. 
OOC (% W/W) = 
(sample) g
x M 0.3x  (sammple)] ml(blank) [ml −  
Where 
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OOC = Oxidizable organic carbon 
ml (sample) = FAS required to titrate the sample solution 
Total Organic Carbon (%W/W) =1.334 X OOC 
Organic Matter (%W/W) = 1.724 X TOC = 2.3 X OOC. 
 
3.1.2.3.2 Determination of Nitrogen 
Reagents 
A) Sulfuric Acid (H2SO4) conc. Reagent grade. 
B) Potassium Permanganate solution: 50 gm of KMnO4 was dissolved 
in 1 litter of deionized water and the solution was stored in an 
amber bottle. 
C) Sulfuric acid, 50%V/V: One litter of conc. H2SO4 was added 
slowly with continuous stirring to 1 litter of deionized water in a 4 
litter flask. 
D) Reduced Iron: It was grind in ball mill and sieve to remove any 
material which dose not pass a 0.15-mm screen. 
E) N-Octyl Alcohol. 
F) Digestion Catalyst Mixture, K2 SO4 - CuSO4 .5H2.O- Se in 100:10:1 
w/w ratio. The reagents were grind separately before mixing; using 
a mortar to pass a 60 mesh screen (0.250mm). 
G) EDTA, reagent-grade disodium salt (M.W. = 372.2). Stored in a 
desiccator. 
H) NaOH Solution (10N): Two kg NaOH was transferred into a 
heavy-walled 5-L Pyrex flask, 2 liter of distilled water was added 
and the flask was swirled until dissolve. The bottle was closed, 
cooled and was brought to volume with distilled water. 
I) Saturated Boric acid: 500g H3BO3 was added to 5-liter flask and 3 
liter deionized water was added and swirled vigorously then left 
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overnight. There should always be solid H3BO3 on the bottom of 
the flask. 
J) TRIS Solution (hydroxymethyl aminomethane) C4H11NO3, 0.01N: 
The reagent was dried at 80˚C for 3 hours and in a desiccator was 
cooled and stored in a tightly stopper bottle. 1.2114 gm TRIS was 
dissolved in 1liter deionized water. 
K) Dilute Sulfuric Acid 0.01N: Approximately 500 ml deionized 
water was added to a 1-liter calibrated flask and 28 ml conc. H2SO4 
was added to the flask (in the fume hood) and diluted with 
deionized water to volume; this solution is about (1N) then dilute 
100 times (10 ml to 1litter) to obtain a 0.01 N H2SO4 solution. 
Procedure for determination of nitrogen 
 The stone powder was mixed and spread in a thin layer on a sheet 
of paper, ensuring that root material is uniformly mixed in the sample. 
Representative sample was taken, which contains about 3 to 8mg 
N, by withdrawing 10 small portions from the sample, e.g. 10 g. 
0.01 g of the sample was weighted and place in 250ml volume 
digestion tube and at the same time, sample was taken for moisture 
determination (105oC) then 10ml of deionized water was added to each 
tube and swirl thoroughly to wet the sample then allowed to stand for 30 
min. 
Blank digest and an EDTA standard digest were prepared as (0.1g 
EDTA accurately weighed to 0.1mg) with each batch and 10ml of 
KMnO4 solution was added, swirl, and allowed 30 sec., then the digestion 
tube was held at 45o angle and 20 ml of 50% H2SO4 was added slowly in 
a manner which washes down material adhering to the tube neck 
digestion tube did not swirl immediately after adding acid because this 
may result in excessive frothing. 
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The digestion tube was allowed 15 min. then swirled and 2 drops 
of N-Octyl alcohol were added then a few pumice granules were added to 
the blank and EDTA digests. 2.5 g reduced iron was added through a 
long-stem funnel and placed immediately a 5-cm glass funnel (with stem 
removed ) in the tube neck, and swirled. 
Excessive frothing at this stage was halted by pouring 5ml water 
through the 5-cm, funnel; without swirl then the tubes were allowed to 
stand overnight. 
Pre-digest the samples were placed on the cold block and heated at 
100oC for 1 hr. The block comes to 100oC within 15 min.; therefore, total 
time on the block was 1 hr. and 15 min. then samples were swirled for 45 
min. 
Tubes were removed from the block and cooled then left 
overnight. Five gm of catalyst mixture was added through a long stem 
funnel, then 25ml of H2SO4 was added to each tube and swirled. 
The tubes were placed back on the block digester heated to 100oC, 
the block temperature was increased to 240oC and the funnels were 
removed. Arranged funnels afterwards were placed into the same 
digestion tube. It takes 40 min. to reach 240oC. Boiling of the water 
continues for 1 hr. after reaching 240oC. 
After the water has been removed, the funnels were replaced and 
the temperature was raised to 380oC, then the timer was set on the block 
and digest for 4 hr at this temperature. 
The tubes from the block were removed, then 50 ml of DI water 
was added and mixed using vortex mixture to break any precipitate of the 
sample remain in the tubes and after cooling, DI water was added to 250 
ml mark. 
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Distillation 
Prior to distillation, the digestion tube was trembled thoroughly to 
mix its contents, and then 50ml were pipette into 250ml distillation flask 
and acid digests were distilled with excess NaOH. The quantity of 10N 
NaOH required for sample digestion is 25 ml and 50 ml for distillation of 
50 ml and 100 ml aliquot, respectively. Distillation was carried out as 
follows: 
1 ml of boric acid solution and 1ml of deionized water were 
dispensed into 100ml dish. Then the dish was placed underneath the 
condenser tip on the distillation apparatus, with the tip below the surface 
of the solution. 
The distillation flask containing the digest was held at a 50o 
angle, then the appropriate volume of 10N NaOH was dispensed carefully 
down the side of the flask and the flask was connected immediately to the 
distillation unit and distillation was started. 
The timer was set for 4 min. after the distillate started flowing 
into the collecting dish. After 2 min. the dish was lowered away from the 
condenser tip to allow the condenser tip to be rinsed by the condensing 
liquid. 
After 4 min steam supply was turn off, then the tip of the 
condenser was washed into the dish using small amount of deionized 
water. 
The first appearance of distillate was delayed when used large 
aliquots and the distillation time 4min. form the first appearance of 
distillate flow. 
The distillation flask was removed and an empty 100ml 
distillation flask was connected to the distillation unit. The water was 
drained from the condenser jacket then the apparatus was steamed out for 
90 seconds before connecting the next sample. 
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The distillate was titrated to pH 5 with the standardized 0.01N 
H2SO4 using the autotitrator, and the volume of acid was recorded. The 
electrode was washed with deionized water into the dish. 
 
Calculations 
Percentage of recovery of EDTA standard 
1000x  W
100x  186.1x  x R Ax  B)(V%Recovery 
1
−=  
Percentage Nitrogen in sample: 
1000x  W
100x  14.01x  x R Ax  B)(VN%
2
−=  
Where:  
V = volume of acid titrated for the sample (ml) 
B = digested blank titration volume (ml) 
A = acid normality 
14.01 = atomic weight of N 
R = Ratio of total digest volume to distillation volume. 
W1 = weight of EDTA (gm) 
W2 = dry sample weight (gm) 
186.1 = equivalent weight of the EDTA 
3.1.2.4 Identification the elements by Atomic absorption 
 This was done at the Ministry of Energy and Mining (Geological 
research authority of Sudan chemical laboratory). 
It determines most elements of the cycle three and four in the 
periodic table of elements (Fishman, et al. 1966). 
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3.1.2.4.1 Identification of (Fe, Ca, Mg, Mn, Ni, Cr, Co, Na) 
Method 
0.5 gm of the stone sample was weighed and added to a mixture of 
10 ml of hydrofloride (HF), 5 ml of HNO3 and 3ml of HClO4, and put on 
sand bath until dryness. 10 ml of 50% HCl was added to dissolve the dry 
mixture with sample then transferred to the volumetric flask 250ml and 
diluted with distilled water to the mark (stock). From the stock solution 
10 ml was taken to a 100 ml volumetric flask and 3 ml of Lanthanide 
chloride (LaCl3 5%) was added as buffer solution for reading of (Fe, Ca, 
Mg, Mn, Ni, Cr and Co) and dilute to the mark. For determination of Na 
the buffer Cesium chloride (CsCl 5%) 3ml was added then the solution is 
ready to read. 
Preparing the Atomic absorption instrument  
Atomic absorption was prepared by adjustment the following:  
• Slit width between (0.7-0.8). 
• Wave length for each element.  
• Lamp; each element have a specific lamp to change. 
Calculation 
Reading X Dilution Factor =.Part per million (ppm). 
Reading X Dilution Factor X 1/1000000 X100 =...% 
3.1.2.5 Colorimetric methods (Scott et al. 1955). 
3.1.2.5.1 Identification of Silicon oxide (SiO2) 
Preparation of stock solution (A) 
0.05 gm of sample was weighed in a nickel crucible and 1.5 gm of 
sodium hydroxide was added then fused on direct flame till red hot. Then 
allowed 5 minutes and cooled. Three quarter of the crucible was filled 
with distilled water, covered and allows standing overnight. The content 
of the crucible was transferred into 1 liter volumetric flask containing 200 
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ml of distilled water and 10 ml of HCl, and filled up with water to the 
mark and shake well (solution A). 
Reagents of SiO2 
A- Ammonium hepta molybdate solution 
 0.5 gm of ammonium molybdate was weighed into a 100 ml beaker 
then 50 ml of distilled water was added to dissolve. 
25 ml of sulphuric acid was added to the beaker then transferred to 
the a 100 ml volumetric flask and filled up to the mark with water then 
stored in plastic bottle 
B- Tartaric acid (10% solution)  
10 gm of tartaric acid was dissolved into a 100 ml volumetric flask 
(prepared fresh) 
C- Reducing solution 
0.7 gm of sodium sulphite was weighed into a 100 ml beaker then 
10 ml of distilled water and 0.15 gm of (1-amino-2-naphthol-4-sulphuric 
acid) were added (process 1). 
9.0 gm of sodium meta disulphite was placed in a 250 ml beaker 
and 70 ml of distilled water was added (process 2). 
(process 1) was added to (process 2) into a 100 ml volumetric flask. 
Method of identification of SiO2 
Five ml of sample solution(A) was transferred into a 100 ml of 
volumetric flask then 2 ml of ammonium molybdate was added and 
mixed then allow to stand for 10 minutes. 
Five ml of tartaric acid was added and 2ml of reducing solution 
(color blue) was added and filled up to mark with DW then shake. 
The mixture was kept for 45 minutes then read at 640 nm using 
U.V. spectrometer. 
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Calculation 
Reading X Dilution Factor = Part per million (ppm). 
Reading X Dilution Factor X 1/1000000 X100 = Percent 
3.1.2.5.2 Identification of Aluminum oxide (Al2O3) 
Preparation of stock solution (A) 
 0.05 gm of sample was weighed in a nickel crucible and 1.5gm of 
sodium hydroxide was added then fuse on direct flame till red hot then 
wait for 5 minutes and cool. Three quarter of the crucible was filled with 
distilled water, covered and allowed to stand overnight. The content of 
the crucible was then transferred into a 1 liter volumetric flask containing 
200 ml of distilled water and 10 ml of HCl, and filled up to the mark 
distilled water and shacked well (solution A). 
Reagents 
A) Calcium carbonate (CaCO3): 1 gm of CaCO3 was weighed in a 
250ml beaker then 100 ml of distilled water and 15 ml of conc. 
HCl were added then heated to boiling for a few min. and cooled at 
room temperature then diluted with water to 500 ml. 
B) Alizarin red monohydrate: 0.05 % was prepared in a one liter flask 
and the solution was filtered. 
C) Hydroxyl ammonium chloride 10 % 
D) Potassium ferricynide solution 0.75 % 
E) Thioglycolic acid solution 4 % 
F) Sodium acetate (buffer solution): 60 gm of sodium acetate was 
weighed and 30 ml of acetic acid was added to it then the solution 
was diluted with water to 500 ml. 
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Methods for identification of Al2O3 
15 ml of sample solution (A) was transferred into a 100ml volumetric 
flask, and then 2 ml of calcium chloride and 1 ml of hydroxyl ammonium 
chloride were added. 
One ml of potassium ferricynide was added, followed by 2 ml of 
thioglycolic acid and left for 5 min. 
Ten ml of buffer solution was added, left for 10 min. and 10 ml 
alizarin red monohydrate was then added. 
After that the flask was filled up to the mark with distilled water and 
shocked, kept for 40 - 45 min at the shelf and read at 475 nm using U.V. 
spectrometer and the results were recorded. 
3.1.2.6 Gravimetric methods (Bennett, and Hawley, 1965). 
3.1.2.6.1 Identification of sulfur (S) by gravimetric method as barium 
sulphate (BaSO4) 
Reagents 
• Bromine water 
• HCl 50% 
• Methyl red indicator 
• Barium chloride 10% 
Procedure 
One gm of the stone sample was weighed in 250 ml of glass beaker 
and few drops of distilled water were added then 1 ml of bromine water 
was added. 
Twenty ml of 50 % HCl was added and the glass beaker was put on 
hot plate for 3 hours then the solution was filtered in 400 ml beaker, and 
complete to 200 ml by distilled water and two drops of methyl red 
indicator were added and put on hot plate to boil, then 10 ml of BaCl2 
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10% was added drop wise from a burette, heated to boiling and left over 
night. 
The solution was filtered using blue labeled filter paper (ashless) 
and washed with hot distilled water. 
A platinum crucible was washed and dried in an oven at 500oC, 
then in a desiccator was cooled, and the empty crucible was weighed. 
The residue of filtrate was put into the crucible and ignited at 1000oC 
for one hour, and the crucible was reweighed to get the weight of BaSO4.  
 
Calculation: 
Sample ofWt 
100x factor x   BaSOofWt S% 4=  
4 BaSOofWt Molecular 
S ofWt  AtomicFactor =  
Sample ofWt 
100x factor x   BaSOofWt %SO 44 =  
4
4
 BaSOofWt Molecular 
SO ofWt  AtomicFactor =  
3.1.2.6.2 Identification of Chloride 
Two gm of the stone sample was weighed, dried (110˚C), into 250 
ml beaker and 50 ml of distilled water was added. The beaker was 
covered with clock glass and introduce 10 ml of nitric acid was added and 
heated to boil until solution appear to be complete. The residue was 
filtered on a No. 40 Whatman paper and washed thoroughly with hot 
water. The residue was discarded and paper, the filtrate, was boiled to 
remove carbon dioxide and allowed to cool. 
In a subdued light 5 ml of silver nitrate solution was added drop by 
drop because silver chloride is sensitive to light. The solution was heated 
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to boiling for 5 min. Few drops of silver nitrate was added and the 
solution was allowed to stand in the dark overnight. 
Through a weighed crucible with a sintered-glass (porosity 4) the 
solution was filtered. Then the precipitate was transferred to the filter 
with a jet of cold, diluted nitric acid and scrubbing the break with a bobby 
washed thoroughly with cold diluted nitric acid. The crucible and 
contents were dried in an air oven at 110oC for 2hr.then cooled and 
weighed. 
Calculation 
Weigh of AgCl X 0.2474 = weigh of Cl 
3.1.2.7 Chemical tests for Identification of acidic and basic radicals 
 Most of inorganic compounds are soluble salts. They contain two 
types of radicals; anions and cations.  
All chemical tests were done for all acidic radical groups and basic 
radical groups by using chemical reagents to determine the radicals found 
in the stone sample. The chemical tests depended on the observation and 
conclusion e.g. (forming gas, precipitate or changes in color, odor…ect).  
The chemical tests were done at the Pharmaceutical Chemistry 
Laboratory, Faculty of Pharmacy, University of Khartoum. 
3.1.2.7.1 Identification of acidic radical groups 
Methods 
 There are three groups of acidic radicals which were determined 
using the following chemical tests 
1. Determination of Bicarbonate (HCO3-), Carbonate (CO32-), 
Disulfuoxide (S2O32-), Trislufuoxide (SO32-), Sulfur (S2-) and 
Nitrate (NO2-). 
Small amount of sample was taken in a dry test tube then dilute 
HCl was added to it. 
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2. Determination of Chloride (Cl-), Bromide (Br-), Iodide (I-), and 
Natrate (NO3-). 
Small amount of sample was taken in a dry test tube then conc. 
H2SO4 was added to it. 
3. Determination of Sulphate (SO42-) and Posphate (PO43-)  
Small amount of sample solution was placed in a dry test tube then 
BaCl2 was added to it and if white precipitate was formed HCl was 
added to it to differentiate between SO4 and PO4  
3.1.2.7.2 Identification of basic radical groups 
Methods 
 There are five groups of basic radicals. These were determined 
using the following chemical tests 
1. Determination of Lead (pb2+), Silver (Ag+) and Mercury (Hg2+): 
Small amount of sample solution placed in a dry test tube then 
dilute HCl was added to it. This is also was done by adding 
Potassium Iodide (KI). 
2. Determination of Bismuth (Bi3+), Copper (Cu2+), Mercury (Hg2+), 
Antimony (Sb3+), Arsenic (As3+), Arsenic (As5+), Tin (Sn4+) and 
Tin (Sn2+): Small amount of sample solution was added to dry 
test tube then dilute HCL was added followed by H2S. 
3. Determination of ferrous (Fe2+), ferric (Fe3+), Aluminum (Al3+) 
and Chromium (Cr3+): Small amount of sample solution was 
place in a dry test tube then Ammonium thiocyanate was added to 
it. The same test was done by adding NaOH to the sample 
solution. 
4. Determination of Zinc (Zn2+), Manganese (Mn2+), Nickel (Ni2+) 
and Cobalt (Co2+): To a small amount of sample solution in a dry 
test tube, NH4Cl + NH4OH + H2S were added. 
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5. Determination of Barium (Ba2+), Strontium (Sr2+) and Calcium 
(Ca2+): Small amount of sample solution was added to a dry test 
tube followed by NH4Cl + NH4OH + (NH4)2Co3. 
 
3.1.2.8 Identification of the stone powder using Fourier Transform 
Infrared (FTIR) spectrophotometer instrument 
Small amount of the sample as fine powder was taken and diluted 
with potassium bromide which is used as diluents because of its 
insensitivity to FTIR. 
First blank sample was read then very fine stone powder and 
potassium bromide were mixed together. The FTIR cell was filled with 
the mixture. The cell was closed and pressed to form thin layer disc then 
scanning between 500-4000nm was done to determine any functional 
groups within these limits. This process was repeated with pure ferrous 
sulphate and also with pure ferric sulphate and the result was printed.  
3.1.2.9 Identification of the stone powder by using ultra violet (UV) 
Spectrophotometer instrument 
0.5 gm of the sample powder was weighed and dissolved in 500ml 
of distilled water then the solution was filtered and serial dilutions were 
done to prepare different concentrations as follows: 1 µg/ml, 3 µg/ml, 5 
µg/ml, 10 µg/ml, 50 µg/ml. 
The wave length of the UV spectrophotometer was adjusted 
between 200 and 800 nm to scan any wave length of the sample within 
this range. Slit width 2, was used. The UV Cuvette was washed by 
distilled water then a blank solution was added to it and read more than 
once to calibrate the spectrophotometer. Finally the different 
concentrations were read and the result was recorded.  
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3.2 Microbiological study (in vitro study) 
3.2.1. Materials 
3.2.1.1 Chemicals 
 A summary of the chemicals that are used for the invitro 
microbiological studies are illustrated in the table 3.2.1. 
 
Table 3.2.1 Chemicals used for the in vitro microbiological studies 
Chemicals Company country 
Aluminium sulphate Merck UK 
Carbon disulfide BDH company Ltd. UK. 
Ferric sulphate Scharlau Spain 
Ferrous sulphate Scharlau Spain. 
KOH 20% solution BDH company Ltd UK 
Metheline blue stain BDH company Ltd UK 
Normal saline (Nacl) BDH company Ltd UK 
Olive oil Local market Sudan 
Potasium hydroxide Merck UK 
Saburoud agar Himedia laboratories Pvt. 
Ltd 
India 
Saburoud with 
chloramphenicol 
Himedia laboratories Pvt. 
Ltd 
India 
Saburoud, cyclohexamide, 
with chloramphnicol agar 
100mg 
Himedia laboratories Pvt. 
Ltd 
India 
Selenium sulfide Biomedical France 
Sodium thiosulphate CMS Sudan 
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3.2.1.2 Instruments 
 The instrument which are used for the microbiological studies are 
shown in table 3.2.2. 
 
Table 3.2.2 Instrument used in the in vitro microbiological studies. 
Instrument Company country 
Autoclave Macarthy medical LTD England 
Balance Baird & Tatlock Ltd. England 
Blunt scalpel Local market Sudan 
Cover glasses Local market Sudan 
Culture bottles (universal 
bottles )  
Local market Sudan 
Filter Paper packet Local market Sudan 
Benzene burner Local market Sudan 
Incubator 26oC Gallenhamp England 
Incubator 37oC Laboratory-thermal 
equipment LTD. 
England. 
Micro pipette Pharmaceutical Laboratory England 
Microscope Olympus Japan 
Mycological needle Local market Sudan 
Petri dish Local market Sudan 
Refrigerator Samsung Korea 
Slides glass Local market Sudan 
 
3.2.2 Methods 
3.2.2.1 Microbiological study on Malassezia furfur 
Microbiology study (in vitro study) was done at the National 
Health Laboratory, Department of Mycology, Khartoum. 
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The stone extract was used traditionally for treatment of pityriasis 
versicolor (PV). The first study focused on the effect of stone extract on 
Malassezia furfur (MF) the causative organism of PV disease. The 
second study compared the effect of the stone extract with the effect of 
other drugs used topically for treatment of PV. The last study investigated 
the effect of stone extract as solution and aqueous cream on most fungal, 
dermatophytes and (gram +ve and gram –ve) bacteria. 
3.2.2.1.1 Collection of specimens 
The organism of MF was collected from three patients; two males 
and one female by scraping (Figure 4.2.1) the skin lesions with sterilized 
solid blunt scalpel and the scales were collected on glass slide. 
3.2.2.1.2 Methods for identification of MF organism 
There are different methods used for identification MF organism 
(microscopically method, macroscopically method (culture method), PCR 
methods   ect). Two methods are used in this study. 
I. Microscopic examination: This is divided into two methods 
A) Direct examination (unstained method): After specimen's collection 
it was divided into two parts. The first part of the scales was examined 
directly unstained under microscope. One drop of 20% potassium 
hydroxide solution was taken and put on a sterile glass slide then small 
piece of sample was smear and the slide was covered. The slide was 
examines either directly under the microscope or after gentle heating for 
better fixation according to a method reported by Berman (2006). The 
result was recorded and a photograph was taken (Figure 4.2.2). 
B) Stain method: The second part of specimen was examined with stain 
method as follows: Smear from specimen was made by addition of NaCl 
solution (normal saline). The slide was heated to fix the smear and 
stained by metheline blue (1 gm of metheline blue powder was dissolved 
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on 100 ml of distilled water). The dried smear was fixed by heat or with 
potassium permanganate for 10 min then the smear with the stain was 
covered for 1 to 2 min. After that it was washed off with clean water and 
placed in draining rack for smear to air dry. 
Finally the smear was examined microscopically with oil 
immersion and the result was recorded and a photograph was taken 
(Figure 4.2.3). 
II. Macroscopic examination (Culture method) 
The organism of MF was collected from the patients as previously 
mentioned in 3.2.2.1.1. 
The medium which was used for the culture of MF was a mixture 
of sabouroud agar + chloramphenicol + cyclohexamide (actidion) 
(Sharquie, 2005). 
The medium was prepared by weighing 45.54 gm of the mixture 
above and dissolve in 1000 ml of distilled water then sterilize by steam 
sterilization using autoclave at 121˚C for 15 min. 
 MF was taken from patients and part of the specimen was 
examined under microscope. If the result was positive the other part was 
cultured. Following media preparation, it was poured, near the flame, in 
sterilized universal bottles to the mark and covered. The slope was then 
made before congealing and the bottles were kept in the shelf for 24 
hours to ensure the absence of contaminants. After that a piece of 
specimen was taken by sterile needle and was cultured in the center of 
media and olive oil was added over the surface of culture and incubates in 
26˚c for 10-15 days. This method was adopted from a procedure 
described by Kurtzman and Fell (2000) (Figure 4.2.4). 
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3.2.2.1.3 Determination of the effect of stone extract on MF 
microorganism  
Volcanic stone was crushed and milled to a fine powder then 25 
gram of the powder was weighed and dissolved in 100 ml of distilled 
water and filtrated.  
The medium was prepared as previously mentioned and poured in 
sterile universal bottles marked from one to seven. Before cooling the 
media, different volumes of the stone extracted drug were taken by 
micropipettes (200µL, 500µL, 1000µL, 1500µL and 2000µL) and added 
to the bottles labelled 2 - 6. Bottle No. one was used as control. The 
bottles were then covered and the media was mixed carefully with the 
drug. Slope was done for each bottle then incubates at room temperature 
for 24 hours.  
After that, subculture of the organism was done as follows: a piece 
from the growth in figure 4.2.4 was taken by sterile needle and cultured 
in the center of the media in each bottle. Olive oil was added over the 
surface of the culture. The culture was incubated at 26˚C for 10-15 days 
and the results were recorded and photographs were taken (Figure 4.2.5). 
A) Determination of the minimum effective concentration of stone 
extract on MF microorganism 
The media was prepared as previously mentioned and was poured 
into five sterile universal bottles marked from one to five. Before cooling 
five volumes of drug extract were taken (250µL, 300µL, 350µL, 400µL 
and 450µL) and added to the bottles. The bottles were covered and the 
media was mixed carefully with the drug. Slope was done for each bottle 
then incubates at room temperature for 24 hours.  
After that subculture of the organism was done as follows: small 
piece from the growth in figure 4.2.4 was taken by sterile needle and 
cultured in the center of the media in each bottle. Olive oil was added 
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over the surface of the culture. The culture was incubated at 26˚C for 10-
15 days and the results were recorded and photographs were taken 
(Figure 4.2.6). 
B) Determination of the effect of the main constituents of the stone on 
MF microorganism  
 Following identification of the chemical contents of the volcanic 
stone in chapter 3.1, the main constituents were used in this part of the 
study. These main constituents are ferrous, ferric, aluminum and sulphate. 
 After determination of the conc. of stone extract which gives 
inhibitory effect on the organism. The same experiment was repeated to 
determine whether the individual constituents will give the same effect or 
not. 
From each of the constituent; FeSO4, Fe2 (SO4)3, Al2 (SO4)3. 10gm 
were taken and dissolved in 100ml of distilled water to prepare three 
solutions with a concentration of 100mg/ml. 
 The media were prepared as previously mentioned and poured into 
sterile universal bottles which were divided into three groups. The bottles 
in each group were marked from one to seven. Before cooling the media; 
200µL, 500µL, 1000µL, 1500µL and 2000µL were taken by 
micropipettes from each drug and was added to each group of bottles 
labeled 2 - 6 with bottle No. 1 as control. The bottles were covered and 
the media was mixed with the drug, the slope was determined for each 
bottle then incubates at room temperature for 24 hours. Subculture was 
then done as follows: small pieces from the growth of MF in figure 4.3.4 
was taken by sterile needle and cultured in the center of the media in each 
bottle. Olive oil was added over the surface of the culture. The culture 
was incubated at 26˚C for 10-15 days and the results were recorded and 
photographs were taken (Figure 4.2.7)  
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3.2.2.1.4 In vitro comparative studies of the effect of stone extract 
with other drugs used for treatment of PV 
Many drugs were used for treatment PV such as Sodium 
thiosulphate 25% Selenium sulfide 2.5%, (selsun blue shampoo®) and 
Sulfur (Soap). In this part of the study the efficacy of these drugs were 
compared with the efficacy of the stone extract formulation. 
Sodium thiosuphate 25 gm was dissolved in 100 ml of distilled water. 
Selenium sulfide 2.5 gm was dissolved in 100 ml of carbon disulfide. 
Yellow sulfur 25 gm was dissolved in 100 ml of distilled water. 
From each solution volumes of 200µL, 500µL, 1000µL, 1500µL and 
2000µL were taken. 
The media were prepared as previously mentioned and was poured 
in sterile universal bottles which were divided into three groups. The 
bottles in each group were marked from one to six. Before cooling the 
media; 200µL, 500µL, 1000µL, 1500µL and 2000µL were taken by 
micropipettes from each drug and was added to each group of bottles 
labeled 2 - 6 with bottle No. one as control. The bottles were covered and 
the media was mixed with the drug, the slope was determined for each 
bottle then incubates at room temperature for 24 hours. Subculture was 
then done as follows: small pieces from the growth of MF in figure 4.2.4 
was taken by sterile needle and cultured in each center of the media in the 
bottles and olive oil was added over the surface of the culture. Finally 
incubate at 26˚C for 10-15 days and the results were recorded and 
photographs were taken (Figure 4.2.8). 
 Selenium sulfide is not completely dissolved when mixed with the 
media so in this experiment the drug was mixed with the olive oil. 
The media were prepared as previously mentioned and poured in 
sterile universal bottles marked from one to five. The slope was 
determined for each bottle then incubates at room temperature for 24 
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hours. Subculture was done as follow: small pieces from the growth of 
MF in figure 4.2.4 was taken by sterile needle and cultured in the center 
of the media in the bottles and olive oil was added over the surface of the 
culture then 200µL, 500µL, 1000µL, 1500µL and 2000µL were taken 
and added to the bottles mixed with olive oil. Finally incubate at 26˚C for 
10-15 days and the results were recorded and photographs were taken 
(Figure 4.2.9). 
Effect of Carbon disulfide (solvent of selenium sulfide) on the organism 
of MF 
Carbon disulfide is a solvent which used for dissolve Selenium 
sulfide and this solvent not dissolve completely when mixed with media. 
Three concentrations of the solvent carbon disulfide; 200µL, 
500µL and 1000µL, were taken. 
The media was prepared as previously mentioned and poured in 
sterile universal bottles which labeled.1-6 was divided into two groups. 
200µL, 500µL and 1000µL were taken from solvent of carbon 
disulfide and added to the first group 1 – 3. The bottles were covered and 
the media was carefully mixed with the drug, the slope was determined 
for each bottle then incubates at room temperature for 24 hours.  
Subculture was then done as follow: small pieces from the growth 
of MF in figure 4.2.4 was taken by sterile needle and cultured in the 
center of the media of the six bottles. The olive oil was added over the 
surface of the culture then 200µL, 500µL and 1000µL were taken from 
the carbon disulfide and added to the second group of bottles labeled 4 – 
6 and mixed. The bottles were covered and incubate at 26˚C for 10-15 
days and the results were recorded and photographs were taken (Figure 
4.2.10). 
 
 
 89
3.2.2.1.5 Subculture preparation  
Subcultures were done from the above result of culture of MF with 
selenium sulfide, carbon dislfids, sulfur, aluminum sulphate and ferric 
sulphate  
 The media were prepared as previously mention and was poured 
into sterile universal bottles were covered. The slope was determined then 
incubates at room temperature for 24 hours. From the above result of MF 
cultures with selenium sulfide, carbon disulfide, sulfur, aluminum 
sulphate and ferric sulphate subculture were done as follows: small piece 
from the growth was taken by sterile needle and cultured in each center of 
the media in the bottles. The olive oil was added over the surface of the 
culture. Finally incubate at 26˚C for 10 - 15 days and the results were 
recorded and photographs were taken (Figure 4.2.11). 
3.2.2.1.6 Determination of the effect of aqueous cream formulation on 
MF 
 Stone extract was formulated as aqueous cream which mention in 
the 3.3 and the effect of the cream formulation on MF was done. 
 The media were prepared as previously mentioned and poured into 
sterile Petri dish then small amount of cream was added to the media and 
mixed till the cream was dissolved in the media. The Petri dish was 
covered and incubated at room temperature for 24 hours. Subculture was 
done as follows: small piece from the growth in figure 4.2.4 was taken by 
sterile needle and cultured in each center of the media in the Petri dish 
and olive oil was added over the surface of the culture. Finally incubate at 
26˚C for 10-15 days and the results was recorded and photographs was 
taken (Figure 4.2.12). 
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3.2.2.2 Effect of stone extract on others fungi 
3.2.2.2.1 Candida 
All the specimens of dermatophytes were taken from the National 
Health Laboratory Department of Mycology. 
Media: The media which were used for these experiments are mixture of 
subroud agar with chloramphenicol. The media was prepared by 
weighing 65 gm of the mixture above and dissolve in 1000 ml of distilled 
water then the solution was shaking till dissolve all the media after that 
sterilized in autoclave at 121˚C for 15 minutes. 
Treatment preparation: 25 gm of stone as powder was weighed and 
dissolved in 100ml of distilled water and the solution was filtered. 
• The media were prepared as previously mentioned and poured in 4 
sterile Petri dishes then the organism of Candida albicans was 
mixed with the media in two Petri dish and Candida species was 
mixed with the media in the other two Petri dishes. In the center of 
two Petri dishes (one for each type) a pore was made and 500µL of 
drug was taken by micropipette and added to the pore. The other 
two Petri dishes were used as control without drug. After that 
incubate at 37˚C for two days and the results were recorded and 
photographs were taken (Figure 3.2.13). 
• The media were prepared as previously mentioned and poured in 
six sterile Petri dishes marked from one to six. 200µL, 500µL were 
taken from stone extract solution by micropipettes and added to 
Petri dish. 1, 2, 3 and 4 and Petri dish. 5 and 6 was used as control; 
then incubate at room temperature for 24 hours. Candida albicans 
was cultured in the Petri dish No.1, 2 and 5and Candida spp. was 
cultured in the Petri dish No.3, 4 and 6. Petri dishes were incubated 
at 37˚C for two days after that the results were recorded and 
photographs were taken (Figure 4.2.14). 
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• The media were prepared as previously mentioned then poured in 
two sterile Petri dishes then the aqueous cream was added as small 
amount to one Petri dish and mixed. The other Petri dish was used 
as a control. Then incubate at room temperature for 24 hours. After 
that Candida albicans and Candida species were cultured in the two 
Petri dishes and incubate at 37˚C for two days. Finally the results 
were recorded and photographs were taken (Figure 4.2.15). 
3.2.2.2.2 Dermatophytes 
A) Microsporum canis 
The media were prepared as previously mentioned and poured in 
five universal sterile bottles then 200µL, 500µL, 1000µL and 1500µL 
were taken by micropipettes from stone extract solution and added to the 
bottles. One was used as a control then the drug was mixed with the 
media and slope was determined. Incubate at room temperature for 24 
hours, after that a piece from the growth of M. canis was taken by sterile 
needle and cultured in the center of the media in each bottle. Finally 
incubate at 26˚C for 15-20 days. The results were recorded and 
photographs were taken (Figure 4.2.16). 
B) Trichophyton violaceum 
 The same method used above with M. canis was performed here 
with the microorganism T. violaceum. Following incubatation at 26˚C for 
15-20 days, the results were recorded and photographs were taken (Figure 
4.2.17). 
C) Trichophyton soudanense 
 The method used for the two above microorganism i.e. M. canis 
and T. violaceum was performed for T soudanense. (Figure 4.2.18). 
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D) Effect of stone extract as cream on the four types of dermatophytes 
(T. soudanense, T. violaceum, M. canis and M. audouinii). 
The media were prepared as previously mentioned and poured in a 
large Petri dish. Small amount of aqueous cream was taken and mixed 
with the media then incubate at room temperature for 24 hours. From the 
four types of dermatophytes (T. soudanense, T. violaceum, M. canis and 
M. audouinii) a small piece were taken and cultured in each corner of the 
Petri dish. Finally incubate at 26˚C for 15 - 20 days. The results were 
recorded and photographs were taken (Figure 4.2.19). 
3.2.2.2.3 Actinomycetoma 
 All the specimens of Actinomycetoma (Actinomadura madourae 
Am, Actinomadura pelletierii Ap, Nocardia barasilienses N.b and 
Madurella mycetomatis) were taken from the National Health Laboratory, 
Department of Mycology. 
Media: The media used was the same as that used in the study of 
Malasesia furfur. 
The media were prepared as previously mentioned and was poured 
in three sterile universal bottles; one bottle was used as control. 500µL 
and 1000 µL from stone extract was taken and added in the bottles then 
closed and mixed. The slope was determined and incubates at room 
temperature for 24 hours. After that small piece from the growth of 
Actinomadura madourae was taken by sterile needle and cultured in the 
center of the media in each bottle. Finally incubate at 37˚c for 20 - 30 
days and the results were recorded and photographs were taken (Figure 
4.2.20). 
The same experiment was done for the other types of 
Actinomycetoma (Actinomadura pelletierii Ap, Nocardia barasilienses 
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N.b ) and the results were recorded and photos were taken (Figure 
4.2.21). 
Madurella mycetomatis: The media were prepared as previously 
mentioned then were poured in six sterile universal bottles; one bottle 
was used as control. Five concentrations of stone extract were taken; 
200µL, 500 µL, 1000 µL, 1500µL and 2000 µL and added to the bottles. 
The bottles were closed and mixed then slope was determined and 
incubate at room temperature for 24 hours. After that a small piece of 
Madurella mycetomatis was taken by sterile needle and cultured in each 
center of the media in the bottles. Finally incubate at 37˚C for 20 - 30 
days and the results were recorded and photographs were taken (Figure 
4.2.22). 
The medium prepared as previously mentioned was poured in a 
large Petri dish and small amount of aqueous cream was taken and mixed 
with the media then incubate at room temperature for 24 hours. Small 
pieces from the growth of the four types of Actinomycetoma 
(Actinomadura madourae Am, Actinomadura pelletierii Ap, Nocardia 
barasilienses N.b and Madurella mycetomatis) were taken and cultured in 
each corner of the Petri dish. Finally incubate at 37˚C for 20 - 30 days 
and the results were recorded and photographs were taken (Figure 
4.2.23). 
3.2.2.2.4 Aspergillus 
All the specimens of Aspergillus (Aspergillus flavus, Aspergillus 
niger, and Aspergillus fumigutus) were taken from the National Health 
Laboratory department of mycology. 
The medium which was used in the study of Aspergillus was the 
same media as that used in the study of dermatophytes. 
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The media were prepared as previously mentioned then were 
poured in two sterile universal bottles, one bottle used as controlled. 
1000µL from stone extract drug was taken and was added to one bottle 
and was closed and mixed. The slope was determined and incubates at 
room temperature for 24 hours. After that a piece from the growth of 
Aspergillus flavus was taken by sterile needle and cultured in the center 
of the media in each bottle. Finally incubate at 26˚C for 3 - 7 days and the 
results were recorded and photographs were taken (Figure 4.2.24). 
The same experiment above was done for the other types of 
Aspergillus (Aspergillus niger, and Aspergillus fumigutus) and the results 
were recorded and photographs were taken (Figure 4.2.25). 
The media were prepared as previously mentioned then was poured 
in a large Petri dish and small amount of aqueous cream was taken and 
was mixed with the media then incubate at room temperature for 24 
hours. Small pieces from the growth of Aspergillus (1- Aspergillus flavus 
, 2- Aspergillus niger , 3- Aspergillus fumigutus and 4- Aspergillus 
terrues) were taken and cultured in each corner of the Petri dish. Finally 
incubate at 26˚C for 3-7 days, then the results were recorded and 
photographs were taken (Figure 4.2.26). 
3.2.2.3 Bacteriology  
The effect of stone extract on (G +ve and G –ve) of bacteria was 
done in laboratory of microbiology Faculty of pharmacy, University of 
Khartoum. 
3.2.2.3.1 Preparation of culture (Monica 1991): 
Culture of the standard strain of the test organism was maintained 
on suitable agar slopes and stored at 4˚C. 
A loop full of the test organism 18-24 hours was suspended in 
10ml of nutrient broth and incubated at 37˚C for 18-24 hours. 
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The overnight broth culture of the test organism was diluted with 
0.9 normal saline to give 106-107 colony forming unit (C.F.U.) / ml. 
 
3.2.2.3.2 Preparation of medium 
20gm of nutrient agar was dissolved in 100 ml of water and the 
volume completed to one liter and divided into fifty Bottles of 20 ml, then 
autoclaved in 120˚C for 15 minutes after that the bottles lift at the shelf. 
The bottles of sterilized nutrient agar were melted at water bath 
adjusted to 45-50˚C till used. (Hugo and Russell 1980) 
3.2.2.3.3 Antimicrobial activity 
Bottles of 20 ml nutrient agar were inoculated with prepared 
microorganism. Some bottles with (Pseudomonas aeruginose) as G-ve 
and the other bottles with (Staphylococcus aureus) as G+ve and poured in 
a Petri dish to give 4-5 mm uniform thickness then inoculated. Nutrient 
agar was maintained at room temperature till complete solidification, then 
by sterile cark-borer a well (cups) was made in previously inoculated N. 
agar plate  
Using standard micropipette antimicrobial solution (Stone extract) 
was added to the cups then the plate maintained at room temperature for 2 
hours to let the antimicrobial to diffuse then incubate the plate at 37˚C for 
18-24 hour after that zone of inhibition was measured which induced of 
the activity.(Figure 4.2.27). 
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3.3 Pharmaceutical Formulation 
3.3.1 Materials 
3.3.1.1 Chemicals 
The chemicals that are used for the experiments incorporated in 
this section are summarized in table 3.3.1. 
Table 3.3.1 Chemicals used for formulation study 
Chemicals company country 
Carbomer 980 American international 
chemical 
USA 
Emulsifying wax BP Boots Co. Ltd England 
Ferrous sulphate BDH England 
Glycerin Local market Sudan 
Liquid paraffin BP Boots Co. Ltd England 
Lutrol F 127 American international 
chemical 
USA 
NaOH 10% Central Medical Supplied Sudan 
Polyethylene glycol Evans®, Evans Medical ltd England 
Povidon 30 American international 
chemical 
USA 
Propylene glycol Kic chemicals USA 
Tween 20 Acros Organics USA 
White soft paraffin 
BP/USP 
Boots Co. Ltd England 
 
3.3.1.2 Instruments 
The equipment used for formulation studies are shown in table 3.3.2. 
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Table 3.3.2 Instruments used for formulation study 
Instrument  company country 
ERWAKA®GMBH AR400E Heusen Stamm Germany 
Filter Papers Sartorius Germany 
Incubater 30 and 26oC Memmert Company India 
Incubater45oC Memmert Company India 
Jars 120ml Ningbo Yuda China 
Magnetic Stirrer hotplate Stuart Scientific U.K 
Nurcomatic 700 Nurcoma pack Swedan 
Petri dish Local market Sudan 
pH meter Sartorius Germany 
Refrigerator LG Korea 
Sensitive balance Sartorius Germany 
Tubes for creams 50ml from Shifaco factory Yemen 
Vacuum Press (motor unit) 
X15522050 
Sartorious Germany 
Viscotester-VT5® Haake Spain 
 
3.3.2 Methods 
 Stone extract was traditionally used for treatment of PV, skin 
dermatophyte diseases and other superficial fungi. In this work the stone 
water extract was formulated in different topical dosage forms such as 
Ointment, Aqueous Cream, Gel, Solution and Emulsion, in an attempt to 
choose the most suitable formulation. 
3.3.2.1 Ointment 
Stone water extract was formulated as ointment form. The 
following formulations were prepared depending on the choice of base 
(Reilly., 2006). 
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3.3.2.1.1 Water in oil emulsion bases 
White wax                                          12%  
Cetyl esters wax (spermaceti)        12.5%  
Mineral oil                                          56%  
Sodium borate                                0.5% 
Water with drug                              19% 
Procedure for preparation: 
a) The white wax and spermaceti were melted on a hot plate. 
b) The mineral oil was added to this mixture and the temperature was 
brought to 70oC. 
c) The sodium borate and stone extract were dissolved in water. 
d) 25gm of stone as powder weighed and dissolved in 100ml of 
distilled1 water then filtered 
e) The sodium borate solution was heated to 70oC. 
f) When both phases have reached the desired temperature, both 
phases were removed from the hot plate and the aqueous phase was 
added slowly and with constant stirring to the oil phase. 
g) The mixture was stirred briskly and continuously until congealed. 
3.3.2.1.2 Oil in water emulsion bases (Hydrophilic ointment) 
Sodium lauryl sulfate          1% 
Propylene glycol                12% 
Stearyl alcohol                   25% 
White petrolatum               25% 
Water with drug                 37% 
(25gm of stone as powder was dissolved in 100 ml of stilled water and 
filtrated then 37 %was taken). 
Procedure for preparation: 
a) The stearyl alcohol and white petrolatum were melted on hot plate. 
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b) This mixture was heated to 70oC. 
c) The remaining ingredients were dissolved in water with stone 
extract and the solution was heated to 70oC. 
d) The oleaginous phase was added slowly to the aqueous phase and 
stirred constantly. 
e) The mixture was removed from the heat and stirred until it 
congealed. 
3.3.2.1.3 Water soluble ointment base 
Polyethylene glycol (3350)                  400 gm 
Polyethylene glycol (400)                  600 gm 
Procedure for preparation: 
a) The PEG 400 and PEG 3350 were melted together on hot plate. 
b) The mixture was wormed to about 65oC. 
c) The mixture was removed from the hot plate and stirred until 
congealed. 
d) The aqueous phase (water contain drug) was wormed to the same 
temperature of the base and was added slowly with stirring until 
congealed. 
3.3.2.2 Gel formulation 
Formulation of the extract as gel formula was preformed according 
to a method adopted from Shifaco pharmaceutical industries. 
3.3.2.2.1 Gel formulation 1 
Carbomer 980                                      0.6 gm 
NaOH 10%                                          2 gm 
Povidon 30                                           1.5 gm 
Water with active ingredient                 95.9 gm 
(25gm of stone as powder was dissolved in 100 ml of distilled water 
and filtrated then 95.9 gm was taken) 
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Procedure for preparation  
1) 85.9 ml of water with active ingredient was added to 0.6 gm of 
carbomer and stirred until gel was formed. 
2) 2 gm of NaoH 10 % was added to step 1. 
3) 1.5 gm of povidon 30 was mixed with 10 ml of water with active 
ingredient and added to step 2. 
3.3.2.2.2 Gel formulation 2 
Lutrol F 127                                   20 gm 
Water with active ingredient          80 gm 
(25gm of stone as powder was dissolved in 100 ml of distilled water and 
filtrated then 80 gm was taken) 
Procedure for preparation  
1) Water with active ingredient was heated at 70˚C.  
2) Step1 was added gradually to the lutrol F 127 and stir until gel is 
formed  
3) Then heated on water bath until all bubbles were removed. 
3.3.2.3 Aqueous cream formulation 
The formulation of aqueous cream was prepared according to the 
British Pharmacopoeia, B.P. (2002). 
White soft paraffin                                50gm 
Emulsifying wax                                   30gm 
Liquid paraffin                                   20gm 
Liquid phase: 
Water with active ingredient                 70ml 
Fifty gram of white soft paraffin was weighed and melted with 30 
gm of emulsifying wax on a water bath, 20 gm of liquid paraffin was 
added and heated at 70˚C and stirred until congealed to form emulsifying 
ointment. 
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Twenty five gram of stone as powder was weighed and dissolved in 
100ml of distilled water then filtrate was done using filter paper and 70 
ml from the filtrate was taken and heated on a water bath at 70˚C. Thirty 
gram from the emulsifying ointment was taken and heated on a water 
bath at 70˚C till the two phase have the same temperature then the liquid 
phase was added gradually to the base with continues stir until congealed. 
3.3.2.4 Modified aqueous cream formulation  
The above formulation was improvement by the addition of one gm of 
tween 20 to the liquid phase to overcome the separation of the cream and 
10 gm of propylene glycol as emollient to smooth and improve the 
texture of the cream and overcome the layer which form on the surface of 
the cream. The final formulation was as follow: 
White soft paraffin                               50 gm 
Emulsifying wax                                30 gm 
Liquid paraffin                                      20 gm 
Liquid phase: 
Water with active ingredient                 59 gm 
Tween 20                                           1 gm 
Propylene glycol                                   10gm 
Fifty gram of white soft paraffin was weighed and melted with 30 
gm of emulsifying wax on a water bath, 20 gm of liquid paraffin was 
added and heated at 70˚C and stirred until congealed to form emulsifying 
ointment. 
Twenty five gram of stone as powder was weighed and dissolved in 
100 ml of distilled water then filtrate was done using filter paper and 59 
ml from the filtrate was taken and mixed with one gm of tween 20 and 10 
gm of propylene glycol then heated on a water bath at 70˚C. Thirty gram 
from the emulsifying ointment was taken and heated on a water bath at 
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70˚C till the two phase have the same temperature then the liquid phase 
was added gradually to the base with continues stirring until congealed. 
3.3.2.5 Preparation of large quantity (10Kg) from the modified 
formulation of aqueous cream 
Preparation of large quantity of aqueous cream and microbiology 
and stability study were done in Shifaco Pharmaceutical Industries. 
Sana'a, Yemen. 
After the formulation of aqueous cream was proved to be stable large 
quantity (5Kg) of the aqueous cream was prepared as follows 
White soft paraffin                               750 gm 
Emulsifying wax                                450 gm 
Liquid paraffin                                   300 gm 
Liquid phase: 
Water with active ingredient             2950 gm 
Tween 20                                            50 gm 
Propylene glycol                                500 gm 
Seven hundred and Fifty gram of white soft paraffin was weighed 
and melted with 450 gm of emulsifying wax on Erweka® machine (Figure 
3.3.1), 300 gm of liquid paraffin was added and heated at 70˚C and stirred 
until congealed to form emulsifying ointment. 
One thousand two hundred fifty gram of stone as powder was 
weighed and dissolved in 4500 ml of distilled water then filtrate was done 
using filter vacuum press (motor unit) instrument (Figure 3.3.2). 2950 ml 
from the filtrate was taken and mixed with 50 gm of tween 20 and 500 
gm of propylene glycol then heated at 70˚C on magnetic stirrer hot plate 
using magnetic rod for stirring.  
When the temperature of the two phases reached 70˚C liquid phase 
was added gradually to the base on Erweka® machine pan and stirring of 
 103
the machine was continued at 250 RPM till the liquid phase is completely 
added. After that the temperature of the machine was switched off and 
stirring of the machine was continued at 250RPM for one hr., until the 
aqueous cream was formed then the stirring was stopped and the cream 
was filled in collapsible tubes (40 gm) then folded and crimped. 
Part of quantity was used for pilot clinical trail on volunteers in 
Yemen. About 12kg were prepared in the pharmaceutics laboratory and 
used for clinical trails on volunteers in Sudan. 
 
Figure.3.3.1: ERWAKA®GMBH AR400E machine and magnetic hot 
plate. 
 
Figure.3.3.2: Vacuum press (motor unit) instrument. 
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3.3.2.6 Quality Control test for aqueous Cream formulation 
 The quality control tests used in this study are: physicochemical 
properties, viscosity, pH, microbiological quality, chemical assay and 
stability study. 
3.3.2.6.1 Physicochemical properties 
 The physicochemical properties of the aqueous cream 
(Appearance, color, Homogeneity, pH, Spreadability, Consistency 
(Texture) and Washability) were determined and summarized in the table 
4.3.1. 
3.3.2.6.2 Viscosity 
 Visco tester instrument was used for measurement of the viscosity 
of the stone formulation. 
The instrument position was adjusted to a balanced position, it’s 
key was opened and allowed to calibrate. Different spindles (SP) (R1, R2, 
R3, R4, R5   etc) were chosen according to the quantity of the sample 
which was used.  
The spindle R3 was immersed in the sample to the mark after that 
the start key was opened and the result was recorded (Figure 3.3.3). 
 
Figure 3.3.3 Visco tester instrument 
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3.3.2.6.3 pH 
 The pH meter was adjusted and calibrated by using neutral 
solution to adjust the pH to seven then the rod of the instrument was 
cleaned and dried. One gm of the aqueous cream was taken and dissolved 
in 100ml of distilled water and pH was measured. 
3.3.2.6.4 Microbiology quality of pharmaceutical preparation (BP 
2002) 
I. Sample preparation  
Sampling plan: sampling of the product must follow a well defined 
sampling plan which dependent on factors such as Bach size and health 
hazard associated with unacceptably highly contaminated products. 
According to the B.P. (2002) 10 gm of the sample of raw material 
(stone powder), 10 ml of the extract solution and 10 gm from the finished 
product (cream) were taken randomly from the bulk material, a container 
the extract solution and from the finished products.  
 The microbial test was done for each sample separately. Each 
sample was dissolved or diluted with distilled water to be examined in 
buffered sodium chloride peptone solution pH 7.0. The dilution was 1:10. 
Serial dilutions were made till pH was adjusted 7.0. 
II. Sample examination: 
There are two methods for examination: 
(1)  Membrane filtration method 
(2)  Plate count method which is divided into two types  
(a)  pour-plate method 
(b)  surface-spread method. 
 Plate count method was used in this study using pour-plate method. 
Sterilized Petri dishes 9 cm in diameter were used. To each dish 1ml of 
the samples prepared above was added and 15 to 20 ml of a liquefied agar 
 106
medium (peptone agar) suitable for the cultivation of bacteria (medium 
A) or 15 to 20 ml of a liquefied agar medium (dextrose agar) suitable for 
the cultivation of fungi (medium B) was added at not more than 45˚C. 
Three Petri dishes from each media were prepared for each sample. 
The plates were incubated at 30˚C to 35˚C for bacteria and 20˚C to 25˚C 
for fungi for five days. The plate with a highest number of colonies less 
than 300 for bacteria and less than 100 for fungi was selected. By using 
arithmetic average of the count, the number of colony-forming units (cfu) 
was calculated per gram or milliliter. 
3.3.2.6.5 Chemical assay 
Chemical analysis for the main constituents in the sample of 
aqueous cream was performed in the Chemical Laboratory of Geological 
Research Ministry of Energy and Mining, Khartoum, Sudan. 
The analysis was done for sulphate group (SO4) and for iron as ferrous 
and ferric. 
Gravimetric method was used for analysis the sulphate and Atomic 
Absorption analysis was used for iron. 
The two methods of analysis are mention in the chapter (3.1) 
“chemical analysis”.  
3.3.2.6.6 Stability studies 
Accelerated stability for the aqueous cream at 45˚C and 75% 
Relative humidity (RH), at refrigerator 5˚C and at zero time were studied 
for three month and at (shelf life) room temperature for two year. 
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3.4 Pharmacological Studies 
 In these chapter studies on the effect of stone extract on different 
isolated muscles (intestine muscle, rectum muscle, skeletal muscle and 
aortic muscle) were carried out. 
3.4.1 Materials 
3.4.1.1 Chemicals 
 The chemicals used for the pharmacological studies are shown in 
table 3.4.1. 
 
Table 3.4.1 Chemicals used in the pharmacological studies. 
Chemical company Country 
Acetylcholine Sigma UK. 
Animals (Rats, Rabbits, Frogs ) Veterinary National 
Research Center (Soba) 
Sudan 
Atropine Sigma UK. 
Calcium chloride Scharlau Spain. 
D- glucose Scharlau Spain. 
Magnesium chloride Scharlau Spain. 
Noradrenalin Sigma UK. 
Potassium chloride BDH UK. 
Propanolol Sigma UK. 
Sodium bicarbonate Scharlau Spain. 
Sodium chloride Scharlau Spain. 
Sodium dihyrogen phosphate BDH UK. 
Tolozoline Sigma UK. 
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3.4.1.2 Instruments 
The instruments used for the pharmacological studies are shown in 
table 3.4.2. 
 
Table 3.4.2 Instruments used in the pharmacological studies 
Instrument Company Country 
Research tissue bath Harvard UK. 
Sensitive balance Sarturius Germany 
Universal Oscillograph Harvard UK. 
 
3.4.2 Methods 
3.4.2.1. The effect of stone extract on isolated rabbit small intestine 
 Intestinal muscle is innervated by both parasympathetic and 
sympathetic fibers of the autonomic nervous system. 
Adrenergic agonists have predominantly inhibitory action on the 
intestine, the effect is only observed as relaxation in the intestinal muscle. 
The inhibitory effect of mixed α and β receptors agonist can be 
inhibited by mixture of tolozoline and propanolol. 
The cholinergic drugs on the other hand are predominantly 
stimulant and their effect on the intestinal smooth muscle is effectively 
blocked by the muscarinic antagonist such as atropine. The effect of stone 
extract was investigated on the intestinal smooth muscle to show its 
possible effect on the adrenergic and cholinergic receptors. 
3.4.2.2 The effect of the stone extract on the cholinergic receptors 
A rabbit of local strain was killed by dislocating the neck and the 
animal was exanguinated. The abdomen was opened and the jejunal area 
of the intestine was located. This is the proximal part where the 
mesenteric supply was professed. A proximately 4cm in length was cut 
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into segment and transferred to the Petri dish containing tyrode solution 
and the mesentery and fat surrounding the muscle were trimmed away. 
Thread was passed through one wall of the tissue at both top and 
bottom, the bottom thread was attached to the tissue holder. The mounted 
tissue was transferred to the organ bath and attached to isotonic 
transducer connected to Harvard Oscillograph recorder (Figure 3.4.1). 
The preparation was allowed adaptation period of about 30 minutes 
then washed and the test solution was administered. The stone extract was 
added to the tissue in separate doses of 1mg/ml, 2mg/ml, and 4mg/ml gut 
bath. Muscaranic receptors of the tissue were blocked by 0.5µg/ml of 
atropine. Stone extract was added to the tissue in a concentration of 
1mg/ml gut bath. 
The experimental parameters are shown in table 3.4.3. 
 
 
Figure 3.4 1 Organ Bath and Harvard Oscillograph Record. 
 
 
 
 110
Table 3.4.3 The experimental parameters used in the experiments of 
cholinergic receptors 
Rabbit Animal 
25 ml Organ bath 
Tyrode Ringer solution 
Air Aeration 
37c˚ Bath temperature 
Isotonic Recording 
0.5-4gm Resting tension 
30 minutes Equilibration period 
3-5 minutes Dose cycle 
30 seconds Contact time 
3.4.2.3. The effect of the stone extract on the adrenergic receptors 
The tissue was prepared as previously described in 3.4.2.2. The 
Experimental parameters are summarized in table 3.4.4. 
Table 3.4.4 Experimental parameters used in the experiment of 
adrenergic receptors. 
Rabbit Animal 
25 ml Organ bath 
Tyrode Ringer solution 
Air Aeration 
37c˚ Bath temperature 
Isotonic Recording 
0.5-4gm Resting tension 
30 minutes Equilibration period 
3-5 minutes Dose cycle 
30 seconds Contact time 
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The preparation was allowed adaptation period of about 30 minutes 
with continuous washing. Stone extract was added to the tissue in 
increasing doses of 1mg/ml, 2mg/ml, 4mg/ml. α adrenergic receptors of 
the tissue were blocked by 40µg/ml of tolozoline then 4mg/ml of stone 
extract was added and after one minute washing was done. β adrenergic 
receptors of the tissue were blocked by 40µg/ml of propanolol then 
4mg/ml of stone extract was added and after one minute washing was 
done. Mixtures of 20µg/ml tolozoline and 20µg/ml propanolol were 
added to the tissue then 4mg/ml of stone extract was added and after one 
minute washing was done. 
3.4.2.4. The effect of stone extract on isolated rat uterus  
The uterus was innervated by sympathetic nerves and possibly a 
parasympathetic supply which runs to the wall of the tissue. The response 
of the uterus to the drugs varies from species to species. The uterus of the 
rabbit gives responses which closely approximate those of the human.  In 
contractile response this tissue is a typical of smooth muscle. There is 
often a latent period after drug addition before initiation of contraction, 
the response is invariably all or none, and the contraction is not 
maintained even when the drug is still present. This failure to the sustain 
contraction is a physiological phenomenon known as transient 
depolarization. The dose response characteristics of the tissue are 
temperature and ringer dependent, and steep dose response curves are 
obtained at 37oC. 32oC is usually chosen for experiments with the uterus 
in order to reduce spontaneous contraction. Such activity is also reduced 
by using low Ca++ ringer such as De Jalons solution. So the rat uterus 
muscle is used for this experiment. Cholinergic agonists (acetylcholine) 
which stimulate muscarinic receptors cause contraction of the isolated 
uterus muscle and their effect can be blocked by appropriate antagonists 
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such as atropine. The experimental parameters of this part of the study are 
shown in table 3.4.5. 
Table 3.4.5 Experimental parameters used in the experiment of uterus 
muscle  
Rat Animal 
25 ml Organ bath 
De Jalons Ringer solution 
95%O2  and 5%CO2 Aeration 
32oC Bath temperature 
Isotonic Recording 
0.5gm Resting tension 
30 minutes Equilibration period 
3 minutes Dose cycle 
15-30 seconds Contact time 
 
A female Wister albino rat was injected with 0.1mg/kg stilboestrol 
subcutaneously 24hours before the experiment. The rat was killed by a 
blow on the head and exsanguinated. The abdomen was opened and the 
two uterine horns were exposed by pulling aside the intestine. They were 
easily distinguishable by their pink coloration. 
Each horn was gently freed from fat and mesenteric attachments, a 
cut out and transferred to a Petri dish containing aerated De Jalon 
solution. Threads were passed through one wall of the uterus at both top 
and bottom. The bottom thread was attached to the tissue holder and 
transferred to an isolated organ bath and the top thread was attached to 
isometric transducer connected to Harvard oscillographic recorder. 
The preparation was allowed an adaptation period of about 30 
minutes. Response of the rat uterus was shown with adding 1µg/ml of 
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acetylcholine for one minute then washed. Stone extract was added in 
increasing dose of 1mg/ml, 2mg/ml, 4mg/ml and was washed after each 
concentration. Stone extract in a dose of 4mg/ml was added to the uterus 
muscle, after one minute acetylcholine was added to the uterus tissue. 
3.4.2.5. The effect of stone extract on isolated frog rectus abdominal 
muscle (Skeletal muscle)  
Skeletal muscle is so named because of its anatomical attachment 
to the skeleton which is innervated by somatic motor nerves that are fast 
conducting and myelineated. The frog rectus abdominal contains both 
multiply- innervated and focally-innervated fibres but the characteristics 
of response are typical of multiply-innervated fibres. The effect of 
stimulation produces depolarization of small areas of muscle fibre at the 
nerve ending and there is no action potential generated. 
Since frogs are cold-blooded, the rectus preparation is used at room 
temperature. A specialized frog ringer solution is also employed 
equivalent to 0.6% saline which is iso-osmotic for frog tissue. 
Drugs which stimulate nicotinic receptors such as acetylcholine 
cause contracture of slow muscle fibres and have no effect, or facilitate 
twitch responses of fast fibres. At high concentration or in the presence of 
anticholinestrase drugs the twitch response is inhibited due to 
depolarisation block. Table 3.4.6 show the parameters used for this 
experiment. 
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Table 3.4.6 Experimental parameters used in the experiment of 
abdominal muscle (skeletal muscle) 
frog Animal 
25 ml Organ bath 
Frog ringer Ringer solution 
air Aeration 
20oC Bath temperature 
Isotonic Recording 
0.5gm Resting tension 
30-45 minutes Equilibration period 
4-7 minutes Dose cycle 
1-1.5 minutes Contact time 
 
A frog was decapitated after stunning using a patching needle. The 
frog was placed ventral side up on a cork board and cut was made in mid 
ventral line of the trunk. 
The skin was separated along the mid line, the recti muscles were 
exposed and moistened with frog ringer. Two longitudinal cuts were 
made on either side of the xiphoid cartilage and was followed the line of 
the recti muscles to their attachment to the pubis. The striated appearance 
of the recti muscle was made it easy to distinguish them from the 
surrounding pectoralis posterior muscles at the upper end and the 
obliques externis muscle at the lower end. 
Transverse cut through the xiphoid cartilage, whilst supporting the 
muscles by forceps, was made. The tissue was freed from its attachment 
to the pubis. The recti muscles were transferred to Petri dish containing 
frog ringer solution and they were separated from the xiphoid cartilage. 
Threads were passed through the muscle at both top and bottom and 
bottom thread was attached to the tissue holder. 
The preparation was transferred to the organ bath and the top thread was 
attached to an isotonic transducer connected to Harvard Osillographic 
recorder. 
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The preparation was allowed an adaptation period of about 30 
minute for the instrument then the organ bath was washed and normal 
graph was done then 2µg/ml of acetylcholine was added for one minute 
then washed. Stone extract was added to the tissue in increasing dose of 
1mg/ml, 2mg/ml, 4mg/ml and washing after each concentration. Stone 
extract was added to the tissue in a concentration of 4mg/ml for one 
minute then without washing 2µg/ml of acetylcholine was added. 
3.4.2.6. The effect of stone extract drug on isolated rabbit aortic strip 
preparation 
In order to study in vitro constriction of blood vessels in response 
to drugs, it is necessary to cut spiral strips of arteries. The movement of 
circular muscle can therefore be measured in a longitudinal plane. The 
aortic strip is a suitable preparation and possesses mixed α and β 
receptors as well as isolated muscarinic receptors. Innervated by 
sympathetic fiber of the autonomic nervous system. Noradrenaline 
agonist drug have response effect on mixed α and β receptors.  
The parameters used in the experiment are illustrated in the table 
3.4.7. 
 
Table 3.4.7 Experimental parameters used in the experiment of the 
isolated rabbit aortic strip preparation: 
Rabbit Animal 
25 ml Organ bath 
Krebs Ringer solution 
95% O2 and 5%CO2 Aeration 
37oC Bath temperature 
Isotonic Recording 
2-3gm Resting tension 
45 minutes Equilibration period 
7 minutes Dose cycle 
2-3 minutes Contact time 
 
 116
 A rabbit was killed by a blow on the neck and the animal was 
exanguinated. The chest was opened and the internal viscera were pulling 
to one side exposing the aorta was cut, closed to the heart, and aorta was 
dissected\out as far as possible. 
Several strip preparations can be made from one rabbit, the tissue 
was transferred to a Petri dish containing aerated ringer solution and the 
aorta was divided into 3-4 cm length.  
The aorta was located over large serum needle or thin glass rod to 
facilitated preparation of a strip of tissue.  
Any surrounding fat or connective tissue was removed and the 
aorta was cut spirally to produce continuous strip by using curved 
scissors for this purposes. 
Thread to each end of the strip was tied and one end was attached 
to the tissue holder then the mounted tissue was transferred to the organ 
bath and upper tread was attached to the transducer. 
The preparation was allowed an adaptation period of about 30 
minute then washing and normal working then stone extract was added to 
the tissue in a concentration of 4mg/ml and washed after three minutes. 
Noradrenaline 1µg/ml was added to the tissue then after 2-3 minutes 
stone extract was added to the tissue in a dose of 4mg/ml. The contents of 
the different physiological salts solutions used in the pharmacological 
studies are summarized in table 3.4.8. 
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Table 3.4.-8 Physiological salt solutions (Ringer solutions) (Salts 
g/5litter): 
Krebs Frog ringer De Jalons Tyrode Salts 
34.5 32.5 4.5 40 NaCL 
10.5 1 2.5 5 NaHCO3 
10 - 2.5 5 D Glucose 
0.8 - - - KH2PO4 
- - - 0.25 NaH2PO4 
1.8 0.7 2.1 1 KCL 
1.45 - - - MgSO4.7H2O 
- - - 0.5 MgCL2 
1.85 0.79 0.4 1.32 CaCL2.2H2O 
95% O2 
5% CO2 
air 95% O2 
5% CO2 
Air Aeration 
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3.5 Toxicological studies of the stone extract drug 
3.5.1 Materials 
3.5.1.1 Chemicals 
The chemicals used for the toxicological studies are shown in table 
3.5.1. 
 
Table 3.5.1 Chemicals used in the toxicological studies 
Chemicals company country 
Alkaline phosphate (ALP) Plasmatic laboratory 
product(Ltd) 
U.K. 
Diet to rat Grain Sitos Company Sudan 
Formalin Local market Sudan 
Glutamic oxaloacetic 
transaminase (GOT)  
Plasmatic laboratory 
product(Ltd) 
U.K. 
Glutamic pyruvic 
transaminase (GPT) 
Plasmatic laboratory 
product(Ltd) 
U.K. 
Rat Veterinary National 
Research Center (Soba) 
Sudan 
Slide glasses Local market Sudan 
 
3.5.1.2 Instruments 
The instrument used for the toxicological studies are shown in 
table 3.5.1. 
Table 3.5.2 Instrument used in the toxicological studies 
Instrument Company Country 
Centrifuge EBA35 Hettich Japan 
Hematology analyzer Humaccount plus Germany 
Microscope Olympus Japan 
U.V. spectrophotometer 6305 Jenway U.K. 
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3.5.2. Methods 
 The experiments of toxicology were done in the Medicinal and 
aromatic plants research institute. 
 Twelve male Wister rats were obtained from the Aromatic Herbs 
and Medicinal Plants Research Institute (A.H.M.P.R.I), Khartoum, reared 
within the premises of the Institute under illumination at night and early 
morning with feed and drinking water provided ad libitum (Table 3.5.1). 
At the age of 60 days, the rats were allotted at random to two 
groups each of 6 rats. Group 1 received orally distilled water and served 
as a control. The other group was treated with stone extract as 100mg/kg 
body weight. 
The treatment of both groups continued daily for 21 days. At the 
end of the experiment rats from each group were slaughtered to identify 
gross lesions and specimens of the liver, intestines, kidneys, spleen and 
heart were immediately fixed in 10 % neutral buffered formalin and 
processed for histopathology. Blood samples were collected at slaughter 
for hematology and serum analysis. 
 
Table 3.5.3 Percent composition of normal diet* fed to rats 
Ingredients % 
Protein 22.5 
Starch 39.2 
Granulated Sugar 05.0 
Cellulose Powder 03.0 
DL. methionine 00.3 
Corn oil 05.0 
Super Concentrated 05.0 
* Manufactured by Grain Sitos Company, Khartoum North 
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3.5.3. Parameters  
3.5.3.1 Growth changes  
Average body weight and weight gain for each group of rats were 
measured weekly throughout the 3 weeks period. 
3.5.3.2 Biochemical parameters  
Blood samples were collected at slaughter in dry test tubes, and 
serum was separated and stored at -20ºC until analyzed for the activities 
of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and 
alkaline phosphatase (ALP). 
3.5.3.3 Hematology parameters 
Blood samples were collected in dry test tubes containing EDTA 
(Ethylene diamine tetra acetic acid) and examined for hemoglobin 
concentration (Hb), red blood cells (RBC) counts, packed cell volume 
(PCV), mean corpuscular volume (MCV), mean corpuscular hemoglobin 
(MCH), and mean corpuscular hemoglobin concentration (MCHC) and 
total white blood cell (WBC). 
3.5.4 Methods 
3.5.4.1 Serobiochemical methods 
Blood samples were collected and allowed to clot and sera were 
separated by centrifugation at 3000 r.p.m for 5 min and stored at -20°C 
until analyzed. 
3.5.4.1.1 Aspartate aminotransferase (AST) 
This enzyme is also known as aspartate transaminase, L-Aspartate: 
2-oxoglutarate aminotransferase, glutamate oxaloacetate transaminase 
(GOT, E.C.2.6.1.1). 
Serum AST activity was measured by a spectrophotometric method 
using commercial kits (Plasmatec laboratory product Ltd, U.K.). 
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Test principle 
The enzyme catalyzes the transfer of an amino group from 
aspartate to α-ketoglutarate (α-kg) in a reversible reaction. The end 
products formed in this reaction are oxaloacetate and glutamate. 2, 4, 
Dinitrophenyl hydrazine is added to form hydrazone of the keto acid 
present. These hydrazones sequentially react with sodium hydroxide to 
form a colour, which can be read by the spectrophotometer (Jenway Ltd, 
Essex U.K) at a wavelength of 505nm.The enzymatic activity was then 
read off on the standard curve. 
3.5.4.1.2 Alanine aminotransferase (ALT) 
Alanine transaminase, L-alanine: 2-oxoglutarate aminotransferase, 
glutamate pyruvate transaminase (GPT, E.C.2.6.1.2). 
Serum ALT activity was measured by a spectrophotometric 
method using commercial kits (Plasmatec laboratory product Ltd, U.K.). 
Test principle 
The enzyme catalyzes the transfer of amino group from alanine to 
α - ketoglutarate in a reversible reaction. The end products formed in the 
reaction are glutamate and pyruvate. The transaminase activity is 
proportional to the amount of pyruvic acid formed over a definite period 
of time and is measured by a reaction with 2, 4, dinitrophenyl hydrazine 
(DNPH) in alkaline solution (NaOH). The absorbance was read by the 
spectrophotometer at a wavelength of 505 nm. The enzymatic activity 
was then read off on the standard curve. 
3.5.4.1.3 Alkaline phosphatase (ALP) 
This enzyme is also known as Orthophosphoric monoester 
phosphohydrolase (ALP. E.C.3.1.3.1).The serum ALP activity was 
measured photometrically using commercial kits (Plasmatec Laboratory 
Products Ltd, U.K.).  
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Test principles  
ALP catalyzes the hydrolysis of p-nitrophenylphosphate liberating 
p-nitrophenol and inorganic phosphate. The rate of p-nitrophenol 
formation is proportional to ALP activity present in the serum.  
P-nitrophenyl phosphate + H2O  ALP  P- nitrophnol + inorganic phosphate. 
Non – hemolyzed serum was added to a chromogenic substrate and 
mixture was incubated at -37 ºC for 5 min. A colour developer was then 
added and mean absorbance change per min at 405nm /min was utilized 
for calculation of enzyme activity as follows:  
Enzyme activity (i .u) = A 405 / minute x 2764 (A = Absorbance)  
3.5.4.2 Hematological methods 
These techniques were performed according to those described by 
Schalm et al (1975). 
3.5.4.2.1 Haemoglobin concentration  
Hemoglobin concentration was determined by the 
cyanomethemoglobin technique using a hematology analyzer (Figure 
3.5.1) (Humacount plus, German). The method is based on the conversion 
of haemoglobin by means of Drabkin΄s solution (0.2g Potassium cyanide, 
0.2g potassium ferricyanide, and 1g sodium bicarbonate per one litter of 
distilled water) to cyanomethaemoglobin. Haemoglobin concentration 
was measured in g/dl of blood. 
 
Figure 3.5.1: Humacount plus, German which was used as hematology 
analyzer 
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3.5.4.2.2 Red blood cell (RBC) count 
Red blood cells were counted by hematology analyzer (Humacount 
plus, German). Formal citrate was used as a diluents. 
3.5.4.2.3 Packed cell volume (PCV) 
 Fresh blood samples were centrifuged in a microhaematocrit 
centrifuge (Humacount plus, German) for 5 minutes. The PCV 
percentage was read off on the scaling instrument provided with the 
centrifuge. 
3.5.4.2.4 Mean corpuscular volume (MCV) 
The MCV, in cubic microns, was calculated from RBC count and 
PCV values as follows:  
)million/m incount  (RBC
10)x  (PCVcrons)(incubicmi MCV 3=  
3.5.4.2.5 Mean corpuscular hemoglobin (MCH) 
 The MCH was calculated from Hb and RBC values as follows:  
3million/mincount RBC
10x  (g/dl) Hb(pg)MCH =  
3.5.4.2.6 Mean corpuscular hemoglobin concentration (MCHC) 
 The MCHC was calculated from Hb and PCV values as follows: 
(%) PCV
100x  (g/dl) Hb(%) MCHC =  
3.5.4.2.7 White blood cell (WBC) count 
 White blood cells were counted with an improved hematology 
analyzer (Humacount plus, German).Turk’s fluid (1% glacial acetic acid, 
tinged with gention violet) was used as diluents. 
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3.5.4.3 Pathological methods  
All pathological methods were done in the nationality center of 
veterinary research laboratory of histopathology, Soba, Khartoum, Sudan. 
3.5.4.3.1 Collection of the samples 
 Necropsy was conducted to identify gross lesions and specimens of 
the liver, kidneys, heart, spleen, and intestines were immediately fixed in 
10% neutral buffered formalin (Figure 3.5.2) 
 
Figure 3.5.2 Necropsy of the rats and specimens of the liver, kidneys, 
heart, spleen, and intestines  
3.5.4.3.2 Fixation  
 Fixation is the preservation of cells and tissue constituents as a life 
like manner as possible and 10% neutral formalin are most commonly 
used as fixatives. 
3.5.4.3.3 Dehydration  
 Dehydration means removal of water from tissues. First the tissues 
were cut (trimmed) into small square pieces about one cubic cm. Then 
washed in running tap water for 15 min. to remove the fixing agent. 
 The following different concentrations of alcohol were used to 
remove water from the tissues: 70% alcohol, 90% alcohol and 100% 
alcohol (absolute alcohol). 
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3.5.4.3.4 Clearing  
 Clearing is to increase the refractive index and to make the sections 
transparent so it can be examined microscopically and their are different 
clearing agents such as 1-chloroform 2-Zylene 3-Benzene 4-cedar wood 
oil. 
3.5.4.3.5 Impregnation  
 Melted paraffin wax was used to remove the clearing agent from 
the tissue and penetrate the tissues to fill the intracellular spaces. 
3.5.4.3.6 Blocking (embedding) 
 Tissues were blocked in melted paraffin wax, and quickly cooled. 
Blocking was done to facilitate cutting. 
3.5.4.3.7 Section cutting  
 In the usual manner, sections were cut with aid of rotary 
microtome. 5-6 microns (1 micron = 0.001millimeter) gives suitable thin 
sections for routine work. 
3.5.4.3.8 Fixing section to slide  
 To a warm water bath 50-54oC containing little amount of gelatin 
powder the section was transferred and left to float then fixed to the slide 
glass and incubated for 30min. at 60oC to dry. 
3.5.4.3.9 Staining 
 Haematoxyline and Eosin (H & E), a common method for staining 
according to the following procedure: 
 Sections were stained in heamatoxyline for 10min then washed in 
running tap water several times and differentiated in 1% acid alcohol.  
Blue in running tap water for at least 10min and counter stain with Eosin 
2-3min then rinse quickly in tap water. The section was dehydrated in 
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70%, 90% and absolute alcohol after that the excess of alcohol sections 
were removed then cleared in Zylene.  
3.5.4.3.10 Mounting  
 The section was covered with a cover glass (cover slip) using 
suitable mounting media such as Canada balsam. After overnight drying 
at room temperature, sections were then ready to be examined 
microscopically. 
3.5.4.4 Statistical analysis 
All the results of the toxicological studies were analyzed 
statistically using SPSS analysis. 
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3.6 Clinical trials 
3.6.1 Materials 
3.6.1.1 Chemicals 
 The chemicals used for clinical trials are shown in table 3.6.1. 
Table 3.6.1 chemicals used in the clinical trials study 
Chemicals Company Country 
Clotrimazole cream 1% (Candid) Glenmark India 
Clotrimazole cream 1% (Mycoril) Remedica Limassol-Cyprus
Formulation of stone as aqueous 
cream 
Pharmaceutics 
Laboratory 
Sudan 
KOH BDH U.K 
 
3.6.1.2 Instruments 
 The instruments used for clinical trials are shown in table 3.6.2. 
Table 3.6.2 Instruments used in the clinical trail study 
Instrument Company Country 
Camera digital Sony Japan 
Microscope Olympus Japan 
Slides and covers Local market Sudan 
Surgical Blade Sky brilliant(HK) industry Ltd. China 
 
3.6.3 Study design 
Hospital based comparative clinical study. 
3.6.3 Study area 
 Skin and Sexually Transmitted Diseases, Khartoum 
Teaching Hospital.  
Sample analysis was done in the National Health Laboratory 
Department of Mycology. 
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3.6.4 Study population 
100 adult (male / female) volunteers of comparable age and weight 
were selected from the out patient clinics of the skin and sexually 
transmitted disease unit of Khartoum Teaching Hospital. They were 
assessed for abnormalities according to physical tests and laboratory 
examinations. Written informed consent forms were signed by the 
volunteers. The volunteers were screened to assure that they didn’t take 
any of the study compounds or any other antifungal for at least one month 
before the study. They were advised not to take any medication before 
consulting the research team. Volunteers were included in the study after 
fulfilling certain criteria. 
Sampling: 100 volunteers were randomly selected and assigned to two 
different groups (60 volunteer on one group and 40 on the other group). 
The first group of volunteer for PV was divided into two groups of 
30 volunteers each. One group treated with control drug (clotrimazole 
cream) and the other group treated with test drug (stone extract as cream). 
The second group volunteer for dermatophytes was divided into 
two groups of 20 volunteers each. One group treated with control drug 
(clotrimazole cream) and the other group treated with test drug (stone 
extract as cream). 
3.6.5 Inclusion criteria 
• Males and females more than 15 years old. 
• Positive mycology diagnosis for Malassezia species or 
dermatophytes. 
• Patients that voluntarily agree to participate in the study and sign 
the informed consent. 
• Consent to attend all the visits punctually (initial, treatment and 
follow-up)  
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• Acceptance of not using any other treatment of antifungal during 
the study. 
3.6.6 Exclusion criteria 
• Pregnant women 
• Presence of any condition or disease that compromises the patient 
immunologically (i.e. cancer, AIDs, ect.) or any other, that, based 
on the judgment of the medical team and researches, could alter the 
course of Malassezia species or dermatophytes. 
• Patients with history of hepatic, renal or cardiovascular disease. 
• Mentally or neurologically disabled patients that are considered not 
fit to approve their participation in the study. 
• Patient exposed to sun light during treatment for more than eight 
hours per day 
• Patients with other skin disease  
• Patient who used another drug for treatment including other 
antifungal agents. 
3.6.7 Ethical consideration 
 The study was approved by the Ethics Committee of the Research 
Administration at the FMOH and ethical clearance was obtained (See 
page 230). For the ethical consideration all volunteers were told about the 
research and about the drugs which are to be used. Then they were asked 
to sign a written informed consent for participation in the study. 
3.6.8 Clinical protocol 
Mycology diagnosis for Malassezia species and dermatophytes 
were performed to confirm the infection. Volunteer with positive results 
were recruited for the study. Volunteers were divided into four groups 
and each group was given one type of treatment according to the 
treatment schedule shown in table 3.6.3. The patients were advised to 
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change clothes before and after using the treatment and washed the 
infected area before applying the drug. The patients were advised not to 
use any cosmetics, emollients or any antifungal drug during treatment.  
3.6.9 Clinical examination 
Skin scrapping tests of the infected area were performed before 
treatment, during and after treatment for one month. The results were 
recorded and the effect of the test drug and controls on the volunteers 
were assessed by direct examination of the microorganism under 
microscope using KOH 20%, and also change in batch color and 
appearance (Sylvester and San Antonio, 2008). 
Table 3.6.3 Treatment schedule 
Formulation(code) Formulation strength* Dose* 
Clotrimazole cream (A)**  1% w/w Twice daily 
Stone extract cream (B)***  25%w/v Twice daily 
* As specified in the official compendia. (A)** = control drug, (B)*** = test drug 
3.6.10 Follow up 
Each volunteer was followed up weekly for four weeks and sample 
scraping was taken to test the efficacy of the drug. 
3.6.11 Data analysis 
All the results of the clinical trail were analyzed statistically using 
SPSS analysis. 
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4. RESULTS AND DISCUSSIONS 
4.1 Chemical analysis 
4.1.1 Physicochemical properties  
 Stone has different shapes; the color of its outer layer is white to 
yellowish and the inner layer has grey color and it has iron rust odor. 
 1% w/v solution in water has acidic pH (2.82 – 3.00). It is soluble 
in water and alcohol. When dissolved in water it gives a solution which 
becomes orange in color with time. This solution gives green precipitate 
with 0.1M NaOH and the precipitate disappears on addition of 0.1M HCl. 
This is an indication for the presence of iron. 
 
 
Figure 4.1.1 shape and color of stone after milling 
 
4.1.2 Elemental analysis for Identification of organic (C&N) atoms 
 Elemental analysis showed that organic carbon content is 
0.66 percent and the nitrogen is 0.25 percent. These strongly indicate that 
the stone does not contain any organic compounds. It is most probably 
composed of inorganic material(s). 
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4.1.3 Identification the elements by atomic absorption, gravimetric 
and calorimetric methods 
Table 4.1.1 shows the results of identification of stone elements by 
atomic absorption, gravimetric and calorimetric methods. 
The elements investigated are those belonging to the third and forth 
cycle of the periodic table. This is due to the fact that most available 
treatment for PV contain elements of this group (Ngan, et al., 2005, 
Gupta et al. 2004) 
Atomic absorption was used to identify nine elements. The results 
showed that only seven are present with varying percentages. Nickel and 
chromium were not detected. 
Cobalt and manganese showed very low percentages 0.000132 and 
0.022 %, respectively. 
The stone contains sodium, magnesium as oxide and calcium as 
oxide at 0.32, 0.46 and 0.62 %, respectively. The highest percentages 
were detected as ferrous and ferric oxide 10.4 and 11.6 %, respectively.  
To determine the exact contents of the iron on the sample 
appropriate factor was used as follows: 
Fe = FeO / factor → Fe =10.446 /1.2865 = 8.11% 
Fe = Fe2O3 / factor → Fe =11.595 / 1.4297 = 8.11% 
This shows that the iron content is about 8%. 
Gravimetric analysis was used to quantify sulphate and chloride 
which were detected at 27.2 and 2.3 %, respectively. The sulphate was 
present as barium sulphate.  
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Calculations: 
 To determine the content of the sulphate the following calculation 
was performed: 
Sample ofWt 
100x factor x   BaSOofWt S% 4=  
4 BaSOofWt Molecular 
S ofWt  AtomicFactor =  
%1.9
1gm
100 x 0.1.374 x 0.663% S ==  
Sample ofWt 
100x factor x   BaSOofWt %SO 44 =  
4
4
 BaSOofWt Molecular 
SO ofWt  AtomicFactor =  
%2.27
1gm
100 x 0.412 x 0.663%SO4 ==  
 Chloride was detected as silver chloride and the content of chloride 
were determined as follow: 
Sample ofWt 
100factor x  x AgCL ofWt  % Cl =  
Wt of AgCL = 0.0946 
1gm
100 x 0.2474 x 0.0946 % Cl =  
Cl % = 2.34% 
Calorimetric analysis quantified for silicon oxide and aluminum 
oxide. Silicon oxide showed the highest percentage (47.51 %). This is 
obvious since all soil contain silicon. 
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If the silicon percent 50% was ignore because it’s found in any 
soil; the major component remain in the stone sulphate 54% and iron as 
(ferrous and ferric) 46%. 
 
Table 4.1.1: Identification of stone elements by atomic absorption, 
gravimetric and calorimetric methods 
NO Element Method % 
1 CaO Atomic absorption 0.62 
2 MgO Atomic absorption 0.464 
3 Fe2O3 Atomic absorption 11.595 
4 FeO Atomic absorption 10.446 
5 Mn Atomic absorption 0.022 
6 Na Atomic absorption 0.32 
7 Ni Atomic absorption N.D* 
8 Cr Atomic absorption N.D 
9 Co Atomic absorption 0.000132 
10 SO4 Gravimetric 27.20 
11 Cl Gravimetric 2.34 
12 SiO2 Calorimetric 47.51 
13 Al2O3 Calorimetric 6.44 
ND*= Not detected 
4.1.4 Chemical tests for identification of acidic and basic radicals 
4.1.4.1 Identification of acidic radicals group 
Three tests were performed to identify the presence of acidic 
radicals groups. 
From the chemical test results of the acidic radicals groups in the 
table 4.1-2 the test excluded the presence of carbonates, sulpher oxides, 
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nitrates, halogens and phosphate. This indicate that the acidic radical 
groups in the stone is sulphate group (SO4)2-. 
 
Table 4.1.2: Determination of the acidic radicals groups 
No Test Observation Conclusion 
1 HCl dil + Sample 
(solid) 
No reaction (-Ve test) The sample do not 
contain HCO3-, CO32-, 
S2O32-, SO32-, S2- and 
NO2- 
2 (H2SO4) con + 
Sample (solid) 
No reaction (-Ve test) The sample do not 
contain Cl-, Br-, I-, and 
NO3- 
3 1-BaCl2 + Sample 
(solution) 
 
White precipitate + 
HCl 
 
2-AgNO3+ Sample 
(solution) 
White precipitate 
 
 
The precipitate not soluble 
 
 
White precipitate formed 
not yellow precipitate 
The sample contains SO4 
or PO4 
 
The precipitate is BaSO4 
 
 
The precipitate is 
(Ag2SO4) and the sample 
contain SO42- 
4.1.4.2 Identification of basic radicals group 
 The identification of basic radicals was performed according to 
table 4.1.3. The result excluded all elements of the fifth group of periodic 
table except for iron as ferrous (Fe+2). Therefore, the chemical analysis 
proved that the main constituents of the stone are Fe+2 and SO4. 
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Table 4.1.3: Determination of the basic radicals groups 
N Test Observation Conclusion 
1 HCl dil + Sample 
(solution) 
 
KI + Sample (solution) 
No reaction (-Ve test) 
 
 
No reaction (-Ve test) 
Sample not contain pb2+, 
Ag+ and Hg2+  
 
Sample not contain pb2+, 
Ag+ and Hg2+ 
2 H2S + HCl (dil) + 
Sample (solution) 
No reaction (-Ve test) The sample not contain 
Bi3+, Cu2+, Hg2+, sb3+, 
As3+, As5+, Sn4+, Sn2+ 
3 Ammonium thiocyanate 
+ Sample (solution) 
 
Sample (solution) + 
NaOH 
 
Red brownish color 
change to blood color 
 
Green precipitate formed 
and not soluble with 
excess of NaOH and 
change to brown with 
time 
The sample contain Fe2+, 
Fe3+, Al3+, Cr3+ 
 
The sample contain Fe2+ 
4 Sample (solution) + 
NH4Cl + NH4OH + H2S 
No reaction (-Ve test) The sample not contain 
Zn2+, Mn2+, Ni2+, Co2+ 
5 Sample (solution) + 
NH4Cl + NH4OH + 
NH4)2CO3 
Sample (solution) + 
Ammonium oxalate 
No reaction (-Ve test) 
 
 
No reaction (-Ve test) 
The sample not contains 
Ba2+, Sr2+, Ca2+ 
 
The sample not contains 
Ba2+, Sr2+, Ca2+ 
 
4.1.5 Fourier Transform Infrared spectrophotometer Identification 
 Fourier Transform Infrared (FTIR) analysis in the range of (500 – 
4000 nm) was carried for sample of stone. It is clear from the figure 
(Figure 4.1.1) that the stone material gave absorption at 3693 and 3620 
cm-1 and a broad bands at 3550 – 2500, 1200 – 900 and 1637cm-1. 
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FTIR was carried out for similarly treated sample of standard 
ferrous sulphate (Figure 4.1.2) and ferric sulphate (Figure 4.1.3). 
 Similar absorption bands to those found in stone sample were 
detected on the IR of ferrous sulphate mainly, which is a further support 
that the stone’s major component is made of that salt. It should be stated 
that the bands of 3693 and 3620 cm-1 were detected in the IR of stone and 
not found in the IR of both ferrous sulphate and ferric sulphate. 
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Figure 4.1.2: Spectrum of Fourier Transform Infrared analysis for stone 
sample. 
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Figure 4.1.3: Spectrum of Fourier Transform Infrared analysis for ferrous 
sulphate. 
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Figure 4.1.4: Spectrum of Fourier Transform Infrared analysis for ferric 
sulphate 
 
4.1.6 Ultra violet spectrophotometer Identification 
 Different concentrations (1, 3, 5, 10 and 50 µg/ml) of the stone 
extract were prepared and scanned by ultra violet visible 
spectrophotometer at 200 – 800 nm. 
 It has been observed that the solution containing the lowest 
concentration (1 µg/ml) was clear. The solutions started to develop color 
with increase in concentration. The sample with the highest concentration 
(50 µg/ml) showed light orange color. The solutions showed no 
absorbance at low concentrations 5 µg/ml (Figure 4.1.2) but peak started 
to appear at higher concentration 50 µg/ml (λ ≈ 288 nm) (figure 4.1.3). 
 There was a clear relation between the intensity of color and the 
concentration of the substance. 
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Figure 4.1.5: Spectrum of Ultra violet analysis of 5 µg/ml of stone. 
 
 
 
Figure 4.1.6: Spectrum of Ultra violet analysis of 50 µg/ml of stone. 
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4.2 Microbiological studies  
4.2.1 Identification of MF 
Figure 4.2.1 shows PV in two patients spread in the arms, back and 
neck. The first patient showed white batches (a hypopigmentation) and 
the other patient showed brown or livery colored batches (b 
hyperpigmentation). 
a) Hypopigmentation b) Hyperpigmentation 
Figure 4.2.1: Patients with pityriasis versicolor which was used for 
collection of specimens 
Figures 4.2.2 and 4.2.3 show the result of the direct microscopic 
examination of the sample which was taken from the patient in figure 
4.2.1 using 20% KOH (Figure 4.2.2) and with methylene blue (Figure 
4.2.3) (Kindo, et al. 2004). Short angular hyphae surrounded with clusters 
and thick wall, round cells, 3-8µm in diameter were observed. These 
characteristics of M. furfur. 
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Figure 4.2.2: The organism of MF under direct microscopic examination.  
 
. 
Figure 4.2.3: The organism of MF under microscopic examination 
following stain with methylene blue. 
Following confirmation of the presence of MF, the organism was 
cultured. The organism of MF in culture showed thick forms, convex 
colonies (Figure 4.2.4). The surface is usually smooth but rough variants 
occurred. The texture is soft and the cells are easier to emulsify.  
The color of the colonies is cream. The cellular morphology is 
variable with elongated, spherical or oval yeasts but most isolates show 
elongated cells reaching 6.0 µm in length. These are typical 
characteristics of MF (Kurtzman, and Fell, 2000). 
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Figure 4.2.4 Growth of MF in the culture media. 
4.2.2 Determination of minimum inhibitory dose 
The effect of stone extract on culture of MF and the minimum 
inhibitory dose (MID) of stone extract drug which kill the organism of 
MF were determined by culture of microorganism at different stone 
concentration (Figure 4.2.5 and 4.2.6). 
Figure 4.2.5 shows that there is a growth in the culture which 
contains 200µL of the stone extract drug. The cultures which contain 
500µL and above showed no growth. Accordingly different 
concentrations between 200µL and 500µL were tested to determine the 
minimum inhibitory dose (Figure 4.2.6). 
 
Figure 4.2.5 The effect of different doses of stone extract drug on the 
organism of MF. 
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From figure 4.2.6 it can be seen that the MID is about 350µL. With 
a dose less than 350µL growth appeared and with a dose equal to or more 
than 350µL there was no growth. 
 
Figure 4.2.6 Determination of the optimum dose of stone extract drug 
against MF. 
Calculation of the minimum inhibitory concentration 
According to the chemical analysis of stone extract each 100gm of 
stone contains (ferrous = 10.5gm, ferric = 11.6gm, sulphate (SO4) = 
27gm, aluminum = 6gm and CL = 2gm) so each 25gm of stone contain 
(ferrous=2.6gm, ferric=2.9gm, sulphate (SO4) = 6.8gm, aluminum = 
1.5gm and CL = 0.5gm). 
25gm of stone extract was taken and dissolved in 100ml of distilled 
water. 
350µL contains (ferrous = 9.1 mg, ferric = 10.2 mg, sulphate (SO4) = 
23.8 mg, aluminum = 5.3 mg). 
4.2.3 The effect of stone individual constituents on MF 
Figure 4.2.7 shows the result of the effect of the three main 
constituents on the culture of MF. Ferrous sulphate and ferric sulphate 
showed high activity against MF but aluminum sulphate showed very low 
activity against MF. When the subculture from the culture containing 
aluminum sulphate was done the MF grow again.  
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But no growth was observed when subculture was done from 
culture containing ferric sulphate (Figure 4.2.11). This means that the 
activity of the stone extract was the result of ferrous and ferric sulphate.  
The MICD for each one of FeSO4, Fe2SO4)3 and Al2SO4)3 was 
calculated and found to be 20 mg. 
Calculations:  
10gm of ferrous sulphate was taken and dissolve in 100ml of distil 
water, so each 100µL contain 10mg of FeSO4. 
The MICD of FeSO4 is 10 mg/100 ml. 200µL of stone extract 
contain 20 mg of FeSO4 and the same is applicable to other constituents. 
 
Ferrous sulphate 
 
Ferric sulphate 
 
Aluminum sulphate 
Figures 4.2.7 The effect of the stone main constituents on the organism of 
MF 
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4.2.4 Comparative in vitro studies between stone extract and other 
topical antifungal drugs against MF 
Figure 4.2.8 depicts the results of the comparison of activity of 
three drugs (selenium sulfide, sodium thiosulphate and yellow sulfur) 
which are commonly used for treatment of PV with activity of stone 
extract drug. 
Sodium thiosulphate and yellow sulfur have low activity at high 
concentration and no activity at low conc. against in vitro treatment of 
MF. Selenium sulfide has high activity; the same activity as that of the 
stone. However, the activity of pure ferrous sulphate is more than 
selenium sulfide (Figure 4.2.7). 
Selenium sulfide in media 
 
Sodium thiosulphate 
 
Yellow sulfur 
Figures 4.2.8: The effect of selenium sulfide, yellow sulfur and sodium 
thiosulphate on the MF 
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Selenium sulfide does not completely dissolve when mixed with 
media so it was mixed it with olive oil (Figure 4.2.9) gave good results no 
growth but also selenium sulfide was not completely dissolved. 
Carbon disulfide is known to be the solvent of selenium sulfide. 
Figure 4.2.10 shows the effect of carbon disulfide on the growth of MF 
when mixed with the media and olive oil. The results showed that the 
growth is not inhibited. When subculture was done the growth appeared 
so carbon disulfide seems to have fungi static effect. 
 
 
Figure 4.2.9: The effect of selenium sulfide when mixed with olive oil on 
the organism MF 
 
Carbon disulfide mixed with media 
 
Carbon disulfide mixed with olive oil 
Figure 4.2.10: The effect of carbon disulfide on the organism of MF. 
 
For further confirmation of drug activity against MF different 
subcultures were prepared. Figure 4.2.11 shows the results of subcultures 
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from figures (4.2.8 and 4.2.9) of selenium sulfide, carbon disulfide, ferric 
sulphate, aluminum sulphate and sulfur. 
Subculture from the 
culture of MF with 
aluminum sulphate  
 Subculture from the 
culture of MF with carbon 
disulfide (media). 
 Subculture from the 
culture of MF with 
selenium sulfide (media). 
 
Subculture from the 
culture of MF with 
sulphur 
Subculture from the culture 
of MF with carbon 
disulfide (olive oil). 
Subculture from the culture 
of MF with selenium 
sulfide (olive oil). 
 
Subculture from the culture of MF with ferric sulphate 
Figure 4.2.11: Subcultures of MF when treated with selenium sulfide, 
aluminum sulphate, carbon sulfide, sulfur and ferric sulphate. 
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The organism of MF does not grow when subcultures were done 
from selenium sulfide and ferric sulphate, but it grows again when 
subcultures were done from sulfur, aluminum sulphate and carbon 
disulfide (solvent of selenium sulfide). 
From the above it can be concluded that the activity of the stone 
extract is mainly due to ferrous sulphate. 
4.2.5 Effect of aqueous cream on MF 
Figure 4.2.12 illustrates the effect of stone extract formulated as 
aqueous cream on the culture of MF. The result showed no MF growth on 
culture containing the aqueous cream. It is obvious that the drug as cream 
is very effective against MF organism. 
 
Figure 4.2.12: The effect of aqueous cream formulation on MF 
4.2.6 Effect of stone extracts drug and aqueous cream against other 
microorganism 
Following its proven microbiological activity against MF the 
aqueous cream and stone extract were tested for activity against other 
microorganism; fungi and bacteria.  
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4.2.6.1 Activity against Candida 
Figures 4.2.13, 14 and 15 show the results of effect of stone as 
extract and as cream on Candida albicans and Candida species.  
In Figure 4.2.13 the microorganisms were mixed with the media in 
three Petri dishes, allowed time to grow then the drug was added to the two 
Petri dishes containing Candida albicans and Candida SSP separately. 
It can be observed that there is growth on the Petri dish with no drug 
and inhibition zones appeared on the Petri dishes containing the drug. 
In the next experiment the stone extract drug was mixed with the 
media in two Petri dishes at different doses; 500 µL and 1000 µL then the 
microorganisms were added to the three Petri dishes. The results showed 
no growth of Candida albicans and Candida SSP in the two Petri dishes 
containing the drug. While on the third Petri dish that contains no drugs 
obvious growth was observed (Figures 4.2.14). 
In another experiment two Petri dishes were prepared. One with the 
drug mixed with the media and the other one without the drug. Candida 
albicans and Candida SSP were cultured in the two Petri dishes. The 
results obtained showed growth of the Candida albicans and Candida SSP 
in the Petri dish containing no drug while no growth was observed in the 
Petri dish containing the drug (Figures 4.2.15). This shows that the drug 
has good in vitro activity against Candida. 
 
Figure 4.2.13: The effect of stone extract on Candida spp. and Candida 
albicans (the organisms is mixed with the media). 
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Candida Albicans Candida species 
Figure 4.2.14: The effect of stone extract on Candida spp. and Candida 
albicans (stone extract drug is mixed with media). 
 
Figure 4.2.15: The effect of stone as aqueous cream on Candida albicans 
and Candida species. 
4.2.6.2 Activity against dermatophytes 
The stone extract and aqueous cream were tested for invitro 
activity against four types of dermatophyte fungi (M. canis, T. violaceum, 
T. soudanesis and M. audouinii). The results are illustrated in Figures 
4.2.16, 17, 18 and 19.  
The drug showed very good in vitro activity against all four 
microorganism. Upon comparing the culture which contains the drug with 
the culture without the drug, there was no growth in M.canis, T.violaceum 
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at all doses. T. soudanesis showed growth at low dose (200µL). Above 
200 µL no growth was observed. The drug as cream (Figure 4.2.19) 
showed no growth of the four types of dermatophytes. 
 
Figure 4.2.16: Effect of stone extract on M. canis 
 
 
Figure 4.2.17: Effect of stone extract on T. violaceum. 
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Figure 4.2.18: Effect of stone extract drug on T. soudanense. 
 
 
Figure 4.2.19: Effect of stone extract as cream on the four types of 
dermatophytes (T. soudanense, T. violaceum, M. canis and M. audouinii). 
4.2.6.3 Activity against Actinomycetoma 
The previous experiment was repeated with four types of 
Actinomycetoma (Actinomadura madourae Am, Actinomadura pelletierii 
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Ap, Nocardia barasilienses N.b and Madurella mycetomatis ). The results 
are shown in Figure 4.2.20 and 21, 22, and 23.  
The drug showed in vitro activity against the four types of 
Actinomycetoma in doses ranged from 500µl to 2000 µl. 
 
Figure 4.2.20: Effect of stone extract drug on Actinomadura madourae 
Actinomadura pelletierii Nocardia barasilienses 
Figure 4.2.21: Effect of stone extract drug on Actinomadura pelletierii 
and Nocardia barasilienses 
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Figure 4.2.22: Effect of stone extract drug on Madurella mycetomatis 
From figures (4.2.23) aqueous cream showed a good in vitro 
activity against all types of Actinomycetoma (Actinomadura madourae 
Am, Actinomadura pelletierii Ap, Nocardia barasilienses N.b and 
Madurella mycetomatis).  
 
 
Figure 4.2.23: Effect of the aqueous cream on four types of 
actinomycetoma (Actinomadura madourae Am, Actinomadura pelletierii 
Ap, Nocardia barasilienses N.b and Madurella mycetomatis) 
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4.2.6.4 Activity against Aspergillus 
The stone extract and the aqueous cream were also tested against 
Aspergillus. Four different species (Aspergillus fumigutus, Aspergillus 
niger, Aspergillus flavus and Aspergillus terrues) were used. The results 
are depicted in Figure 4.2.24, 25 and 26. The drug has high activity 
against Aspergillus niger, and low activity against Aspergillus flavus, but 
Aspergillus fumigutus is not affected by the drug. 
 
Figure 4.2.24: Effect of stone extract drug on Aspergillus flavus 
Aspergillus fumigutus 
 
Aspergillus niger 
Figure 4.2.25: Effect of stone extract drug on Aspergillus fumigutus and 
Aspergillus niger 
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Figure 4.2.26: Effect of stone extract drug as aqueous cream on four types 
of Aspergillus (Aspergillus niger, Aspergillus flavus, Aspergillus 
fumigutus, and Aspergillus terrues). 
4.2.7 Effect of stone extract against bacteria 
The stone extract was tested against G +ve and G -ve bacteria. 
Figure 4.2.27 shows the results of the in vitro effect of stone extract on 
the gram +ve (Staphylococcus aureus) and gram -ve (Pseudomonas 
aeruginose) bacteria. The drug is active against bacteria and gives an 
inhibition zone of 19mm diameter. 
 
Staphylococcus aureus (G +ve) 
zone19mm 
Pseudomonas aeruginose (G -ve) zone 
19mm 
Figure 4.2.27: Effect of stone extract drug on G +ve and G -ve bacteria. 
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From the above results it is very clear that the drug has very good 
in vitro activity against the Malassezia furfur organism which cause PV 
disease compared with other drugs and also the drug has activity against 
others fungi such as dermatophytes, Candida, Aspergillus and 
Actinomycetoma fungi. 
The drug has in vitro activity against gram +ve (Staphylococcus 
aureus) and gram –ve (Pseudomonas aeruginose) bacteria 
Stone extract drug as solution or as cream has a good in vitro 
activity against superficial and cutaneous fungi compared with other 
drugs used for treatment of such fungal infection. e.g. 
(sodiumthiosulphate, selenium sulfide, yellow sulfur). 
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4.3 Pharmaceutical formulation 
There are many natural products which are used traditionally 
worldwide. Drugs from natural resources are cheap, safe, and free of side 
effects and have high patient compliance. Natural products need to be 
prepared in a suitable dosage formulation. The goal of this is to a 
optimize its contents and dosing regimen in an attempt to maximize its 
pharmacological effect and minimize its side effect. 
Pharmaceutical formulations of the natural products become more 
interesting in many countries such as Indonesia, Malaysia, India, China   
etc. In Egypt the Arab Company for Pharma and Medicinal Plants 
produces some medicine like Ginseng with Nigella sativa, Immulant plus 
(Echinaceae root dry extract and Golden seal root), Pepon (Pumpkin seed 
oil), Kellagon (Khelline) …ect. 
Eugenol solution for topical treatment of cutaneous dermatology 
and Leshmaniasis are manufactured by Sanhorial Factory, Khartoum, 
Sudan, and also Senna tablet by Climax for drugs, Khartoum North. 
An alternative treatment for pityriasis versicolor, tinea cruris, tinea 
corporis and tinea faciei with topical application of honey, olive oil and 
beeswax mixture was reported. Waili (2004) evaluated the possible role 
of honey, olive oil and beeswax in the treatment of skin fungal infections.  
Thirty-seven patients with pityriasis versicolor, tinea cruris, tinea 
corporis and tinea faciei were studied. After clinical evaluation of 
redness, scaling, pruritis and burning/pain sensation and mycological 
assessment, honey mixture containing honey, olive oil and beeswax 
(1:1:1) was applied to the lesions three times daily for a maximum of 4 
weeks. Clinical response was obtained in 86% of patients with pityriasis 
versicolor, 78% of patients with tinea cruris and in 75% of patients with 
tinea corporis. Mycological cure was obtained in 75, 71 and 62% of 
patients with PV, tinea cruris and tinea corporis, respectively. The patient 
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with tinea faciei showed clinical and mycological cure 3 weeks after 
commencement of therapy. The author concluded that honey mixture may 
have place in the management of these skin conditions and rigorous, 
controlled trials are justified 
In the present study different semisolid dosage forms were 
prepared using the water extracted stone sample. 
4.3.1 Ointment formulations 
 The stone extract was prepared as ointment using different bases. 
The oleaginous base showed good incorporation of the stone material.  
However, the formulation was characterized by high viscosity, not 
water washable and the lipid phase is more than the aqueous phase. It has 
been shown that the growth of the fungi which cause pityriasis versicolor 
(M. furfur and M. globosa) enhances in lipid media (Kindo, et al. 2004 
and Rathi, 2003). 
Pityriasis versicolor disease disperses in the exposed areas of the 
body (neck, arms, face,   etc). The use of ointment on these areas is 
exposed to particulate matters. For these reasons formulation of stone as 
oleaginous ointment was excluded  
 The water soluble ointment (polyethylene glycol) when formulated, 
the drug dissolved in the aqueous phase. Unfortunately, when the two 
phases are mixed, drug precipitated. 
There is possible competition between water and drug to the base. 
Water has high affinity to the base so it incorporates with the base and 
precipitates the drug. Accordingly the water soluble ointment formulation 
of stone was also excluded. 
4.3.2 Gel formulation 
 Two gel formulations were compounded. The first formulation 
contains NaOH 10%. This resulted in a green precipitate due to the 
reaction between NaOH and the active ingredients of the stone. 
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 The second gel base, which was used for formulation of diclofinac 
sodium in most pharmaceutical companies, failed to incorporate the stone 
extract. Therefore, the gel formulation was excluded. 
4.3.3 Cream formulation 
 Several standard formulations of creams were investigated (BP, 
volume IV, 2005 USP, 2000). The aqueous cream formulation was 
chosen for incorporation of the stone extract. The standard formulation 
was modified to include tween 20 which is used as a solubilizing agent to 
overcome the separation of the cream. 
10 % of propylene glycol was also added as humectants and 
emollient. In addition propylene glycol is known to have penetration 
enhancing and preservative properties which are well recommended for 
such preparations. Propylene glycol 50 % also used for treatment of PV 
(Faergemann, 2000, Oakley, 2005 and Ellis, 2005). 
 The aqueous cream is characterized by being less viscous, water 
washable, of low lipid contents, not expensive, easy to formulate, more 
suitable for tropical country. In addition all material used are readily 
available and most topical antifungal drugs in the market are formulated 
as creams. 
4.3.3.1 Quality control tests of the aqueous cream 
 Quality control tests; physicochemical and rheological test, 
microbiological test and chemical assay test were carried for the aqueous 
cream. Stability of the cream formulation was also investigated. 
4.3.3.1.1 Physicochemical and Rheological properties of the aqueous 
cream 
It is a yellowish white in color, washable and easy to spread. pH of 
the aqueous cream was measured by pH meter and found to be in the 
range of 3 – 4. Physicochemical properties were summaries in table 4.3.1. 
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Table 4.3.1: Physical properties of the aqueous cream 
Appearance Smooth 
Color Yellowish white  
Homogeneity Conform 
pH 3 – 4 
Spreadability Easy to spread 
Consistency (Texture) Good 
Washability Easy to washable 
 
The viscosity of the cream when measured by viscometer was 
within the range of 9117 – 29190 CP (1centipoise = 1 millipascal) at 
speed of 12 rpm and spindle 3. Viscosity range between 55.2% - 73%. 
4.3.3.1.2 Microbiological studies aqueous cream 
According to the (BP, 2005) there are three recognized classes of 
sample acceptability regarding microbial growth. 
(1) Acceptable samples: samples containing less than m colony-
forming units (cfu) per gm or ml.  
(2) Marginal samples: samples containing more than m colony-
forming units (cfu) but less than 10m (cfu) per gm or ml. 
(3) Defective samples: samples containing more than 10m colony-
forming units (cfu) per gm or ml.  
Where m = is a limit not more than 102 micro organisms (aerobic 
bacteria plus fungi) per gm or ml (B.P. 2005, volume IV Appendix 
XVID). 
This study was performed for the raw material, an extract and the 
aqueous cream (Figure 4.3.1, 2 and 3). 
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Figure 4.3.1: Microbiology study for samples of stone powder. 
 
 
Figure 4.3.2: Microbiology studies for samples of stone extract solution  
 
 
Figure 4.3.3: Microbiology study for samples of aqueous cream 
The result of this study for the raw material (stone powder) is a 
marginal sample in the case of bacteria but in case of fungi is acceptable. 
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The stone extract solution and finished product (cream) are 
acceptable because number of cfu per ml or gm were less than m. The 
bacteria were 10 cfu /gm and the fungi were less than 10 cfu /gm. 
4.3.3.1.3 Stability result 
The result of the stability studies of the aqueous cream mentioned 
in tables 4.3.2 and 4.3.3 showed that the aqueous cream is stable at room 
temperature and in refrigerator (temperature 5oC) for two years. In Sudan 
room temperature is not less than 30oC. Accelerated stability test at 45oC 
temperature and 75% relative humidity for three months showed that the 
cream was stable in the first two months but in the third month separation 
and change in color started. However; there was no significant change in 
chemical contents observed. High temperature affects stability of the 
aqueous cream so the formulation must be keep at the refrigerator or at 
temperatures less than 30OC. 
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4.4 Pharmacological studies 
4.4.1 The effect of the stone extract on the cholinergic receptors 
 Small dose of the stone extract (1mg/ml and 2mg/ml) stimulate the 
intestinal smooth muscles (Fig 4.4.1). 
 
Figure 4.4.1: Effect of stone extract (x) and cholinergic antagonist 
(Atropine) on smooth muscle of rabbit intestine  
Where N= normal, W= wash, At= atropine and X= stone extract 
The stimulant effect of the stone extract on the intestine was 
refractory to the antagonistic effect of the cholinergic blocker atropine. 
 The stimulant effect of the stone extract is not cholinergic in 
nature, probably due to a direct effect on the intestinal smooth muscles. 
4.4.2 The effect of the stone extract on the adrenergic receptors  
 Large dose of the stone extract (4mg/ml) markedly relaxed the 
intestinal smooth muscle (Fig 4.4.2). 
The inhibitory effect of the stone extract on the intestine was 
refractory to the antagonistic effect of the adrenergic blockers tolozoline 
and propranolol as well as the mixture of the two antagonists. 
 The relaxant effect of the large dose 4mg/ml of the stone extract is 
not an adrenergic effect most likely to be a direct effect on the smooth 
muscle. 
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Figure 4.4.2: Effect of stone extract (x) and adrenergic antagonist 
(tolozoline & propranolol) on smooth muscle of rabbit intestine muscle  
Where N= normal, W= wash, T= tolozoline, P= propranolol and X= stone extract 
4.4.3 The effect of stone extract drug on isolated rat uterus muscle  
 When acetylcholine was added to the rat uterus muscle response 
was appeared. 
When stone extract drug was added to the tissue as agonist and antagonist 
no response appeared (Fig 4.4.3).  
 The stone extract has no any pharmacological effect on the rat 
uterus muscle. 
 
 
Figure 4.4.3 Effect of stone extract (x) and cholinergic agonist 
(Acetylcholine) on rat uterus muscle  
Where N= normal, W= wash, Ach= acetylcholine and X= stone extract 
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4.4.4 The effect of stone extract drug on isolated frog rectum 
abdominal muscle (Skeletal muscle) 
 Acetylcholine stimulated the rectum abdominal muscle (dose 
dependant). 
Different doses of the stone extract were without agonistic or antagonist 
effect on the striated muscle (Fig 4.4.4).  
 
 
Figure 4.4.4: The agonistic and antagonistic effect of stone extract (x) on 
isolated frog rectum abdominal muscle.  
Where N= normal, W= wash, Ach= acetylcholine and X= stone extract. 
 
 Stone extract drug has not any pharmacological effect on the frog 
rectum abdominal muscle. 
4.4.5 The effect of stone extract drug on isolated rabbit aortic strip 
preparation 
 Large dose of the stone extract up to 4mg/ml was without any 
effect on rabbit aortic strip tissue (Fig 4.4.5). 
Noradrenalin give contractile effect on this vascular strip that did 
not affected by stone extract drug. 
 Stone extract drug has no any effect on the isolated aortic strip 
tissue. 
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Figure 4.4.5 The agonistic and antagonistic effect of stone extract (x) on 
aortic muscle  
Where N= normal, W= wash and NA= noradrenalin X= stone extract. 
From the above it is obvious that the stone extract has no 
pharmacological activity on isolated tissues investigated. 
4.5 Toxicological Studies 
Several toxicological studies were carried out these include 
hematology, enzymes and histology. 
There were no differences in mean body weight between the two 
groups of rats for the 3-week pretrial period. This may be explained by 
the feeding of identical diets to each group and the useful randomized 
assignment for examination.  
The results of the present study indicate that feeding rats with stone 
extract at 2% of the normal diet for 21 days is not toxic 
4.5.1 Hematology parameters 
 Table 4.5.1 shows the results of hematology studies. The mean 
value for hemoglobin (Hb) was found to be 13.2 ± 2.05(SD) for test rats 
compared to 12.57 ± 0.85 for control rats. There was no significant 
differences between the two groups (P = 0.199). 
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The mean value for red blood cells (RBC) was found to be 7.97 ± 
1.40 test rats compared to 7.66 ± 0.56 control rats there was no significant 
differences between the two groups (P = 0.051) 
The mean value for packed cell volume (PCV) was found to be 
46.5 ± 6.77 test rats compared to 2.35 ± 0.47 control rats there was no 
significant differences between the two groups (P = 0.087) 
The mean value for mean corpuscular volume (MCV) was found to 
be 58.83 ± 2.23 test rats compared to 58.67 ± 2.08 control rats there was 
no significant differences between the two groups (P = 0.77) 
The mean value for mean corpuscular hemoglobin (MCH) was 
found to be 16.65 ± 0.71 test rats compared to 16.4 ± 0.80 control rats 
there was no significant differences between the two groups (P = 1.00) 
The mean value for mean corpuscular hemoglobin concentration 
(MCHC) was found to be 283.5 ± 7.50 test rats compared to 278.7 ± 5.13 
control rats there was no significant differences between the two groups 
(P = 0.71) 
The mean value for white blood cell (WBC). was found to be 4.95 
± 0.31 test rats compared to 5.61 ± 0.29 control rats there was no 
significant differences between the two groups (P = 0.97) 
The mean value for lymphocytes (LY). was found to be 49.87 ± 
30.54 test rats compared to 60.27 ± 16.47 control rats there was 
significant differences between the two groups (P = 0.014) 
The mean value for monocytes (MO). was found to be 4.72 ± 2.44 
test rats compared to 7.4 ± 4.16 control rats there was no significant 
differences between the two groups (P = 0.21) 
The mean value for granulocytes (GR) was found to be 49.9 ± 26.9 
test rats compared to 32.3 ± 17.16 control rats there was no significant 
differences between the two groups (P = 0.051) 
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The results of hematology parameter showed that there are no 
significant differences in all parameters between test and control groups.  
The only exception is in the lymphocytes which showed significant 
differences (P = 0.014). 
4.5.2 Serobiochemical enzymes 
 Table 4.5.2 shows the results of enzymes studies. The mean value 
for Aspartate aminotransferase (AST) was found to be 13.8 ± 2.23 test 
rats compared to 11.7 ± 1.53 control rats there was no significant 
differences between the two groups (P = 0.292). 
 The mean value for Alanine aminotransferase (ALT) was found to 
be 13.2± 3.49t rats compared to 8.1± 2.71 control rats there was no 
significant differences between the two groups (P = 0.415). 
The mean value for Alkaline phosphatase (ALP) was found to be 
221.3 ± 36.97 rats compared to 290.5 ± 89.41 control rats there was no 
significant differences between the two groups (P = 0.052). 
The data presented in table 5.4.2 as mean ± SD show that the 
activity of serum AST and ALT were higher in the test group than control 
group but the activity of serum ALP was lower in the test groups than 
control group. These changes do not indicate any effect because they are 
within the limits. They become serious if the enzyme level is increased. 
The results of serobiochemical enzymes parameter showed that 
there are no significant differences in all parameters between test and 
control groups. 
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4.5.3 Histopathology for five important organs 
Slides of five important organ (Figures 4.5.1 – 4.5.5) show that the 
histopathology of the five organs is not affected, there are no damages or 
otherwise observed. This indicate that the stone extract drug has no any 
toxic effect  
 
 
Figure 4.5.1 Liver tissue following administration 100mg /kg body 
weight of stone extract for 21days. 
 
 
Figure 4.5.2 Kidney tissue following administration of 100 mg/kg body 
weight of stone extract for 21days. 
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Figure 4.5.3 Heart tissue following administration 100mg /kg body 
weight of stone extract for 21days. 
 
 
Figure 4.5.4 Intestine tissue following administration of 100 mg/kg body 
weight of stone extract for 21days. 
 
 
Figure 4.5.5 Spleen tissue following administration of 100 mg/kg body 
weight of stone extract for 21days. 
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4.6 Clinical trials 
Several studies have been reported in the literature comparing 
different treatments for PV. These studies are comparative but the 
number of volunteers which are involved is different. Some used forty 
volunteers such as Nagpal, et al. (2003). They carried out a comparative 
study of oral and topical ketoconazole therapy in pityriasis versicolor.  
Forty patients suffering from pityriasis versicolor were treated 
either with oral ketoconazole 200 mg per day or 2% ketoconazole cream 
topically once daily for 2 week. The study concludes that no significant 
difference was observed in the response rates in the two groups. Relapse 
occurred in two patients of the systemic ketoconazole group and six 
patients of the topical ketoconazole group during the follow-up period of 
three months.  
A comparative study of ketoconazole versus selenium sulphide 
shampoo in pityriasis versicolor was reported (Aggarwal, et al. 2003). 
Forty patients suffering from pityriasis versicolor were treated with 2% 
ketoconazole shampoo (20 patients) or 2.5% selenium sulphide shampoo 
(20 patients), once a week for three weeks. The study concludes no 
significant difference was observed in the response rates in the two 
groups. Relapse occurred in one patient of ketoconazole group and two 
patients of selenium sulphide group during the follow-up period of three 
months. 
A double-blind comparative study of sodium sulfacetamide lotion 
10% versus selenium sulfide lotion 2.5% in the treatment of pityriasis 
(tinea) versicolor. Pityriasis (tinea) versicolor, which consists of 
hyperpigmented and hypopigmented scaly patches, is often difficult to 
treat. A double-blind comparative study between once-a-day sodium 
sulfacetamide lotion and selenium sulfide lotion was undertaken. Both 
 177
treatments were safe and efficacious. Selenium sulfide was statistically 
more efficacious (76.2% vs 47.8%, P=.013) (Hull, 1997). 
Kose. et al. (2002) studied the comparison of a single 400 mg dose 
versus a 7-day 200 mg daily dose of itraconazole in the treatment of tinea 
versicolor to evaluate the efficacy and safety of a 400 mg single dose or 
7-day 200 mg daily dose of itraconazole capsules in the treatment of 
mycologically confirmed pityriasis versicolor. A total of 50 patients were 
entered into a randomized, open, clinical trial comparing a 400 mg single 
dose (n = 24 for group 1) with a 7-day 200 mg daily dose (n = 26 for 
group 2) of itraconazole. Clinical signs and symptoms and mycologic 
evaluation (potassium hydroxide preparation and Wood's lamp) were 
performed before treatment and at weeks 3 and 6 after treatment. Both 
regimens of itraconazole were effective. Our results showed that there 
were no significant differences in efficacy and safety between the two 
treatment regimens (chi-square tests, P > 0.05). On the basis of these 
findings, a single dose of itraconazole 400 mg/day was reported as 
effective as the 7-day 200 mg daily dose in the treatment of pityriasis 
versicolor. 
Rigopoulos, et al. (2007) in a randomized double-blind 
comparative trial studied flutrimazole shampoo 1% versus ketokonazole 
shampoo 2% in the treatment of pityriasis versicolor with 60 volunteers. 
They concluded that Flutrimazole shampoo 1% appears to present 
efficacy comparable with ketoconazole 2% in the treatment of tinea 
versicolor. 
Another comparative study between fluconazole and ketoconazole 
efficacy in the treatment of PV was reported by Yazdanpanah, et al. 
(2007). Topical drugs are often effective in limited lesions of pityriasis 
versicolor; but in extensive cases, systemic drugs are more suitable. 
Previous studies have shown that ketoconazole and fluconazole are 
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effective in 42-97% and 74-100% of lesions, respectively. The purpose of 
this study was to compare the effectiveness of a single dose of 400 mg 
ketoconazole with two doses of 300 mg of fluconazole with 2 weeks 
interval. Ninety patients with extensive pityriasis versicolor (body 
involved area > or =25%) were randomly assigned to treatment with 
either a single dose of 400 mg of ketoconazole or with two doses of 300 
mg of fluconazole with 2 weeks interval. One month after the treatment, 
the improvement rate and side effects were evaluated by clinical 
examination and questionnaire. Sixty cases (66.7%) completed the study. 
They were 51 males and nine females, with a mean age of 30 years. At 
the follow-up visit (1 month after the end of treatment), the improvement 
rate for ketoconazole (87.9%) was not significantly different from 
fluconazole (81.5%), (Fisher test: P = 0.37). Due to the hepatotoxicity of 
ketoconazole, fluconazole appears to be more suitable in the treatment of 
extensive pityriasis versicolor 
In the present study one hundred patients suffering from pityriasis 
versicolor and skin dermatophyte, visiting the out-patient clinics of Skin 
and Sexually Transmitted Diseases, Khartoum Teaching Hospital, were 
treated with 5% aqueous cream (50 patients; 20 suffering with SD and 30 
with TV) and 1% clotrimazole cream (50 patients; 20 suffering with SD 
and 30 with TV), for two to four weeks. On global assessment within one 
month of start of therapy each patient was assigned a file. Before 
treatment the patient information was taken (name, address, age, weight, 
date of inclusion, gender, Ethnic group, date of ill, distribution and 
medications prior to inclusion). After that identification was done for 
each volunteer by taking a sample and diagnosis under microscope. If 
positive a photograph was taken and treatment was started and followed 
up for one month. 
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Follow up was continued monthly up to 5 - 18 month depending on 
date of inclusion in the study and the end of the study by September 
2008. 
4.6.1 Skin dermatophytes  
Demographic information about skin dermatophytes (S.D) 
volunteers are illustrated in table 4.6.1.  
Table 4.6.1 Demographic data on skin dermatophytes. 
Age 23.45 ± 9.29 
male 24 (60%) 
Gender 
female 16 (40%) 
Weight 60.23 ± 5.24 
Treatment before 10 % 
 
Clinical trails were carried in 40 volunteers with skin 
dermatophytes (T. corporis, T. capitis, T. cruris, T. pedis, T. manuum, 
Candida albican, Candida spacies and onchomycosis). Twenty 
volunteers treated with control drug (clotrimazole cream) and the other 
twenty treated with test drug. 60% of the volunteers are males and 40% 
are females. The average age of the volunteers involved in this part of the 
study is 23.45 ± 9.29 years and the average weight is 60.23 ± 5.24 kg. 
(table 4.6.1).  
Treatment period was one month and the volunteers were followed 
up thereafter. 
At the first 10 days, 70% of the volunteers treated with test drug 
gave negative results following direct examination and only 30% showed 
positive results. From the volunteers who are treated with control drug 
only 30% showed negative result and 70% showed positive results. 
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After 20 days all volunteers treated with test drug are completely 
cured; 100% negative results. On the other hand, 65% of the volunteers 
treated with control drug showed negative results and 35% showed 
positive results.  
After 30 days the volunteers on the test group remained cured 
while the control group showed 95% cure and 1% positive results (Table 
4.6.2). 
The mean cure period for the test drug was 11.5 ± 3.85 days and 
mean cure period for control drug was 17.0 ± 1.68 days. The difference 
was statistically significant (P = 0.006) (See figures 4.6.1 and 4.6.2, and 
Table 4.6.3) 
Tinea pedis and Tinea manuum were resistant to treatment by 
control drug but volunteers were successfully treated for these tinea 
species by test drug. 
 
Table 4.6.2: Effect of test and control drugs on skin dermatophytes (n = 
40) 
Test Drug (n = 20) Control Drug (n = 20)  
Day +ve (%) -ve (%) +ve (%) -ve (%) 
P-Value 
D10 6 (30) 14 (70) 14 (70) 6 (30) 0.011 
D20 0.00 (0.00) 20 (100) 7 (35) 13 (65) 0.008 
D30 0.00 (0.00) 20 (100) 1 (5) 19 (95) 1.00 
 
Table 4.6.3: The cure-period for test and control drugs on skin 
dermatophytes during one month (n = 40) 
 Mean ± SD (day) P-Value 
Test 11.5 ± 3.846 
Control 17 ± 7.504 
0.006 
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4.6.2 Tinea versicolor 
Demographic data on PV volunteers is illustrated in table 4.6.4. 
 
Table 4.6.4: Illustrate demographic data. 
Age 28.27 ± 11.21 
male 42 (70%) 
Gender 
female 18 (30%) 
Weight 58.22 ± 3.20 
Treatment before 15 % 
 
Clinical trails in this part involved 60 volunteers with Tinea 
versicolor  
Thirty volunteers were treated with control drug (clotrimazole 
cream) and the other thirty with test drug. Forty two (70%) of the 
volunteers are males and eighteen (30%) are females. Their mean age is 
28.27 ± 11.29 and mean weight is 58.22 ± 3.20. Fifteen percent of the 
volunteers used different treatments for TV sometime before the study 
(table 4.6.4). 
Treatment period was one month and the volunteers were followed 
up thereafter. 
At the first 10 days 0.0% of the volunteers treated with neither test 
drug nor control showed negative results when direct examination was 
done. The volunteers remained symptomatic. 
After 20 days 66.7% of the volunteers treated with test drug gave 
negative results when direct examination was done. Only 33.3% gave 
positive results. Only 16.7% of the volunteers who are treated with 
control drug gave negative results and 83.3% gave positive results.  
After 30 days volunteers on both groups remained negative (Table 
4.6.5.) 
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The mean cure period for the test drug was found to be 21.2 ± 4.71 
days and mean cure period for control drug was 25 ± 3.92 days. The 
difference was statistically significant (P = 0.001). (See figures 4.6.3 and 
4.6.4 and Table 4.6.6) 
As has been previously mentioned, tinea Versicolor is very 
difficult to treat. Moreover, treatment with currently available 
medications is reported to show high recurrence rates. More than 40% of 
the volunteers involved in this study are treated before with azole drugs 
especially clotrimazole and recurrences of TV occurred. From the above 
results, test drug proved to have faster and very good effect against both 
skin dermatophytes and tinea versicolor. However, its effect on TV is 
slower than on SD. 
 
Table 4.6.5: Effect of test and control drugs on Tinea versicolor (n = 60) 
 
Test Drug (n = 30) Control Drug (n = 30)  
Day +ve (%) -ve (%) +ve (%) -ve (%) 
P-Value 
D10 30 (100) 0.00 (0.00) 30 (100) 0.00 (0.00) 0.00 
D20 10 (33.30) 20 (66.7) 25 (83.3) 5.0 (16.7) 0.000 
D30 0.00 (0.00) 30 (100) 0.00 (0.00) 30 (100) 0.00 
 
Table 4.6.6: The cure-period for test and control drugs on Tinea 
versicolor during one month (n=60) 
 Mean ± SD (day) P-Value 
Test 21.2 ± 4.708 
Control 25 ± 3.922 
0.001 
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Figure.6.1: The percent of volunteers who are treated with test and 
control drugs during one month in the case of skin dermatophytes (n=40). 
 
Figure.6.2: The mean cure period for test and control drugs during one 
month in the case of skin dermatophytes (n = 40). 
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Figure.6.3: The percent of volunteers who are treated with test and 
control drugs during one month in the case of Tinea versicolor (n=60) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6.4: The mean cure period for test and control drugs during one 
month in the case of TV (n=60) 
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4.6.3 Case studies: 
Ten cases were selected from the patients who were treated with 
test drug. History, Microbiological diagnosis under microscope and 
photographs for each case were taken before, during 2-4 weeks and after 
treatment. Microbiological examination and photographs were taken 5-18 
month after treatment to ensure no recurrence of infection.  
Case (1) 
F.A. is a 22 years old, 55 kg male patient from North of Sudan. He 
came to the out-patient clinics of Skin and Sexually Transmitted 
Diseases, Khartoum Teaching Hospital; suffering form extensive TV 
(hypopigmentation) for eight month and no medications prior treatment 
are used. Particulars of this patient are shown in table 4.6.7. 
The disease excessively spread as white large patches on the chest, 
back, shoulder and arms (Figure 4.6.6). 
A sample was taken by scraping and examined under microscope 
(Figure 4.6.5). The result were +ve for TV. 
Treatment started on 25/3/2008 with aqueous cream, and continued 
till examination under microscope appeared –ve (on the 20/4/2008, 
Figure 4.6.7). The patient was followed up till September /2008 (Figure 
4.6.8) and no recurrence was observed. 
This confirms the efficacy of the formulated aqueous cream in 
treatment of TV. 
 
Figure 4.6.5: Direct microscope of skin scraping from patient with Tinea 
versicolor. (hypopigmentation) sample taken from case 1. 
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Figure 4.6.6: Tinea versicolor at the shoulders and chest of case 1 before 
treatment 
 
Figure 4.6.7: Tinea versicolor at the shoulders and chest of case 1 one 
month after treatment. 
 
Figure 4.6.8: Tinea versicolor at the shoulders and chest of case 1 six 
month after treatment. 
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Case (2) 
N.A. is a male patient from North of Sudan, 18 years old, 50 kg. 
He visited the out-patient clinics of Skin and Sexually Transmitted 
Diseases, Khartoum Teaching Hospital, suffering form PV 
(hyperpigmentation) for two year. The medication used prior treatment 
was clotrimazole cream but the disease reoccurred. Particulars of this 
patient are shown in table 4.6.7. 
The disease manifested it self as brown patches located on the 
chest, back and arms (Figure 4.6.10). 
Before treatment sample scraping was taken and examined under 
microscope (Figure 4.6.9). The results were +ve for TV. Treatment 
started on 20/3/2008 with aqueous cream, and continued till examination 
under microscope appeared –ve on the 12/4/2008 (Figure 4.6.11). The 
patient was followed up till September /2008 (Figure 4.6.12) no any 
recurrence was observed. This further confirms the efficacy of the 
formulated aqueous cream in treatment of TV. 
 
Figure 4.6.9: Direct microscope of skin scraping from patient with Tinea 
versicolor (hyperpigmentation). Sample taken from case 2. 
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Figure 4.610: Hyperpigmentation Tinea versicolor at the back of case 2 
before treatment  
 
Figure 4.6.11: Hyperpigmentation Tinea versicolor at the back of case 2 
one month after treatment  
 
 
Figure 4.6.12: Hyperpigmentation Tinea versicolor at the back of case 2 
six month after treatment.  
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Case (3) 
S.M. is a male patient, 45 years old, 60 kg from Khartoum. He 
came to the out-patient clinics of Skin and Sexually Transmitted 
Diseases, Khartoum Teaching Hospital; suffering form PV 
(hypopigmentation) since six year. The medication used prior treatment 
was sulfur but the disease reoccurred. Particulars of this patient are shown 
in table 4.6.7. 
The disease excessively spread as white patches located on the 
neck, chest, back and arms (Figure 4.6.14). A sample was taken by 
scraping and examinated under microscope (Figure 4.6.13). The result 
was + ve for TV. Treatment started on 8/4/2007 with aqueous cream, and 
continued till examination under microscope appeared – ve. This was on 
the 30/4/2007 (Figure 4.6.15). The patient was followed up till September 
/2008 (Figure 4.6.16) no any recurrence was observed. 
 
Figure 4.6.13: Direct microscope of skin scraping from patient with Tinea 
versicolor. Sample taken from case 3. 
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Figure 4.6.14: Tinea versicolor at the arm of case 3 before treatment. 
 
Figure 4.6.15: Tinea versicolor at the arm of case 3 one month after 
treatment. 
 
Figure 4.6.16: Tinea versicolor at the arm of case 3 more than one year 
after treatment. 
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Case (4) 
E.A. from Central of Sudan, male patient, 70 kg and 21 years old. 
He came to the out-patient clinics of Skin and Sexually Transmitted 
Diseases, Khartoum Teaching Hospital suffering form TV 
(hypopigmentation) since four month and no medication prior the trial 
were used. Particulars of this patient are shown in table 4.6.7. 
The disease manifested as white patches on the chest, neck and 
arms (Figure 4.6.18). A sample was taken by scraping and examined 
under microscope (Figure 4.6.17). The result was +ve for TV. Treatment 
started on 4/4/2008 with aqueous cream and continued till examination 
under microscope appeared –ve. This was on the 25/4/2008 (Figure 
4.6.19). The patient was followed up till September /2008 (Figure 4.6.20) 
no recurrence was observed. 
 
 
Figure 4.6.17: Direct microscope of skin scraping from patient with Tinea 
versicolor. Sample taken from case 4. 
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Figure 4.6.18: Tinea versicolor at the neck of case 4 before treatment. 
 
Figure 4.6.19: Tinea versicolor at the neck of case 4 one month after 
treatment. 
 
Figure 4.6.20: Tinea versicolor at the neck of case 4 six month after 
treatment 
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Case (5) 
A.D is an Ethiopian imunocompremized male patient 25 years old, 
60 kg. He visited the out-patient clinics of Skin and Sexually Transmitted 
Diseases, Khartoum Teaching Hospital; suffering form extensive fungal 
infection since twelve year. Particulars of this patient are shown in table 
4.6.7. 
The medication used prior treatment was griseofulvine, 
clotrimazole and benzoic acid. They all gave no effect. The disease 
manifested itself as large brownish white patches on all of his body 
except head (Figure 4.6.22). 
A sample was taken by scraping and examined under microscope 
(Figure 4.6.21). The result were +ve for fugal infection. 
Treatment started on 7/4/2008 with aqueous cream and continued 
till examination under microscope appeared –ve. This occurred on the 
30/4/2008 (Figure 4.6.23). The patient was followed up till September 
/2008 (Figure 4.6.24) no recurrence was observed. This patient was 
treated for more than one year with known antifungal drug. 
Unfortunately, all showed no activity against fungi in this patient. 
However, when the patient was treated with the test cream, complete cure 
was achieved in about three week with no recurrence for five months. 
 
Figure 4.6.21: Direct microscope of skin scraping from patient with 
fungal infection showing fungal hyphae. Sample taken from case 5. 
 194
 
Figure 4.6.22: Fungal infection of imunocompremized patient (case 5) 
before treatment 
 
Figure 4.6.23: Fungal infection of imunocompremized patient (case 5) 
one month after treatment. 
 
Figure 4.6.24: Fungal infection of imunocompremized patient (case 5) 
five month after treatment. 
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Case (6) 
A.M. Is a male patient from Central of Sudan, 40 kg and 18 years 
old. He came to the out-patient clinics of Skin and Sexually Transmitted 
Diseases, Khartoum Teaching Hospital suffering form Tinea corporis 
since one month and no medication prior treatment are used. Particulars 
of this patient are shown in table 4.6.7. The disease manifested as large 
brown patch between chest and neck (Figure 4.6.26). 
A sample was taken by scraping and examinated under microscope 
(Figure 4.6.25). The result were +ve for T. corporis. 
Treatment started on 12/3/2008 with aqueous cream, and continued 
till examination under microscope appeared –ve. This was done on the 
21/3/2008 (Figure 4.6.27). The patient was followed up till September 
/2008 (Figure 4.6.28) no any recurrence was observed. 
This confirms the efficacy of the formulated aqueous cream in 
treatment of T. corporis infection. 
 
 
Figure 4.6.25: Direct microscope of skin scraping from patient with Tinea 
corporis showing fungal hyphae. Sample taken from case 6. 
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Figure 4.6.26: Tinea corporis before treatment (case 6) 
 
 
Figure 4.6.27: Tinea corporis one month after treatment (case 6) 
 
 
Figure 4.6.28: Tinea corporis six months after treatment (case 6) 
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Case (7) 
A.M. is a male patient from Central of Sudan, 40 kg and 18 years 
old. He came to the out-patient clinics of Skin and Sexually Transmitted 
Diseases, Khartoum Teaching Hospital suffering form Tinea capitis since 
one month and no medication prior treatment are used. Particulars of this 
patient are shown in table 4.6.7. The disease manifested as large white 
patch on the head (Figure 4.6.30). 
A sample was taken by scraping and examinated under microscope 
(Figure 4.6.29). The result were +ve for T. capitis. 
Treatment started on 9/4/2008 with aqueous cream, and continued 
till examination under microscope appeared -ve. This was done on the 
21/4/2008 (Figure 4.6.31). The patient was followed up till September 
/2008 (Figure 4.6.32) no any recurrence was observed. 
This confirms the efficacy of the formulated aqueous cream in 
treatment of T. capitis infection. 
 
 
Figure 4.6.29: Direct microscope of skin scraping from patient with Tinea 
capitis showing fungal hyphae. Sample taken from case 7. 
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Figure 4.6.30: Tinea capitis from case 7 before treatment 
 
 
Figure 4.6.31: Tinea capitis from case 7 one month after treatment 
 
 
Figure 4.6.32: Tinea capitis from case 7 six month after treatment.  
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Case (8) 
G.M. is a male patient from North of Sudan, 60 kg and 35 years 
old. He came to the out-patient clinics of Skin and Sexually Transmitted 
Diseases, Khartoum Teaching Hospital suffering form Tinea pedis since 
one year and the medication used prior treatment was clotrimazole. 
Particulars of this patient are shown in table 4.6.7.The disease manifested 
as white infection on the feet. 
A sample was taken by scraping and examinated under microscope 
(Figure 4.6.33). The result were +ve for T. pedis. 
Treatment started on 2/3/2008 with aqueous cream, and continued 
till examination under microscope appeared –ve. This was done on the 
28/3/2008 (Figure 4.6.35). The patient was followed up till September 
/2008 (Figure 4.6.36) no any recurrency was observed. 
This confirms the efficacy of the formulated aqueous cream in 
treatment of T. pedis infection. 
 
 
Figure 4.6.33: Direct microscope of skin scraping from patient with Tinea 
pedis showing fungal hyphae. Sample taken from case 8. 
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Figure 4.6.34: Tinea pedis from case 8 before treatment. 
 
 
 
 
Figure 4.6.35: Tinea pedis from case 8 six month after treatment  
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Case (9) 
A.G. is a female patient from Center of Sudan, 75 kg and 38 years 
old. She came to the out-patient clinics of Skin and Sexually Transmitted 
Diseases, Khartoum Teaching Hospital suffering form Tinea manuum 
since one month and no medication prior treatment are used. Particulars 
of this patient are shown in table 4.6.7. The disease manifested as large 
brownish white patch on the hand (Figure 4.6.37). 
A sample was taken by scraping and examinated under microscope 
(Figure 4.6.36). The result were +ve for T. manuum. 
Treatment started on 2/4/2008 with aqueous cream, and continued 
till examination under microscope appeared –ve. This was done on the 
20/4/2008 (Figure 4.6.38). The patient was followed up till September 
/2008 (Figure 4.6.39) no any recurrence was observed. 
This confirms the efficacy of the formulated aqueous cream in treatment 
of T. manuum infection. 
 
 
Figure 4.6.36: Direct microscope of skin scraping from patient with Tinea 
manuum showing fungal hyphae. Sample taken from case 9. 
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Figure 4.6.37 Tinea manuum from case 9 before treatment 
 
Figure 4.6.38: Tinea manuum from case 9 one month after treatment 
 
Figure 4.6.39: Tinea manuum from case 9 six month after treatment.  
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Case (10) 
TA. is a female patient from Khartoum, Sudan, 45 kg and 18 years 
old. She came to the out-patient clinics of Skin and Sexually Transmitted 
Diseases, Khartoum Teaching Hospital suffering form Candida 
onychomycosis since four month and no medication prior treatment are 
used. Particulars of this patient are shown in table 4.6.7.The disease 
manifested as white infection on the nail (Figure 4.6.41). 
A sample was taken by scraping and examinated under microscope 
(Figure 4.6.40). The result were +ve for Candida onychomycosis. 
Treatment started on 27/4/2008 with aqueous cream, and continued 
till examination under microscope appeared –ve. This was done on the 
15/5/2008 (Figure 4.6.42). The patient was followed up till 
September/2008 (Figure 4.6.43) no any recurrency was observed. 
This confirms the efficacy of the formulated aqueous cream in treatment 
of Candida onychomycosis infection. 
 
 
Figure 4.6.40: Direct microscope of skin scraping from patient with 
Candida onychomycosis showing fungal hyphae. Sample taken from case 
10. 
 
 204
 
Figure 4.6.41: Candida onychomycosis from case 10 before treatment 
 
 
Figure 4.6.42 Candida onychomycosis from case 10 one month after 
treatment 
 
 
Figure 4.6.43 Candida onychomycosis from case 10 five month after 
treatment. 
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4.6.4 Recurrences 
 TV has high recurrence rate so the volunteers were following 
up for six month after treatment. Six volunteers who were treated by 
control drug are return again because the disease reoccurred; 
however, volunteers who were treated with test drug show no 
recurrence of disease.  
 Follow up was continued till September 2008. Volunteers 
showed no recurrence for 5-18 month after treatment. 
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5. Conclusion 
In the present study a new drug for treatment of TV and SD from a 
volcanic stone common used traditionally in Yemen is formulated.  
 Chemical analysis of the stone was done using different methods of 
analysis. The results showed that the stone has no organic compound and 
all its constituent are in organic. The main constituents are iron and 
sulphate. 
 In vitro microbiology tests for the stone as extract and cream on 
different cultures of fungi were carried out. In vitro efficacy of the stone 
drug was compared with other drugs such as selenium sulfide shampoo, 
yellow sulfur and sodium thiosulphate solution. The cream gave very 
good effect against a wide rang of fungi. 
The drug also has very good effect against in vitro culture of Gram 
positive and Gram negative bacteria. 
Stone extract was formulated in different topical pharmaceutical 
dosage forms. The most suitable and stable formulation is aqueous cream 
which is cheap and water washable. 
Pharmacological studies of the stone extract on different muscles 
receptors (smooth muscle, uterus muscle, skeletal muscle and aortic 
muscle) showed that the drug has no pharmacological effect. However,  
the drug showed direct effect on the small intestine muscle due to its salts 
constituents. 
Toxicological investigating were performed for the stone extract 
rats, divided into two groups; one as control and the other as test for 21 
day. 
The results showed no significant differences in plasma enzymes 
and in all blood parameters between the two groups (P > 0.05) when 
except lymphocyte gave significant differences P = 0.14. 
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Histopathology for the five important organs (intestine, heart, liver, 
kidney and spleen) for the test group was done and showed no damage or 
change in these tissues. 
Finally clinical trials of the test drug with control drug 
(clotrimazole cream) were carried outs on 100 volunteers divided into 
two groups 40 volunteers with SD and 60 volunteers with TV. 
Test drug gave very good results and faster cure compared with 
control drug. The cure period of test drug (11.5 ± 3.846) are shorter than 
control drug (17 ± 7.504) in case of SD there are significant differences 
(P = 0.006).  
In case of TV cure period of test drug (21.2 ± 4.708) are shorter 
than control drug (25 ± 3.922) and there are significant differences (P = 
0.001). 
The follow up of volunteers with TV treated with test drug was 
continuing up to one year no recurrence was observed. 
The study concludes that test drug (stone extract cream) is cheap, 
safe, and stable, had very good efficacy against SD and TV and had no 
recurrence for up to one year. 
The only side effect noted during clinical trial in case of TV is the 
color of patches which change to black then disappear with the time. 
The cream is recommended to be administered twice a day for 2-4 
weeks. 
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7.2 APPENDICES (B): Eligibility Checklist 
Inclusion Criteria 
If any of the following questions are answered ‘No’, the 
patient is not eligible for the study. 
Y=Yes  
N=No 
1.  Men and women have 15 years old ? 
2.   Positive mycology diagnosis for Malassezia furfur or skin 
dermatophytes (all tinea). ? 
3.   Malassezia furfur and other tinea of more than two weeks 
of evolution ? 
4.   Patients that voluntarily agree to participate in the study 
and sign the informed consent. ? 
5.   Disposition to attend all the visits punctually (initial, 
treatment and follow-up) ? 
6.   Acceptance of not using any other treatment for all tinea 
while in the study ? 
Exclusion Criteria 
If any of the following questions are answered ‘Yes’, the 
patient is not eligible for the study. 
Y=Yes  
N=No 
1.    Pregnant women ? 
2.    Presence of any condition or disease that compromises the 
patient immunologically (i.e. diabetes, cancer, etc.) or, 
any other, that, based on the judgment of the researcher, 
could alter the course of all tinea especial tinea versicolor 
? 
3.    Patients with history of hepatic, renal or cardiovascular 
disease ? 
4.     Mentally or neurologically disabled patients that are 
considered not fit to approve their participation in the 
study 
? 
5.    Patient exposed to sun light more than eight hours during 
treatment ? 
6.    Patient who used another drug for treatment ? 
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Demography & Medical History of Present Illness 
1.    Name ______________________________ 
       Telephone number ______________________________ 
      Approximate Age ?? Years 
2.   Date of Inclusion: ??/??/???? (dd/mm/yyyy) 
3.  Time of Inclusion: ??:?? (24-hour clock) 
4.   Gender: ? Male        ? Female 
5.    Weight: ?? ? kg 
6.   (a) Ethnic Group: ?? (code) (0=Unknown; 1=Northern; 
2=Southern; 3=Eastern; 4=Western 
5=Other groups) 
      (b) If ‘5’, Other group, 
specify: 
_______________________________ 
7.    Number of Days Illness: ?? 
8.   (a) Medications Prior to 
inclusion: 
? Y=Yes  N=No 
      (b) If  ‘Yes’, note drugs, 
dosages, and timing: 
 
_______________________________ 
9.   (a) Other History: ? Y=Yes  N=No 
      (b) If ‘Yes’, describe 
(explain): 
______________________________ 
       
____________________________________________________________
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Physical Examination on Inclusion 
1. Color of the patches ? White   ? Livery   ? Grey ? Others (specify)………………………………… 
2. Location of the patches ? Neck  ? Trunk  ? Upper arms   ? Others (specify)…………………………………. 
3.  Morphological of the 
growth 
? Hypo pigmentation   ? Hyper 
pigmentation. 
4. Diagnosis of disease ? TV  ?  T.corporis  ? T.capitis   ? T.pedis  ? T.manuum   ?  Others 
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A) Microbiology Examination on Inclusion 
1. Direct examination before treatment 
? Date:  
? Results of sample taken: +ve ? -Ve  ?. 
? Type of disease: 
? Others specifications 
2. Direct examination during treatment 
? Date:  
? Results of sample taken: +ve  ? -Ve  ?. 
? Others specifications 
3. Direct examination after treatment 
? Date:  
? Results of sample taken: +ve  ? -Ve  ?. 
? Others specifications: 
B) Treatment: 
?  Type of drugs:   A- ?   B- ?. 
? Dose: twice daily. 
? Quantity: one tube or Jar- ? two tube or Jar- ? others- ?. 
C) Notes: 
1. The patient should ensure cleanness of the infected area 
before application of the treatment. 
2. The patient should not used other anti fungal or cosmetic 
preparation during treatment 
3. The patient must change cloth before and after treatment. 
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